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ABSTRACT 
CARBON NANOTUBES MICRO-ARRAYS: 
CHARACTERIZATION AND APPLICATION IN BIOSENSING OF FREE 
PROTEINS AND LABEL-FREE CAPTURE OF BREAST CANCER CELLS 
 
Farhad Khosravi 
 
Worcester Polytechnic Institute 2016 
 
 Circulating tumor cells (CTCs) are cells released into the bloodstream from 
primary tumors and are suspected to be one of the main causes behind metastatic 
spreading of cancer. The ability to capture and analyze circulating tumor cells in 
clinical samples is of great interest in prevailing patient prognosis and clinical 
management of cancer.  
 Carbon nanotubes, individual rolled-up graphene sheets, have emerged as 
exciting materials for probing the biomolecular interactions. With diameter of about 1 
nm, they can attach themselves to cell surface receptors through specific antibodies and 
hold a great potential for diagnostic cellular profiling. Carbon nanotubes can be either 
semiconducting or metallic, and the electronic properties of either type rivals the best 
known materials. Small size of nanotubes and the ability to functionalize their surface 
using 1-Pyrenebutanoic Acid, Succinimidyl Ester (PASE), enables a versatile probe for 
developing a platform for capture and analysis of cancer biomarkers and circulating 
tumor cells. Although nanotubes have previously been used to electrically detect a 
variety of molecules and proteins, here for the first time we demonstrate the label free 
capture of spiked breast cancer cells using ultra-thin carbon nanotube film micro-array 
devices in a drop of buffy coat and blood. A new statistical approach of using Dynamic 
ii 
 
Time Warping (DTW) was used to classify the electrical signatures with 90% 
sensitivity and 90% specificity in blood. These results suggest such label free devices 
could potentially be useful for clinical capture and further analysis of circulating tumor 
cells.  
 This thesis will go in-depth the properties of carbon nanotubes, device 
fabrication and characterization methodologies, functionalization protocols, and 
experiments in buffy coats and in blood. Combination of nano and biological materials, 
functionalization protocols and advanced statistical classifiers can potentially enable 
clinical translation of such devices in the future.  
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CHAPTER 1 
INTRODUCTION 
 
 Cancer is one of the leading causes of death worldwide. In 2012 about 14.1 
million new cancer cases and 8.2 million deaths occurred worldwide which is expected 
to increase to 13 million in 2030 [1, 2]. In the United States cancer is the second 
leading cause of death currently, after heart disease. In 2016, the National Institute of 
Health (NIH) projected that there will be 1,685,210 new cancer cases and 595,690 
cancer deaths in United States [3]. However, the World health Organization claims at 
least 30% of these deaths can be prevented if patients are diagnosed and treated before 
cancer metastases. The progression of cancer from a localized to metastatic disease is 
fundamental to the advancement of this illness and is believed to cause 90% of all 
cancer related deaths [4-8]. Therefore understanding the state of metastases disease and 
its root cause could have a positive impact on patient management and survival in the 
clinic. 
1.1. CIRCULATING TUMOR CELLS (CTC) 
 In 1869, Thomas Ashworth an Australian physician for the first time reported 
that cells in the blood stream of a man with metastatic cancer were similar to those in 
tumor tissue [9, 10]. He postulated that “cells identical with those of the cancer itself 
being seen in the blood may tend to throw some light upon the mode of origin of 
multiple tumors existing in the same person”. Ashworth observed under an optical 
microscope a tumor like cells at the internal saphena vein of cancer patient’s leg. Based 
on his observations, he concluded that certainly these tumor cells must have come from 
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an existing cancer structure and they must have passed through the greater part of the 
circulatory systems. He then suggested that this phenomenon can shed light upon the 
mode of origin of multiple tumors existing in the same person, metastases cancer [10].   
 The malignant cells shedding from solid tumors, both primary and metastatic 
lesions, were later referred to as circulating tumor cells (CTC). CTCs play a key factor 
in hematogenous dissemination spreading cancer to distant sites and in seeding new 
tumors and cancer metastases, Figure 1 [11, 12]. Tumor cells shed into the blood in 
discontinuous fashion and are eliminated for the most part from circulation. Even 
though most CTCs will never colonize any organs but the few cells that manage to 
establish conditions for growth at distant sites can develop into tumors through the 
seeding process resulting in poor prognosis for patients [13-16]. In the case for 
carcinomas, which are solid tumors derived from epithelial tissues and consist of 80% 
of all cancer cases diagnosed, prognosis of patients is mainly determined by the blood 
borne dissemination of tumor cells from the primary site to distant organs such as bone 
marrow, lungs, liver, or brain [8]. The subsequent outgrowth of these cells in their new 
microenvironment is the primary factor for metastases. After disseminating and 
establishing micrometastases state, these tumor cells can remain in dormant state for 
many years, even after complete resection of the primary tumor, before they give rise to 
overt metastases  [17, 18]. Therefore understanding CTCs may be the first step to 
blocking metastases. Since the 1950s, numbers of studies have demonstrated the 
presence of CTC in blood and the possibility of prognostic value of CTC in breast 
cancer patients [19-27]. Furthermore in 1990s scientist started to express a  
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Figure 1. Schematic showing the shedding of tumor cell into the blood stream and 
seeding new tumors through metastases. The cancer cells that enter the blood vessels 
and circulate with normal blood cells are considered circulating tumor cells (CTC) [28].  
 
understanding of the utility of CTC for diagnosis, studies by Shpall et al. [29, 30], 
Brugger et al. [31] and other researchers showed the presence of primary tumor cells 
lodged in the bone marrow before metastases became evident [32]. This trend has 
continued, a number of more recent studies have presented that CTCs may be used as a 
marker in cancer patients to predict disease progression and survival in metastatic and 
potentially even in early stage cancer patients [33-36]. Therefore, detecting, targeting, 
and controlling CTCs is believed to be a key factor in controlling metastasis and cancer 
[4]. Existing high resolution technologies are unable to detect CTCs; therefore 
alternative techniques are in demand. More recently CTCs have been successfully 
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identified in bone marrow, lymph nodes, and circulating blood with sensitive and 
specific assays [37, 38]. Bone marrow especially, appears to be a common homing 
organ for disseminated tumor cells. These cells are derived from carcinomas of 
different origins. When deposited in bone marrow, they could also act as the reservoir 
for disseminated tumor cells with potential to infect other distant organs [39]. Using a 
needle aspiration technique, bone marrow can be accessed through the iliac crest. 
Analyses of bone marrow samples play a big role as an indicator of the prognosis of 
minimal residual disease, small numbers of leukemic cells (cancer cells from the bone 
marrow) that remain in the patient. In some cases, detection of tumor cells in the bone 
marrow showed a greater clinical value for prognoses of disease in comparison to the 
CTC in blood [40]. 
 Sequential and routine monitoring of prognosis of cancer patients are pivotal to 
disease prognosis. In such case, bone marrow needle aspiration is not an attractive 
technique due to its invasive nature, putting great limitations on sampling frequency. 
The bone marrow sampling process is invasive and can be an extremely painful and 
distressing experience causing anxiety. For children this experience can be even harsher 
and more terrifying [41-44]. Considering the inconvenience of bone marrow biopsy in 
regards to pain and recovery time, an alternative method has to be considered in the 
case of routine CTC testing. On the other hand sampling peripheral blood for CTC 
detection is a minimally invasive way in comparison [45]. Therefore there is a great 
deal of interest within the research community to evaluate the clinical utility of testing 
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for tumor cells in the blood instead of bone marrow for monitoring systemic therapy 
and prognosis of cancer patients [37]. 
 The analysis of CTCs from blood samples is considered a real-time “liquid 
biopsy” for patients with cancer [18]. Capturing and detecting CTCs via different 
technologies that take advantage of their biological and physical properties by liquid 
biopsy can lead the way for personalized targeted therapies and unlock the opportunity 
for dynamic prescriptions according to the existing biomarkers and genotypes, hence 
significantly improving the quality of treatments [18, 46]. Since blood can be collected 
simply and in a minimally invasive manner, CTCs can potentially be easily obtained 
from small amounts of blood samples and provide the real time single cell level data for 
guided therapies [47, 48]. CTC as real time marker could be used as an indicator for 
disease progression and survivals [18]. However, the isolation, detection and 
quantification of CTC in blood is a very difficult task and faces technological hurdles 
due to rarity of these circulating tumor cells. For CTC marker to fulfil its role, 
development of CTC detection devices that can handle small sample volumes is crucial. 
 Cancer Cells including CTCs are originated from body’s own tissue in series of 
mutations [5]. Self-origin of these mutated cells present difficulties in distinguishing 
them from healthy cells, even masking them from the body’s own immune system [49]. 
CTCs are typically found in single digit numbers per milliliter of blood and are very 
similar to leukocytes in their dimensions, making it very difficult to detect using 
traditional microscopy techniques alone [45]. This presents a challenge to identify 
malignant cells among normal ones, making cancer diagnosis and therapies more 
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difficult. Studying cancer cell mutations, scientist have discovered over expression of 
certain proteins embedded in the cellular membrane at much higher levels than normal 
cells. In the case of carcinomas for example, CTC have the potential to be distinguished 
by over expressed epithelial cell membrane markers (receptor proteins). The specific 
membrane biomarkers can serve to identify CTC even at single-cell level [13]. 
Studying such biomarkers has enabled researchers to distinguish cancer cells from 
healthy tissue and even go as far as correlating them to specific cancer types. The 
biomarker overexertion and characteristics are unanimous in-between cancer tumors 
and their corresponding CTCs [50-54]. 
 Large numbers of circulating epithelial cells have been detected in metastatic 
cancer patients, between 50 to 300,000 per mL of blood [55]. CTCs entail fraction of 
these circulating cells. Presence of CTC in blood has been reported anywhere from 1-
10 to as high as 3,149 CTCs per mL of blood in metastatic cancer patients [56, 57]. The 
frequency of CTCs in blood is a strong indicator of the prognosis of cancer patients [33, 
35, 56-60]. CTCs are systemic indicators and are a less invasive sampling option in 
comparison to local tumor biopsy, especially when accessing the tumor is not feasible 
[18, 55]. The information obtained from CTCs can determine the effectiveness of 
certain treatments, assist in more customized therapies, and give deep insights on 
patient survival, Figure 2 [34, 35, 56, 57, 61-64]. Therefore, understanding the 
principles behind CTC enrichment and the different methods for CTC capture and 
detection are of great interest. Table 1 summarizes the different approaches and 
methods for CTC enrichment, capture and detection.
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Figure 2.  Kaplan Meier Analysis of overall survival for patients with metastatic breast 
cancer (a), metastatic colorectal cancer (b), and prostate cancer (c). Patients were 
divided into those with Favorable and Unfavorable CTC. The cutoff value between 
favorable and unfavorable CTC was ≥ 5 CTC/7.5mL blood for breast and prostate 
cancer and ≥ 3 CTC/7.5mL blood for prostate cancer [33, 57]. For example patient with 
1 CTC/7.5 mL was labeled favorable. 
.  
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Table 1. Summary of CTC isolation/detection technologies 
Primary Method Secondary 
Method 
Principle of 
enrichment 
Advantages Limitations Reference 
Immunomagnetic Nanostructure Antibody 
based; 
aptamer 
based [65] 
High intra and inter assay 
precision; standardized 
and semi-automatic, 
detection and capture 
Cost, time, sample volume, labeling, 
microscope image analysis, capture 
or detection only; antigen dependent 
[34, 65-
72]  
Microfluidics Microstructure  Antibody 
based 
Label-free, cell 
collection, molecular 
profiling, rapid 
Antigen dependent, capture only [73-80] 
 
Cell size and 
deformability 
Label-free, allows gentle 
release, antigen 
independent 
Capture only , Limited selectivity due 
to size overlap between CTC and 
WBCs, poor specificity; Limited to 
only CTC clusters (>2cells) [81] 
[81-99] 
 
/Magnetic 
liposomes 
Antigen independent, 
single platform  
Capture only, label dependent, 
limited selectivity due to size overlap 
between CTC and WBCs, poor 
specificity 
[100] 
Nanostructure Antibody or 
aptamer 
based 
CTC collection and 
isolation, stable  
Capture only, can be antigen 
dependent, increased sensitivity 
decreases specificity to a degree 
[101-114] 
 
 
Dielectrophoresis Physical 
properties 
Label-free, antigen 
independent 
Capture only, depends on 
conductivity of CTC  
[115, 116] 
Immunomagnetic Antibody 
based and 
phenotype 
Heterogeneity profiling 
of CTC, cell collection, 
integrated platform,  
Capture only, antigen dependent; 
CTC degradation [117], detection 
only [118, 119] 
[117-120] 
 
Microstructure 
and 
immunomagnetic 
Antibody 
based 
Single platform, 
automated, efficient 
Capture only, sample volume, antigen 
dependent. , fluorescent imaging 
analysis dependent 
[121-126] 
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Immunomagnetic 
and impedance  
Antibody 
based 
Detection and capture, 
single platform 
Antigen dependent [127] 
Filtration Microstructure Cell size and 
deformability 
Label free, antigen 
independent, simple, fast, 
satisfies cell lysis, cell 
collection, and molecular 
profiling 
Limited selectivity due to size 
overlap between CTC and WBCs, 
poor specificity; capture only. 
[128, 129]  
Nanosubstrate   Aptamer 
based 
Capture, detection and 
release of multiple types 
of CTCs 
Antigen based, depends on 
microscopy and flow cytometry 
techniques 
[130] 
    Antibody 
based 
Tunable capture and 
release, cell collection; 
detection [131] 
Capture only, can be antigen 
dependent, increased sensitivity 
decreases specificity to a degree 
[131-133] 
  Microfluidics  Antibody 
based 
Surface capture and 
culture of CTC within 
device 
Capture only, antigen dependent [134] 
In vivo Functionalized 
wire/needle 
Antibody 
based 
In vivo, real time capture, 
no blood sample volume 
limitation 
Antigen dependent, invasive, capture 
only, depends on immune staining 
and fluorescent imaging 
[135-137]  
Cytometry Flow cytometry 
and fluorescent 
nanoparticles 
Genotype Detection of genetic 
marker of CTC, CTC 
culture 
Require larger population of CTC 
(>100/mL of blood) 
[138] 
  Microfluidics 
and aliquoting 
Antibody 
based 
Cell collection, molecular 
profiling, rapid 
Antigen dependent, fluorescence 
labeling 
[139] 
Microcantilever __ Antibody 
based 
Detection and capture antigen dependent, limited sensor 
area for detection, sample volume 
limitations 
[140] 
Table 1. (continued) 
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1.2. PRINCIPLES OF ENRICHMENT FOR CTC 
 Different properties of CTCs distinguishing them from the surrounding normal 
hematopoietic cells have been targeted to develop a large panel of approaches for CTC 
enrichment technologies, Table 1. These techniques are divided into two main 
categories, separation based on physical properties (i.e. cell size, density, electric 
charge, elasticity and deformation) and biological properties of CTC (i.e. cell surface 
protein expression), Figure 3. Here we are going to discuss these approaches and 
understand their advantages and limitation.  
1.2.1. PHYSICAL PROPERTY BASED SEPARATION OF CTC 
 The main advantage to physical property based approaches of CTC enrichment 
is that they allow for label-free separation of tumor cells. Physical property separation 
of CTC include: size based and dielectric based separation of CTC. More recently, cell 
membrane charge has also been explored for CTC separation in combination with 
existing size based separation techniques [100]. 
 1.2.1.1. SIZE BASED SEPARATION OF CTC 
 Size based approach leverages the size difference between tumor cells and the 
normal cell types found in blood. This technique can also be combined with other 
physical properties such as deformability and elasticity to enhance the enrichment 
results [82, 88-91, 129]. This approach is one of the first to arise as an alternative to 
affinity based techniques.  
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Figure 3. Isolation and enrichment of CTCs from blood of cancer patients is based on 
the physical or biological properties of CTCs [18]. Physical property based separation 
include size (membrane filter devices [128, 129]), deformability (microfluidics system 
in a chip [81-99]), electric charge (dielectrophoresis [115, 116]), and density (Ficoll 
centrifugation [58]). Biological based property isolation is based on: the expression of 
cell surface markers, (i.e. epithelial cell adhesion molecule (EpCAM)) for positive 
selection and CD45 for negative selection; anti-body (i.e. anti-EpCAM) or anti-CD45 
antibodies conjugated with magnetic beads, for enriching CTCs in a magnetic field [34, 
65-72]; anti-EpCAM antibodies on microposts or columns of nanobeads [73-80]; anti-
EpCAM antibodies conjugated to 3 μm beads to increase the size of CTCs before 
filtration [141]; anti-EpCAM, anti-HER2/neu, anti-EGFR antibodies on different sizes 
of nanoparticles for capturing and detecting different CTCs [114].
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 In general, CTCs have larger cell diameter, 10-20 μm, in comparison to normal 
red blood cells (RBCs), 4-6 μm,  and white blood cells (WBCs), 7-12 μm, thus offering 
the possibility of size based separation of CTCs with high precision filtration [128, 
142]. Initially sieve-like materials were used to demonstrate the possibility of tumor 
cell separation from blood [143]. Shortly after that more precisely engineered filters 
were microfabricated for the same purposed [83]. To further optimize this technique, 
polycarbonate membranes were used to produce arrays of consistently sized pores 
using ion beam etching, providing an ideal platform to optimize the performance of size 
based CTC separation [85, 144]. Using this material platform, isolation by size of 
epithelial tumor cells technique was developed for very sensitive enumeration of CTCs 
in patient samples [128, 145]. Furthermore, techniques such as fluorescence in situ 
hybridization (FISH) or polymerase chain reaction (PCR) were shown to be compatible 
with the platform and were utilized to perform gene based analysis on the captured 
CTCs. Separately, beads that would specifically bind to tumor cells were also used on 
some platforms to increase the cell diameters, thereby extending the size based 
enrichment approach to a wider range of CTCs, but in contrast this does introduce 
dependence on cell surface markers [141]. 
 Microfluidics plays a big role in size based separation of CTC, this method had 
been introduced as a very promising alternative to traditional filtration methods. For 
example, the Microvortex fluidic platform, Figure 4, has achieved good levels of 
sensitivity and specificity, with purity values close to 95%, sensitivity of 93%, and 
reasonable capture efficiency. This platform uses trapping and inertial focusing of  
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Figure 4. Microvortex chip design and principle. (A and B) show channels and 
reservoir arrangement (WC =40 μm, H =80–85 μm, and LC = 4 mm). (C) Demonstrates 
the wall effect forces (FLW) and shear-gradient lift forces (FLS). (D) Shows the 
migration of cells to dynamic lateral equilibrium positions (Xeq) and (E) trapping of 
CTC in reservoirs (WR = 480 μm and LR = 720 μm) [96].  
 
CTCs in microscale vortices, with fast processing times (0.375 mL/min) providing 
rapid means to isolation high purity samples of CTCs [96, 146]. 
 In conclusion, size based separation of CTCs offers a unique platform for 
development of label free methods for isolation of viable tumor cells, which could also 
be compatible with post capture analysis techniques. However, this approach has 
selectivity limitation due to size overlap between CTCs and WBCs. A portion of all 
CTCs are smaller or the same size as WBCs, resulting in poor specificity and purity of 
the final enriched population [141]. 
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1.2.1.2. Dielectric Separation of CTCs 
 Another label free separation approach using the physical properties of CTC is 
by dielectrophoresis (DEP). Tumor cells can be separated from blood by exploiting the 
intrinsic dielectric differences between cell types. The total plasma membrane 
capacitance and conductance is reported by cell dielectric measurements using 
alternating field gradients. One can separate tumor cells from WBCs using the total 
capacitance. Applying DEP frequency of 60 kHz forces tumor cells to deplete from 
blood, meanwhile shifting the frequency to 15 kHz will result in to cells concentrating 
into fractions [115, 116]. 
 Dielectrophoresis in combination with drag flow can fractionate the sample of 
different types of particles; this method is called dielectrophoresis field flow 
fractionation (depFFF), Figure 5. This method is able to recover up to 90% of the tumor 
cells spiked into blood and recovered cells can be cultured or molecularly analyzed 
[115, 116].  
 However, there are limitations to DEP for CTC separation applications. 
Cytoplasmic and membrane conductivities are susceptible to change over the course of 
the separation process. This can result in poor selectivity but by optimizing the 
separation periods one can minimize these variations and reduce cell-cell interactions. 
1.2.2. BIOLOGICAL PROPERTY BASED ISOLATION OF CTC 
 Approaches using biological properties of cells can significantly improve the 
sensitivity and specificity of CTC capture and analytical methods. Affinity based 
15 
 
 
Figure 5. Schematic diagram of a microfluidic device for cancer cell separation using 
multi-orifice flow fractionation and DEP. In the first separation region, the relatively 
larger MCF-7 cells and a few blood cells pass through the center channel and enter the 
DEP channel, after which most blood cells exit through outlet I. In the focusing region, 
all cells experience a positive DEP force and then align along both sides of the channel. 
Finally, the second separation region selectively isolates MCF-7 cells via DEP [115]. 
 
methods such as antibody and aptamer capture approaches integrated into microdevices 
and nanomaterials have enhanced the capture efficiencies of CTCs in patient samples, 
allowing for detailed molecular level characterization of CTCs to be performed [142]. 
1.2.2.1. ANTIBODY BASED IMMUNOAFFINITY ISOLATION OF CTC  
 An antibody provides a specific binding between itself and the antigen of 
interest. Antibodies have long been employed for investigating CTCs as a very 
effective tool for immunoaffinity isolation of tumor cells, due to antigen expression on 
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the surfaces of CTCs [147-156]. Such assays mainly use antibodies in positive selection 
procedures by targeting the antibody against tumor associated antigen or in negative 
selection by targeting the common leukocyte antigen CD45 [18]. 
 Among positive selection procedures, epithelial cell adhesion molecule 
(EpCAM) plays a big role as a surface marker for CTC detection. EpCAM is over 
expressed in carcinomas such as breast, prostate, neck, head, lung, esophagus, liver, 
rectum, colon and pancreas tumor cells [147-156]. The down side to this marker is that 
capture efficiency is significantly reduced as EpCAM’s overexpression is suppressed. 
Cells that undergo epithelial mesenchymal transition (EMT), express significantly less 
of EpCAM biomarker on their membrane therefore are less susceptible to stick to the 
antibodies as they break into the blood circulation [157].  Additionally, EpCAM 
methods are very effective for non-epithelial cancers such as sarcomas [45]. To address 
these limitations other proteins have been identified as an alternative membrane antigen 
target. As an example PSMA (prostate specific membrane antigen) has been identified 
as a transmembrane metallopeptidase which is widely expressed on prostate cancer 
carcinoma cells [158]. In the case for breast cancer carcinoma, human epidermal 
growth factor receptor 2 (HER-2) has been identified as a target antigen overexpressed 
on the tumor cell membrane [159]. Antibodies targeting cytokeratin (CK), intermediate 
filaments of epithelial cells, are used frequently as secondary means in 
immunocytology to distinguish the captured CTC from impurities in the sample such as 
WBCs which are CK negative and CD45 positive [14]. 
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 Where there is a lack of EpCAM expression, cocktails of antibodies against 
other epithelial cell surface antigens such as HER-2, mucin-1 (MUC1), and epidermal 
growth factor receptor (EGFR) are used [160].  
1.2.2.2. APTAMER BASED ISOLATION OF CTC 
 Aptamers are a category of oligonucleotides such as RNA, DNA, or some 
peptides which can specifically bind to proteins, similar to antibodies, and also ions or 
small molecules. Aptamers are similar to antibodies in function and at the same time 
are more advantages for biological applications in comparative [161, 162]. Therefore 
there has been an increasing shift toward aptamers in the recent years for biological 
applications.  
  Aptamers were first discovered as part of human immunodeficiency virus 
(HIV) and adenovirus research. During these studies, it was discovered that viruses use 
some short RNAs to bind to proteins with high specificity and affinity similar to 
immune binding of antibodies. In 1990 for the first time, Tuerk and Ellington’s 
research groups reported a standard protocol for preparation of aptamers, which utilized 
a three step based systematic evolution of ligands by exponential enrichment [163, 
164]. Aptamers show advantage over antibodies in high affinity and thermal stability, 
reversible denaturation, less batch variation, low cost and simplicity of operation, 
therefore a number of researchers have utilized aptamers for CTC isolation [102, 109, 
165-168]. Tan and co-workers were first to report the application of aptamers for CTC 
enrichment in their microfluidic chip. Cancer cells were spiked into a control sample of 
10
6
 cells mL
-1
 and processed in aptamer coated microchannels. Their method 
18 
 
demonstrated 97% purity and 80% capture yield [109]. In their next attempt, Tan’s 
group developed an S-shaped microfluidic chip to capture three leukemia cell lines in 
three regions respectively.  In case of acute lymphoblastic leukemia cells and Burkitt’s 
lymphoma cells the capture method show a purity of 97%, thereby indicating an 
notable specificity of aptamers to CTCs [109]. This shows a great potential to use 
multiple aptamers in combination with variety of CTC capture methods. 
1.3. METHODS OF CTC ENRICHMENT AND DETECTION  
 In recent years, a variety of methods have been reported for enrichment and 
detection of CTCs. These methods include: immunomagnetic enrichment, microfluidic 
sorting, mechanical filtration, nanosubstrate based capture, in vivo, microcantilever, 
and dielectrophoresis. Utilizing one or more of the principles of enrichments discussed 
earlier, researchers have developed a number of methods, label dependent or 
independent, for capturing and or detecting CTCs as summarized in Table 1.  
1.3.1. IMMUNOMAGNETICS 
 One of the earliest and most commonly used methods to separate CTC from 
blood is immunomagnetic separation [58, 71, 169-176], Figure 6.  Before the 
introduction of micro/nanoengineered platforms and devices, sample preparation for 
immunomagnetics separation consisted of taking the ethylene diamine tetra acetic acid 
(EDTA) treated blood of patients and first centrifuging it in density gradient solution. 
After this step the blood sample is separated into three main components of plasma, red 
blood cells, and buffy coat (containing WBCs and CTCs).  
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Figure 6. Schematic illustrating the CTC capture using antibody conjugated magnetic 
bead and fluorescence imaging [65].  
 
After preliminary enrichment of targeted cells, microbeads modified with antibody (i.e. 
anti-EpCAM) are incubated in the sample to specifically bind to the targeted cell 
membrane protein marker (i.e. EpCAM receptor). Finally by applying a magnetic field 
to the sample, target cells bound to the magnetic microbeads are harvested and 
separated [171, 172]. This method can be effective in capturing CTCs with good 
specificity by combining the principles of cell density gradient and cell affinity. 
However, the immunomagnetic separation method is labor intensive, requires large 
expensive facilities, a technical operator, and a long processing time which can affect 
the CTC capture result and cell loss by repeated pipetting and container to container 
transfer of the sample as part of the process. 
 Veridex CellSearch is a semi-automated system and is the only Food and Drug 
Administration (FDA) approved platform for the prognosis of patients with metastatic 
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breast, colorectal, and prostate cancer. This platform takes advantage of the 
immunomagnetic system with an addition of fluorescence microscopy. After the 
enrichment of the cells using the microbeads, sample are further processed by 
fluorescently staining of CKs (positive marker), the common leukocyte antigen CD45 
(negative marker), and nuclear dye (4’,6-diamidino-2-phenylindole, or DAPI). The 
stained samples are then prepared for fluorescence microscopy enhanced image 
analysis. CTCs are distinguished from background WBCs based on the positive and 
negative fluorescence markers (CK
+
, CD45
-
, and DAPI
+
) [34, 66, 69]. Another more 
recent method utilizing the same principle is the MagSweeper, which positively 
enriches for CTCs expressing EpCAM and allows their subsequent molecular analysis 
[70].  
1.3.2. MICROFLUIDICS 
 Since the early 2000s, microfluidic devices have been a center of focus for CTC 
enumeration for cancer diagnostics. For such applications, microfluidic devices have 
taken advantage of physical and biological principles of CTCs to demonstrate a 
powerful method for efficient cell isolation and focused proteomic/genomic analyses 
[177-179]. Microfluidic devices are generally integrated with biomolecular probes (i.e. 
antibodies or aptamers) to form a functionalized surface to capture specific cells from a 
flowing medium such as unprocessed blood containing CTCs. After isolation and 
capture of target CTC, further analyses is done using optical and electrical methods to 
determine number of isolated cells, type of biological signals, and the characteristics of 
cells [73, 74, 115, 177, 180, 181]. One of the more prominent groups in microfluidics’ 
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field, Nagrath and co-workers, developed a micropost based microfluidic device (CTC-
chip) in 2007 to isolate CTCs, Figure 7. The surface of the microposts were 
functionalized with anti-EpCAM antibodies to isolate CTCs from unprocessed blood 
samples of patients with various cancer types such as prostate, breast, lung pancreatic, 
and colon cancer. They were able to isolate 1-100 CTCs per mL of blood with 50% 
purity, identifying CTC in 115 of 116 samples from patients with various cancer types. 
In the smaller group of patients under systematic treatment, the number of CTCs 
captured were correlated with the clinical prognosis of the disease [73]. Although 
microfluidic devices enhanced with biological probes have shown great promise, they 
still present difficulties in retrieving captured cells from the device for implementing 
cell analysis. Additionally, there have been demonstrations of CTC isolation using 
microfluidic method solely based on physical properties of CTCs, addressing some of 
the limitations with molecular probe based microfluidic devices, eliminating the need 
for antibodies and aptamers. By creating a microfluidic system such as microvortex and 
microspiral, researchers have taken advantage of physical differences (i.e. cell size) 
between CTCs and healthy blood cells to achieve CTC capture and isolation. Even 
though such methods are attractive due to their independence from molecular probes 
such as antibodies, but they have poor specificity and limited selectivity due to size 
overlap between some CTCs and WBCs [81-99]. 
 Microfluidic platforms have overcome the limitations of conventional cell 
isolation techniques such as immunomagnetic sorting of CTC. Microfluidic methods 
have proven to be cost and labor efficient, easy and simple to use, have short 
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Figure 7. CTC-chip for isolation of CTCs from whole blood using a microfluidic 
device. (a) The sample is continually mixed on a rocker, and pumped through the chip 
using a pneumatic-pressure-regulated pump. (b) The CTC-chip with microposts etched 
in silicon. (c) Whole blood flowing through the microfluidic device. (d) Scanning 
electron microscope image of a captured NCI-H1650 lung cancer cell spiked into blood 
(colored red). The inset shows a high magnification view of the cell [73].  
 
processing time, and no preprocessing requirements [182]. However, microfluidic                                                  
methods still need to become more efficient in sample purity and specificity and are 
dependent on secondary methods such as fluorescent image analysis for detection and 
CTC analysis [28]. 
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1.3.3. FILTRATION 
 Filtration method for isolation of CTCs is advantageous because of its 
independence from immunoaffinity isolation techniques [183]. Therefor eliminating the 
need for knowing the specific surface markers of all CTC types such as EpCAM [184]. 
This method of CTC isolation is based on cell size and takes advantage of the fact that 
CTCs in general have a larger size than blood cells, enabling separation of large tumor 
cells through filtering membranes independent of specific binding to antigens, which 
are prompt to miss cells with little or no expression of such biomarkers [82, 83, 85, 89, 
91, 128, 185, 186]. 
 In 2000, isolation by size of epithelial tumor cells (ISET) was the first protocol 
to demonstrate the filtration based method using commercialized filtration membrane 
morphology analysis. In this study, Vona and co-workers illustrated a significant 
difference in cell size between cancer cell lines, 10-20 μm, and normal blood cells, 
RBCs: 4-6 μm and WBCs: 7-12 μm [128]. Similarly, a 2D parylene membrane 
microfilter device was developed by Zheng and co-workers to isolate and electrolyze 
the CTCs. Under this work, they demonstrate processing samples of prostate cancer cell 
lines spiked in Dulbecco’s phosphate buffered saline (DPBS) and human peripheral 
blood at 3.75 mL / min, achieving 90% recovery rate. This was achieved by using a 
microfilter with highly dense and uniformly distributed pores [83]. In clinical specimen 
assays, this method showed detection of CTCs in 51 out of 57 of patients with 
metastatic breast, colon, prostate, and bladder cancer, while the CellSearch system only 
detected CTCs in 26 out of the same 57 patients [85]. Even though the isolation 
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efficiency is satisfactory, high stress and damage from the edges of the pores to cells 
during filtration process compromises the viability of the captured CTCs, prohibiting 
further cell and molecular analysis of captured cells. To address such issues with 
filtration method, Zheng and co-workers later improved their design by introducing a 
3D microfilter to promote viable isolation of CTC [84], Figure 8. This 3D design 
minimized the stress concentration on the cell membrane without significantly 
sacrificing processing time or volume. However, high throughput and flow rate of 
filtration scheme causes clogging of the filtration structure resulting in higher fluid 
stress on cells potentially causing damage to cells and reducing the viability.  
 Size based filtration method remains an attractive high throughput approach for 
CTC capture, independent from surface markers and cancer cell type. However, the 
fundamental limitation to filtration methods still remains. CTCs are heterogeneous, and 
 
 
Figure 8. 3D microfilter device for viable CTC enrichment from blood. (a) Shows the 
filtration process and forces on a trapped cell. FL: force caused by fluidic pressure from 
top. FS: supporting force from bottom membrane. FT: tension stress force on plasma 
membrane. (b) Device design of a single hexagon-shaped microfilter patch [84]. 
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have a large size range (4-30 μm), overlapping with leukocytes causing potential loss of 
sub population of CTCs and effecting specificity and purity [18]. 
1.4.4. NANOSUBSTRATE 
 More recently, researchers have extensively explored nanostructured surfaces 
(i.e. nanopits, nanofibers, and nanogrooves) and their integration with cells in terms of 
proliferation, differentiation, alignment and migration [187-191]. Nanostructures better 
promote protein adherence to surfaces due to a larger surface area resulting in better 
surface functionalization [192].  Nanostructures promote and facilitate cell attachment, 
adhesive forces are improved further more by antigen-ligand binding between cells and 
substrate [193-199].   
 Increasingly nanostructure substrates (i.e. nanowires, nanotubes, nanopillars and 
nanotextured polydimethylsiloxane (PDMS)) have been integrated into microfluidic 
platforms to improve CTC capture in microfluidic devices used for CTC isolation [103, 
105, 107, 110, 167, 200].  Tseng and co-workers developed a NanoVelcro chip based 
on an array of nano-silicon-needles, Figure 9. They functionalized the nanosurface of 
the needles with antibodies, targeting CTC surface markers such at EpCAM and 
showed improved adhesion of CTCs to the capture substrate [103, 200, 201].  
Additionally, nanomaterials such as electrospun TiO2 nanofibers, polymer nanodots, 
and carbon nanotubes have been optimized and tested for CTC capture [108, 110, 133]. 
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Figure 9. NanoVelcro chip. Schematic overlooking the first, second, and third 
generation of the device. This device takes advantage of nanosubstrates and 
microfluidics to capture isolate and release CTCs for further analysis [201]. 
 
1.3.5. IN VIVO 
 Majority of research has focused on ex-vivo analysis of CTCs, meanwhile a 
number of researchers have investigated the in vivo monitoring of these tumor cells 
[135-137].  
 Mouse model studies, showcased a real time in vivo CTC monitoring by 
injecting fluorescent ligands that specifically bind to tumor cells and then using a flow-
cytometry-like technique to monitor cells in blood vessels [202]. They were able to   
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Figure 10. Stainless steel seldinger guidewire functionalized with anti-EpCAM 
antibodies to capture CTC inside the patients vein, in vivo approach [18]. 
 
detect CTCs weeks before metastatic disease became evident, showing great prognostic 
potential for such approach. In another novel approach, a stainless steel medical 
seldinger guidewire (FSMW) was functionalized with anti-EpCAM and was inserted 
into the vein on the patient for half an hour to capture CTCs, Figure 10. 24 lung or 
breast cancer patients were tested with this in vivo approach and captured cells were 
analyzed using immunofluorescence [135]. 
 Such techniques have the potential to provide direct means to monitor CTCs 
levels in real time. However, such approach can prove to be highly challenging due to 
dynamics of blood-borne cells and biocompatibility of such invasive techniques 
complicating the analysis. 
1.3.6. MICROCANTILEVER 
 Microcantilevers have long been used as label-free biosensors, by converting 
biological signals into mechanical deflections that can then be detected using electrical, 
magnetic and optical methods [203-209]. In general, cantilevers are structured with one 
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end fixed and the other end free similar to a diving board and are usually fabricated 
from silicon, silicon oxide, or silicon nitride. Overall, cantilevers are classified into two 
basic groups of static and resonance mode. In static mode operation, deflection of the 
free end of the cantilever caused by biomolecular interactions on cantilever surface is 
observed. On the other hand, resonant mode demonstrates a change in the vibration 
frequency of the cantilever due to addition of biological mass, such as cells, to the 
surface of the cantilever. This change in vibration frequency can be measured using 
optical means to quantify the mass [210]. Variety of cantilever biosensor system based 
on biomolecular probe surface functionalization haven been developed in the past 
decade to detect various biological targets such as E-coli [205], cancer biomarkers 
[208], kinases and myoglobin’s [211], glucose [212], Listeria innocua [204] , Bacillus 
subtilis spores [213], RNA [214], vaccinia virus particles [206]. 
 Recently, Kaur et al. reported a real time detection of breast cancer cells using 
peptide functionalized microcantilever arrays, Figure 11. In this work, they reported 
selectively detecting CTCs using peptide moiety in conjunction with a microcantilever 
array system. Cantilevers were functionalized with peptide 18-4, cancer specific 
peptide, and showed efficient capture and detection of cancer cells in spiked human 
blood samples with a capture yield of 80% [140]. This novel approach present potential 
for capturing and detecting cancer cells using nanomechanical cantilever platform. 
However, this system has limited sensor surface area limiting the number of CTCs that 
can be detected to 50-100 cells.  
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Figure 11. Schematic showing principle of microcantilever sensor operation. (a) 
Microcantilever coated with non-specific reference peptide, shows no response in form 
of a deflection to the presence of normal cells or CTCs. (b) Microcantilever 
functionalized with cancer targeting peptide demonstrates a strong response in form of 
a deflection as CTCs interact with the cantilever [140]. Position sensitive device (PSD). 
 
1.3.7. COMMERCIALLY AVAILABLE CTC DEVICES 
 Advance methods of CTC capture combine two or more methods of CTC 
enrichment and detection techniques to identify these cells. In a single integrated 
platform, combinations of principles of detection are utilized for a more novel and 
effective approach [116-127]. In a most recent effort, Han and co-workers 
demonstrated an electrical detection method for circulating tumor cells by taking 
advantage of nanoparticles, graphene nanoplates (GNPs), and using a microfluidic 
device in combination with impedance cytometry. Here, they presented a two-step 
cascade discrimination lab on a chip device for electrically identifying CTCs from the 
enriched blood samples. CTC device enriches rare CTCs from millions of background 
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blood cells using lateral magnetophoresis and then uses impedance cytometry to 
electrically identify CTCs, modified with GNPs, based on the their electrical 
impedance.  To improve the accuracy of electrical discrimination, GNPs were used as a 
highly conductive material for modifying surface conductivity of CTCs, resulting in 
500-fold enrichment of CTCs using this device [127].  
 In the recent years, there have been number of integrated platforms that have 
found their way to the market and are commercially available technologies for CTC 
enrichment, Table 2. However, the only U.S. Food and Drug Administration (FDA) 
approved method for detection of CTCs is the Veridex CellSearch system [14]. 
CellSearch system uses magnetic nanoparticle and fluorescent dye technology to 
analyze 7.5 mL of blood for CTC, Figure 6. Blood sample is first processed by a 
centrifuge gradient process to separate buffy coat from RBCs and plasma. EpCAM 
conjugated magnetic microbeads are then mixed into the processed blood to bind to the 
EpCAM positive CTCs. Magnetic field is applied to isolate CTCs from the peripheral 
blood. Lastly, captured cells are fixed with 4% paraformaldehyde, immunostained with 
fluorescently labeled anti-CK, anti-CD45, and DAPI, and enumerated by automated 
cell image capture and analysis. CTCs are identified by satisfying the following 
criteria: low eccentricity, size greater than 5 μm, a visible nucleus (DAPI+), positive 
staining for CK, and negative staining for CD45 [57]. This System can detect 85% of 
CTCs in a sample with 95% confidence, although its detection limit at its lowest range 
is 1.2 ± 0.4 CTC per 7.5 mL sample [56]. The CellSearch system is considered as the 
benchmark standard in the industry and is also used in research as an investigative tool
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Table 2. Commercially available technologies for CTC enrichment. 
products techniques specifications Reference 
The 
CellSearch® 
System (Janssen 
Diagnostics) 
Immunomagnetic 
separation (EpCAM-
coated beads) 
Fluorescence imaging 
Sensitivity: ≥2 CTCs in 7.5 mL of 
whole blood               
 Recovery: >80% in cells  
[56] 
AutoMACS® 
Pro separator 
(Miltenyi 
Biotec) 
Immunomagnetic 
separation (EpCAM-
coated beads)  
Sensitivity: 19 ± 24 CTCs per 5 mL                                       
Recovery: >61% at each spiking 
level                               
Throughput: approximately 2 hours  
[215]
IsoFlux™ 
systems 
(FLUXION) 
Immunomagnetic 
separation (EpCAM-
coated beads)  
Sensitivity: ≥5 CTCs per 7.5 mL 
blood                               
Recovery: 80% each cell line  
[216] 
ISET (Isolation 
by Size of 
Epithelial Tumor 
Cells) (rare 
cells) 
Size-based filtration: 8 
μm porous membranes 
Sensitivity: 1 CTCs per 10 mL of 
blood                               
Recovery: —                
Throughput: CTC separation from 
blood in 3 minutes  
[217] 
Parsortix system 
(Parsortix) 
Wier-type step filter: 
size and deformability 
Sensitivity: ability to process up to 
20 ml of whole blood  
Recovery: capture of >60% CTCs 
in samples 
[218] 
RNAscope® 
(Advanced Cell 
Diagnostics) 
Multi-fluorescent RNA 
in situ hybridization 
(FISH) 
Sensitivity: detecting CTCs in 47% 
of patients in 5 ml of blood 
Recovery: 71% ± 12% (n = 17)  
Throughput: 5–10 hours (with ∼2 
hours hands-on time) 
[219] 
CytoTrack CT4 
(Cytotrack) 
Conventional CD/DVD 
technology                             
Flow cytometry & 
Scanning microscopy 
Sensitivity: scanning procedure 
performed in 10–15 minutes per 
sample                           
Recovery: the recovery rate of 10, 
33, and 100 tumor cells in a blood 
sample is 55%, 70%, and 78%, 
respectively                              
Throughput: scan 100 million cells 
in just one minute 
[220] 
ApoStream® 
(Apocell)  
Dielectrophoresis field-
flow assist 
Sensitivity: sample suspension 
collection volume: ∼1.5 mL 
(starting blood volume: 50 μl–10 
ml)                                    
Recovery: —               
Throughput: — 
[221] 
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for understanding the metastatic process [57, 64, 222].  
 While the CellSearch system represented a breakthrough in CTC separation 
technology both in principle and clinical applications but it is ultimately dependent on 
magnetic bead staining, fluorescent molecular labeling, and imaging. This method of 
processing requires sophisticated equipment, multistep processes, technician specialist 
and time, resulting in high operation cost and therefore limited application in real-
patient situations. Meanwhile great number of cells are lost as part of this multi-
processing technique limiting sample purity, sensitivity, and the final yield of the 
device [45]. Likewise, other commercially available techniques that are not yet FDA 
approved suffer from similar downsides. Methods utilized in bulk of these detection 
techniques employ molecular biology technology integrating labeling step and 
subsequent optical imaging step to detect target molecules. Therefore they also suffer 
from the same or similar downsides as the CellSearch system. 
 Labels are molecules that specifically bind to another molecule, i.e. antibodies, 
aptamers. These targeting molecules are tagged with dye or other indicator such as 
fluorescent dyes, enzymes, and quantum dots [223]. Labeling systems typically require 
extensive sample preparation and sophisticated optical imaging devices. Therefore 
label-free techniques are of great interest. Label-free systems that can match the high 
accuracy of existing standard molecular labeling technology have the potential to 
significantly lower the cost and complexity of these systems, thus increasing the 
accessibility. 
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 The ideal CTC isolation technology should be sufficiently versatile to capture a 
heterogeneous population of cells. This requires high specificity, sensitivity, portability, 
and small size for clinical setting and point-of-care testing. Further, the ideal CTC 
detector should be gentle to ensure cell viability, able to capture and count the number 
of CTC at a rapid pace (<1 hour) with high throughput, consume only a small volume 
of blood and have minimum sample preparation or purification steps.  To minimize the 
loss of CTC and to increase yield, it is important that such platform avoids enrichment 
steps. Finally, the ideal CTC platform should also have inexpensive, simple, and 
repeatable fabrication process, have the ability to interpret biological information such 
as different types of biomarkers, genetic mutations in tumor DNA, and any other 
information that reflects the biological process occurring during metastasis. 
Considering all of the above, the development of the ideal CTC platform is far from 
reality and more work in this field is needed to satisfy the true clinical needs for CTC 
detection. Nanotechnology and nanoscale engineering is projected to impact this field 
significantly and overcome current limitations associated with CTC capture and 
analysis. Small size of nanoparticles and their high surface-area-to-volume ratio 
provides the capacity to address the problems of insufficient capture efficiency and low 
purity [199].   
 Nanomaterials such as carbon nanotubes, graphene oxide, nanopillars, and 
nanowires can be manufactured to a high degree of precision by advance 
microfabrication technologies (i.e. photolithography, ion etching, and chemical vapor 
deposition) and modified by customized chemistries, such as pyrenebutanoic acid, 
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succinimidyl ester (PASE) affinity to carbon nanotubes though pie stacking, to fit 
desired applications. Their simple incorporation with microfluidics to facilitate 
prototyping is also of great advantage. As it advances, the field of nanotechnology is 
projected to be the future of rare cell separation [224].  
 In general, the objective of this dissertation is to investigate a novel carbon 
nanotube micro-array device based on ultra-thin CNT films for label-free sensing of 
proteins, and capture and discrimination of CTCs.  
 We begin in Chapter 2 with an overview of the physical properties of carbon 
nanotubes. We describe the structure of nanotubes and methods for fabricating 
them. We then provide background into the carbon nanotube field effect 
transistors and their utilization as sensing tools. Lastly, we reviewed existing 
carbon nanotube based approaches for sensing and their biological applications. 
 Chapter 3 details our approach for developing a platform of carbon nanotube 
micro-arrays based on ultra-thin films using a very cost effective simple 
method. We begin with characterizing the nanotubes utilized for this purpose, 
studying their physical and electrical properties. Next, we discuss the methods 
behind fabrication and characterization of CNT ultra-thin films and micro-array 
devices. Finally, we describe our measurement setup for collecting 
characterization data and electrical measurements presented here and in the next 
chapters.  
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 In Chapter 4, we describe a unique approach for non-covalent functionalization 
of CNT surface. We demonstrate our ability to functionalize the surface of the 
nanotubes with proteins, such as antibodies, and capture nanoparticles on the 
surface of the CNT using the proposed functionalization technique. 
Furthermore, we characterize the sensing capabilities of our CNT micro-array 
devices described in Chapter 3 and their response to ionic charges.  
 In Chapter 5, we investigate the application of nanotube devices for digital 
profiling of cancer biomarker. Showing proof of concept for label-free detection 
of targeted biomarker, further validating the successful functionalization 
protocol developed in Chapter 4 and biosensing capabilities of our CNT 
devices. Here we also discuss the factors behind the change in electrical 
properties of a CNT device due to protein/analyte interaction with the 
nanotubes. 
 Chapter 6 presents the ability to improve upon the sensing capabilities of our 
CNT devices by utilizing an aptamer molecule instead of an antibody as part of 
CNT surface functionalization and targeting antigens. Aptamers, with their 
smaller molecular structure and higher affinity present a promising potential to 
improve biosensors, closing the Debye length. The ultrasensitive 1 pg/mL label-
free sensing of IL-6 biomarker molecule is showcased as an example of 
aptamers based sensing capabilities on our platform. In conclusion, we discuss 
our decision to elect antibody platform for cell capture studies due to 
availability and robustness.  
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 In Chapter 7, we for the first time demonstrate using CNT ultra-thin film micro-
array devices for capture and digital profiling of cancer cells. Here, we present 
the ability to capture and profile spiked circulating tumor cells in phosphate 
buffered saline on nanotube devices utilizing label-free techniques. This is done 
by targeting HER-2 and EpCAM receptors on SKBR-3 and MCF-7 cells using 
antibody molecule functionalized CNTs. 
 Additionally, in Chapter 8 we demonstrates label-free capture of breast cancer 
cells spiked in buffy coats using carbon nanotube micro-arrays. We demonstrate 
identifying the captured cells on the device using immunofluorescence confocal 
microscopy. We also, present a novel classifier based on dynamic time warping 
statistical analysis to distinguish specific vs. non-specific interaction of captured 
cells on the device with great statistical confidence, based on the electrical 
signal captured from the device.    
 In Chapter 9, we further investigate the clinical utility of our CNT device. Here, 
we examine the interaction between carbon nanotube devices and living spiked 
cancer cells in whole blood. In our initial observation, in which 170 devices are 
tested with 4 specific and 13 nonspecific control groups, the specific interaction 
present an increase in device signal, conductance. When plain blood or non-
cancerous cell spiked blood is injected on the device, however, we observe no 
change or decrease in the device conductance. Following up, we utilized the 
statistical classifier discussed in Chapter 8 and observed a significant difference 
between SKBR-3, cancerous, spiked blood samples from plain and MCF-10A, 
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non-cancerous, spiked blood’s electrical signal, targeted by HER-2 antibody. 
Additionally, using optical imaging and image analysis, we present capturing all 
spiked cells, relative to device geometry, and their geometrical properties. For 
the first time, we report a unique arrangement of blood cells and spiked cells on 
the CNT device as part of the sample droplet image analysis, showing direct 
contact between spiked cancer cells and the CNT device surface. Using 
confocal microscopy and immunofluorescent technique, we identified captured 
CTCs on the surface of the device after end of testing. Finally, we discuss the 
possible origins of this signal, as well as questions about this interaction that 
remains to be answered. 
 Chapter 10 concludes the dissertation, here we summarize the results in this 
thesis and provide several suggestions regarding future direction of this work. 
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CHAPTER 2 
BACKGROUND  
 
2.1. CARBON NANOTUBES (CNT) 
 In 1991, Iijima for the first time reported carbon nanotubes when he discovered 
multi-walled carbon nanotubes (MWNTs) in carbon-soot made by an arc-discharge 
evaporation method at Fundamental Research Laboratories (NEC Corp.) [225]. Two 
years later in 1993, he observed single-walled nanotubes (SWNTs) [226]. Since then, 
carbon nanotubes (CNT) have become one of the most actively researched materials, 
opening whole new fields of study in physics, chemistry and materials science. CNTs 
possess a unique combination of properties, such as small size (1-50 nm diameter and 
length of up to several mm) [227], low density (similar to graphene), high stiffness, 
high strength, and a broad range of electronic properties from metallic to p- & n-type 
semiconducting [228]. In the past quarter century, a significant amount of work has 
been done to reveal the unique structure, mechanical, electrical, electro-mechanical and 
chemical properties of CNT and its potential applications in electronics, sensing, and 
actuating to name a few [229]. Such applications include electron sources in field 
emission displays [230], reinforcing elements in high-strength composites [231], small 
X-ray sources, ultra-sharp and resistant local probes [232], components of future 
nanoscale electronics [233],  gas sensors [234], and biosensors [235]. 
 Carbon nanotubes (CNT), more specifically SWNT, are the basic form of a 
graphene sheet rolled over into a cylinder, Figure 12. Typically, SWNTs have diameter 
of 1-2 nm. This narrow diameter distribution, results in SWNTs to often bundle up in 
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form of crystalline ‘ropes’ in which single tubes are held together by van der Waals 
interaction [236]. On the other hand MWNT consist of multilayer cylinders with an 
interlayer spacing that can range from 3.42 Å to 3.75 Å, depending on the diameter and 
number of shells composing the tube [237]. As the interlayer spacing in graphite is 3.35 
Å, one can assume similar weak interaction between individual shells in MWNTs. 
Diameter of MWNTs are in the range of 10-50 nm [227]. The lengths of both types of 
CNTs, SWNTs and MWNTs, can be as short as few hundred nanometers and as long as 
hundreds of microns or even centimeters [229]. 
2.1.1. MOLECULAR BOND STRUCTURE  
 CNT is a cylindrical molecule composed of carbon atoms in hexagon pattern 
that repeat itself periodically in space, Figure 12 (B). Each carbon atom is covalently 
bonded to its three neighboring carbon atoms. CNT’s structure is mainly due to the 
process of sp
2
 hybridization [238]. This structure is consisting of one s-orbital and two 
p-orbitals combined to form three hybrid sp
2
-orbitals at 120° to each other within a 
plane, Figure 13. This covalent bond is referred to as σ-bond and is a very strong 
chemical bond which plays a significant role in the remarkable mechanical properties 
of CNT. Additionally, π-bond is the out-of-plane bond that is relatively weaker than σ- 
bond but plays an important role in the interactions between SWNTs in bundles and the 
layers in MWNTs. It is important to note that the bonding in CNT is not purely sp
2
 
because of the curving the graphene sheet undergoes as it forms a tube resulting in re-
hybridization in the σ and π orbitals, yielding and admixture [239]. 
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Figure 12. Graphene lattice and construction of a carbon nanotube (CNT) and their 
band structure (A) honey comb structure of graphene lattice sheet, a CNT can be 
constructed by rolling up a graphene sheet. The chiral vector Ch points from the origin 
to the point which is rolled up to the origin, here, Ch = 3a1 + 2a2, so this is known as an 
(n, m) = (3, 2) nanotube [228]. (B) shows an illustration of rolled up zigzag, arm-chair, 
and chiral single walled carbon nanotubes (SWNTs) [228]. (C) Rolling a graphene 
sheet into a nanotube quantizes the wave states perpendicular to the nanotube axis, 
resulting in 1-D slices through the 2-D band structure. Depending on the way the tube 
is rolled up, the results can be either a metallic or Semiconducting SWNT [240]. (D) 
The allowed electron states in a CNT are determined by the intersections between the 
allowed wavevectors and the graphene band structure, which, near the fermi energy, EF, 
is well-approximated by a series of cones [240].
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Figure 13. Schematic showing the basic hexagonal bonding structure on a graphene 
sheet. Carbon nuclei shown as filled circle, π-bonds are out-of-plane, and σ-bonds 
connect the carbon nuclei in-plane [239]. 
 
2.1.2. PRODUCTION OF CNT 
 Nanotubes are produced in several different ways. By generating and cooling 
down a carbon plasma between two graphitic electrodes in an inert atmosphere, one can 
produce high quality nanotubes [225]. Lasers can also be used to ablate a graphitic 
target to form carbon plasma [236]. Catalytic decomposition and chemical vapor 
deposition (CVD) are other methods used for producing nanotubes. Here, various 
hydrocarbons such as methane or acetylene mixed with nitrogen or hydrogen in the 
presence of catalysts are used [241]. The CVD approach is of an advantage for 
producing controlled nanoscale structures with integrated CNTs, because of the 
possibility of controlling the growth of nanotubes by patterning the catalyst on a base 
substrate, i.e. silicon wafer [242]. Additionally, this method is also capable of 
producing CNTs in industrial quantities [243]. However, the main disadvantage to 
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CVD method is the higher concentration of defects that affects CNTs stiffness [244] 
and tensile strength [245, 246]. 
2.1.3. CHIRALITY  
 Figure 12 shows the real-space lattice and reciprocal lattice of graphene, as well 
as the construction of a metallic and Semiconducting CNT and its band structure. 
Graphene sheet is folded to create CNT in multiple different fashions.  The real-space 
crystal is a two-dimensional honeycomb lattice of carbon atoms with lattice vectors 
𝑎1⃗⃗⃗⃗ =  (
𝑎√3
2
,
𝑎
2
) and 𝑎2⃗⃗⃗⃗ =  (
𝑎√3
2
, − 
𝑎
2
), where the lattice constant is a = 2.46 Å. As 
shown in Figure 12 (A), a (n, m) nanotube structure is obtain when a beginning and the 
end of a (n, m) lattice vector in the graphene plane join together, making each CNT to 
have uniquely defined chiral vector Ch, where Ch = na1 + ma2 [247]. The (n, m) indices 
at the back bone of the nanotubes determine its diameter and also its ‘chirality’. When 
the tubes are arranged in n = m or (m, m) fashion with the atoms around the 
circumference in an arm chair pattern they are called ‘arm-chair’ tubes, Figure 12 (A & 
B). “arm-chair” CNT is always metallic. On the other hand, (n, 0) nanotubes are called 
‘zigzag’ as they appear in their atomic configuration along the circumference on a side 
view, Figure 12 (A & B). The other types of nanotubes are referred to as chiral, with 
the rows of hexagons spiraling along the nanotube axes, Figure 12 (B). Zigzag and 
chiral CNTs can be either metallic or semiconducting depending on their (n, m) 
structure. 
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2.1.4. ELECTRICAL PROPERTIES AND BAND STRUCTURE 
 CNTs have very interesting electrical properties that originate from their core 
material, structure, and size. CNT are made of graphene which has high intrinsic 
electron mobility due to its lack of lattice defects as compared to most other 
semiconductor materials and its unique linear dispersion relation [248]. Small diameter 
of SWNTs results into quantization of electron wave vectors along the circumferences. 
The angle of orientation of the CNT’s lattice relative to its axis (known as the chiral 
angle) can determine its diameter and chirality, making it semiconducting (with a 
moderate bandgap around 0.5 eV, semiconductor, or a small bandgap around 0.01 eV, 
small-gap semiconductor) or metallic [249]. The electrical properties of both 
semiconducting and metallic CNTs can rival or exceed the best materials known [250].  
 SWNTs have impressive electrical performances, for example high quality 
SWNTs can have a mobility value larger than 10,000 cm
2
V
-1
S
-1
 and mean free path 
longer than 1 μm [251]. Additionally, nanotubes can have minimum capacitance 
coupling with gates when made into field effect transistors (FETs). As a result, 
researchers have demonstrated SWNT FETs operating at up to 50 GHz [252].  
 CNT is also a unique optoelectronic material due to the unique band structure 
and its one dimensionality. Onsets of subbands are a possibility as part of CNT’s 
electron density of states and a serious of singularities. Thereby, CNT can efficiently 
absorb lights of a wide spectrum as it is a semiconductor with multiple bandgaps [253, 
254]. Finally, the doping level of nanotubes can be modulated electrostatically with 
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high spatial resolution to generate electrons and holes at different regions unlike the 
chemical doping requirements in traditional semiconductor devices [255].  
 Since a CNT is a cylindrical graphene sheet, it has a very similar band gap 
structure to that of graphene. The band structure of graphene was first calculated by 
Wallace in 1947 using the tight-binding approximation, in which one assumes that 
interactions between carbon atoms only cause perturbations to electrons in atomic wave 
functions [256]. Later, Wallace’s calculations were improved by including the overlap 
of atomic wave functions of different atoms [247, 257] and also considering third-
nearest-neighbor interactions [258].   
  Graphene sheet itself is semimetallic with a zero band gap. In this case, 
conduction and valence bands touch each other on graphene sheet at the six corner 
points of the first Brillouin zone resulting in electrons filling the states at the highest 
energy (Fermi’s energy) [240], Figure 12 (D). Arm-chair (m, m) CNT are always 
metallic because the electronic states, parallel lines in k space continuous along the tube 
axis and quantized along the circumference, always cross the corner points of the first 
Brillouin zone, Figure 12. The (n, m) nanotubes with n – m ≠ 3 x integer, are 
semiconducting. The energy gap scales with the tube diameter as 1/d is on the order of 
0.5 eV for SWNT with typical diameter d = 1.4 nm. The energy gap for the 
semiconducting nanotubes is dependent on the diameter and can be calculated by the 
following equation: 
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𝐸𝑔𝑎𝑝 ≈
2𝛾0𝑎𝐶−𝐶
𝑑
 (1) 
where 𝛾0is the C-C tight-binding overlap energy, 𝛾0 ≈ 2.7 𝑒𝑉, [258] and 𝑎𝐶−𝐶 the 
nearest-neighbor C-C distance (0.142 nm) and 𝑑 the diameter [259]. Both Odom et al. 
[260] and Wildoer et al. [259] in 1998 experimentally verified the link between 
physical and electronic structure of CNTs using scanning tunneling microscopes 
(STMs) by measuring the chiral angle and diameter of individual SWNTs, allowing (n, 
m) to be determined. They also measured the electronic properties of each tube, 
including the band gaps of semiconducting nanotubes, and their results agreed with the 
theoretical equation presented above.  
 For n – m = 3 x integer, nanotube with electron states landing on the corner of 
the first Broulloin zone would be semimetals but depending on the diameter it can 
become small-gap semiconductors because their band gap scales with 1/d
2
 ~ 10 meV 
and d ~ 1.4 nm due to a curvature induced orbital rehybridization effect [257]. The 
band structure of nanotube is also modified by stain [261] and was experimentally 
confirmed by Minot et al. [262]. The band diagram becomes even more complicated 
when defects and interactions with a substrate are introduced. For sensing applications, 
however, the important fact is simply that nanotubes are semiconducting, and not the 
exact size of their band gap. 
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2.1.5. MECHANICAL PROPERTIES 
 CNTs are among the strongest and most resilient material known to exist in 
nature. The Young’s modulus of nanotubes is ~ 1TPa and is five times higher than that 
of steel [263]. The theoretical limit to the maximum tensile stress one material can 
sustain before failure is 130 GPa [264], for MWNTs this value was reported to be ~63 
GPa at its largest point [265]. One can compare this value to tensile strength of steel 
which is less than 1 GPa. At the same time, nanotubes are extremely light. Considering 
CNT’s extreme mechanical properties, there was even a proposal to build a space 
elevator using SWNT ribbons [266]. However, there are huge fundamental and 
practical challenges standing in the way of this project for the time being.  
 Mechanical properties of CNT discussed above, coupled with its electrical 
conductivity has inspired researchers to integrate SWNTs into nanoelectromechanical 
systems. For example, Sazonova and co-workers demonstrated an electrically actuated 
tunable oscillator using SWNTs [267]. There also have been efforts in the industry to 
take advantage of CNT’s unique properties; a company called Nantero is working 
toward commercializing large density and high speed random access memories based 
on suspended nanotubes that can be modulated by external voltages to switch between 
two states.  
2.1.6. CHEMICAL AND BIOLOGICAL PROPERTIES  
 CNTs are chemically stable and biologically compatible. This is due to the fact 
that they are chemically inert, especially when no defects are present. For example, 
studies have shown that SWNT FETs can operate in aqueous solutions [268, 269]. 
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SWNTs are extremely sensitive to environment because of their molecular-scale size 
and the fact that all the atoms in single wall carbon nanotube are oriented on its surface, 
therefore any change in the surface of these atoms can affect their electron transport 
properties. This makes SWNTs an ideal materials to make detectors that are capable to 
reach single-molecule level sensitivity [270, 271].  
 Potential applications of CNT are not just limited to sensors. On top of being 
chemically stable, SWNTs have large surface to volume ratio which has made them an 
interesting material as electrodes in electrochemistry research. SWNTs have been used 
as electrodes [272] or nucleate sites for nanoparticle growth [273]. The high surface 
area SWNTs are being researched as a candidate for hydrogen storage [274]. For 
biological applications, SWNTs have been used as drug delivery vehicles to bring 
chemicals into cells [275]. Even though there are concerns with toxicity of CNT but 
there have not been a great evidence of such concerns. In one study, Liu and co-
workers showed that injected SWNTs can be excreted out the bodies of mice within a 
couple months, during this time no toxic effects were observed in the subject mice 
[275]. 
2.1.7. PROPERTIES BASED ON SMALL SIZE AND DIAMETER  
 The small diameter of SWNTs is one of their big advantages. This is very useful 
for example with atomic force microscopy (AFM) as the lateral resolution is limited by 
the size of the scanning tip. Wong and co-workers attached a MWNT to a conventional 
AFM tip and used it to interact with sample surface in order to improve resolution 
capability of AFM [276]. Additionally, they chemically modified the end of a SWNT 
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tip with functional groups to do chemical force microscopy [277]. The small size of 
nanotubes makes it possible and easier to study chemical bindings between specifically 
one pair of receptor and target protein.  
 Electron emitters are another application utilizing the small size of nanotubes. 
SWNTs have a very small cross section, this enables electrical field around the tip to 
reach very high value when a potential is applied between SWNTs and the ground. 
Therefore electrons tunnel out due to high electrical field. This unique emission 
characteristic can be used to extract electrons to generate light at different wave lengths 
(i.e. visible light for television or very low wavelengths of light for applications in 
portable and high resolution X-ray machine) [278].  
 Here, we reviewed only a number of applications of nanotubes based on their 
unique characteristics. One can imagine number of more potential applications for 
SWNT as researchers are still exploring different possible applications in different 
fields.  
2.2. CARBON NANOTUBE FIELD EFFECT TRANSISTORS (CNT-FET) 
 The first reported semiconducting SWNT based transistor was fabricated by 
Tans et al. in 1998. This device had a similar geometry as the CNT-FET device 
illustrated in Figure 14. The CNT bridges two metal electrodes, referred to as source 
and drain in transistor terminology. CNT conductance can be determined by applying a 
small voltage bias (VDS) across the nanotube and measuring the resulting current (IDS). 
CNT is laid on a dielectric surface, such as SiO2, separating it from a conducting back 
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gate, like doped silicon substrate. Within such geometry, one can measure the 
conductance of a semiconducting CNT as a function of voltage applied to the back gate 
(VG), Figure 14 (B). CNT stays well conductive at low VG and shuts off at high VG. 
Threshold voltage of a transistor device is referred to as a voltage at which the 
transistor turns off; in this case it is around 5 V.  
 This behavior can be understood by looking at the band diagram for a 
semiconducting CNT, Figure 14 (C). The conductance of a semiconducting CNT at a 
given gate voltage is dependent on two main factors, one is the positon of the Fermi 
level at the contacts, and two its position for the bulk of the nanotube.  
 The metal contact’s work function is the main determinant of the Fermi level at 
the contacts. Gold, palladium, or platinum are the main metals used for contacts, the 
Fermi level typically lies below the valence band end for these metals, causing p-type 
conduction at VG = 0 through the unoccupied valence states, as shown in the middle 
panel of Figure 14 (C). Different techniques are used to promote n-type transistor 
behavior at VG = 0, such as contacting the CNT with a material like calcium that has a 
lower work function than the nanotubes [279]. It is important to note that the p-type 
behavior at VG = 0 is also related to the adsorbed oxygen on the CNT when exposed to 
air and the charges on the oxide surface, therefore annealing the device in vacuum to 
remove the oxygen will also result in n-type transistor behavior [280]. 
 The Fermi level position for the bulk of CNT is determined by the applied 
voltage gate. Electrons are pushed away from the CNT and into the contacts as the gate
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Figure 14. Schematic of a typical carbon nanotube field-effect transistor (CNT-FET). 
(A) side view of a back-gated CNT-FET. Metal electrodes are contacted on either end 
of the CNT, allowing one to apply a source-drain voltage bias VDS across it and to 
measure its conductance as a function of the back gate voltage VG. The CNT is 
insulated from the gate by a dielectric material, typically SiO2. (B) Conduction of a 
semiconducting CNT as a function of gate voltage (VG). (C) Band diagram of CNT for 
different gate voltages (marked with red dots in the IDS vs. VG curve (B)) as a function 
of position along the nanotube axis. At VG = -8 V, the Fermi level is deeper in the 
valence band, therefore allowing for higher conduction. At VG = 0 V, the Fermi level 
typically lies below the valence band edge due to the work function of the metal 
contact, as a result CNT is conducting. At VG = 12 V, the Fermi level lies in the band 
gap, in this case turning the transistor off.  
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voltage is decreased; this is due to Fermi energy going deeper into the valence band 
(unless the voltage is screened by the metal contacts), thus increasing conduction, as 
shown in the left panel of Figure 14 (C).  
 The Fermi level can be raised into the conduction band if the gate voltage is 
raided high enough, VG > 15 V for the device in Figure 14, and conduction can take 
place when electrons tunnel from the valence band at the contacts to these conduction 
band states. This is even more apparent with MWNTs as the inner tubes are not 
affected with oxygen in the air and preserve their n-type nature. As the result of the 
tunnel barrier, the p-type conduction at low VG is larger than n-type conduction at high 
VG. This n-type conduction in air was rarely observed for the devices prepared for the 
experiments in this thesis as SWNT were used for the majority of the work presented. It 
is important to note that the n-type conductance effect was observed sometimes when 
electrolyte solution gating was applied, we will discuss this effect later in this chapter 
when investigate electrolyte-gated CNT-FET.  
 Capacitance between the CNT and the gate can be employed to determine the 
number of electrons added to the CNT for a given VG. The capacitance consists of two 
main components: CE, the classical electrostatic capacitance between CNT and the gate 
which depends on the geometry and dielectric properties between the CNT and the 
gate, and CQ, which depends on the CNT density of states, this is dependent on some 
energy that is required to add an electron to the next available state in the CNT. One 
can ignore the quantum capacitance of the back gate by approximating it as a perfect 
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metal. In this case the total capacitance would be the series combination of those 
components, eqn. 2, so the CNT charging is dominated by smaller capacitance.  
 𝐶 = (𝐶𝑄
−1 + 𝐶𝐸
−1)−1 (2) 
For example, a CNT separated from a back gate by a 200 nm thick SiO2 layer, with a 
dielectric constant K = 4, has a electrostatic capacitance per length of CE ≈ 3 X 10
-17
 
F/μm, on the other hand the quantum capacitance can be estimated as CQ ≈ 4 X 10
-16
 
F/μm, as one can see the electrostatic capacitance will dominate the total capacitance 
[281].  
2.2.1. ELECTROLYTE-GATED CNT-FET 
 Electrolyte-gated CNT-FET enables studying CNT with biochemical systems 
based in solution. In 2000, Kruger and co-workers first showed the MWNTs can be 
used as FET in an electrolyte environment [268]. Later in 2002, Rosenblatt et al. 
demonstrated the same results for SWNTs [269]. These researchers illustrated gating 
the CNT-FET devices through a wire placed in the solution instead of gating the CNT 
by applying a voltage to a back gate. Schematic in Figure 15 illustrates this setup.  
 To better understand this set up we first need to become more familiar with the 
properties of electrolyte solution and its electrical characteristics. 
2.2.1.1. ELECTROLYTE SOLUTION PROPERTIES 
 To best understand the electrical processes that occur in solution, one must have 
a thorough understanding of chemistry and chemical reactions covering topics such as 
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electrochemistry, physical chemistry, and interfacial science. For detailed introduction 
to these topics, the reader is directed to references such as Bard and Faulkner (2001) 
[282], and Harned and Owen (1958) [283]. However, here we will summarize and 
reduce these topics as much as possible and focus on the details more fundamental to 
the scope of this thesis. 
 Conducting solutions or electrolytes include a wide range of constituent ions 
and solvents. Aqueous electrolytes were the main focus for the works in this thesis, 
most commonly Phosphate-buffered saline (PBS), which consist of NaCl (137 
mmol/L), KCl (2.7 mmol/L), Na2HPO4 (10 mmol/L), and KH2PO4 (1.8  mmol/L) [284]. 
NaCl is the most dominant component in these electrolyte solutions. NaCL in a solid 
crystal form does not conduct electricity, but when dissolved in water it separates into 
Na
+
 and Cl
-
 ions as the polar water molecules surround each element and break their 
ionic bonds. The dissolving of NaCl in water produces ions with charge ±1 or 
otherwise known as 1:1 salt. Charged ions floating around, enables NaCl solution to 
conduct electricity just like a metal with free electrons.  
 The resistivity of a bulk electrolyte can generally be used to approximate its 
electrical properties [285]. The concentration of conducting ions plays a big role in the 
solutions conductivity, for example, 1 mM NaCl has ρ = 81 Ω.m while 100 mM NaCl 
solution has ρ = 0.9 Ω.m. The equivalent conductivity (Λ), with units of m2/ Ω.mol, for 
a variety of electrolytes is provided in the “CRC Handbook of Chemistry and Physics”. 
Therefore, the conductivity can be expressed as σ = Λ.𝑐0, where the resistivity is ρ = 
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Figure 15. Schematic of an electrolyte-gated CNT-FET. Similar to Figure 14, CNT is 
contacted by metal electrodes (Ni/Au) on each side, allowing one to take conductance 
measurements. The gate voltage VG is applied by a wire (i.e. Ag/AgCl reference) that is 
in contact with the electrolyte solution (i.e. ionic buffer solution). The voltage applied 
affects the CNT via ions in the electrolyte solution. For example, if voltage is applied to 
make the wire positively charged, the negative ions will get attracted to form a double 
layer. SU-8 polymer layer acts as an insulator to separate the charges in the electrolyte 
solution from the contacts, therefore only directly gating the CNT.
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1/σ and 𝑐0 is the bulk salt concentration. For example, NaCl (0.5-100 mM) the Λ = 
107-126 x 10
-4 
m
2/ Ω.mol, and for most other solutions the Λ ≈ 100 x 10
-4 
m
2/ Ω.mol, 
ranging from 50-425 x 10
-4 
m
2/ Ω.mol [286]. Due to similarity of Λ in most electrolyte 
solutions used in this thesis, we can estimate the resistivity using the following 
equation: 
 ρ ≈  
100
𝑐0[𝑚𝑀]
 𝛺.𝑚.  (3) 
In this case we can continue using the length l and cross-section A to estimate the 
resistance of a section of solution, Rsoln = ρl /A. 
2.2.1.2. MODEL OF ELECTROLYTE-GATED CNT  
 There have been different approaches to model electrolyte-gated CNT and its 
response to the environment [287-289]. McEuen and co-workers, came up with a model 
based on the ratio of the oxidized to reduced molecules ([Ox]/[Red]), i.e. potassium and 
sodium ferrocyanide respectively [288]. They developed a quantitative model to 
understand the expected threshold voltage shift of the CNT-FET response by utilizing 
Nernst equation, which gives the chemical potential of the electrons in a solution of 
redox-active molecules with formal potential E
0
 as: 
 µ𝑖
𝑒
= 𝐸0′ +
𝑘𝑇
𝑛𝑒
 𝐼𝑛
[𝑂𝑥]
[𝑅𝑒𝑑]
 (4) 
where k is Boltzmann’s constant, T is the temperature, n is the number of electrons 
transferred, and e is the electron charge. Then by substituting this expression into:  
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 µ𝑖 = 𝑞𝜑 + µ𝑖 (5) 
where µ𝑖 is the electrochemical potential, which is the electrostatic (𝜑) and chemical 
(µ𝑖) potentials. This integration expresses the voltage, VG, applied to the gold 
electrolyte-gate wire as: 
 
𝑉𝐺 = 
µ𝑖
𝑒
= 𝜑 + [𝐸0
′
+
𝑘𝑇
𝑛𝑒
 𝐼𝑛
[𝑂𝑥]
[𝑅𝑒𝑑]
] (6) 
In this case, if the nanotube behaves as a reference electrode and senses only the 
electrostatic potential, 𝜑, then the shift in the threshold voltage, △ 𝑉𝑡ℎ, is the change in 
𝑉𝐺  needed to produce the same 𝜑, which is just the change in µ𝑖/e. In this case, n is 
fixed at 1, therefore, the expected threshold voltage shift is written as: 
 
△ 𝑉𝑡ℎ = △ 𝐸
0′ + (59.2 𝑚𝑉) 𝑙𝑜𝑔 [
[𝑂𝑥]
[𝑅𝑒𝑑]
] (7) 
 It was concluded that oxide molecules, i.e. potassium ferricyanide, result in a 
positive shift in threshold voltage, Vth, and redox molecules, i.e. sodium ferricyanide, 
cause a negative shift in the threshold voltage, Vth. 
2.3. CARBON NANOTUBES (CNT) FOR SENSING AND BIOLOGICAL 
APPLICATIONS 
 SWNTs are exclusively consist of surface atoms as part of their impressive 
electrical properties making them very sensitive to adsorbents [234, 290]. The 
sensitivity of CNT to adsorbents has been advantageous for sensing applications. 
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Electrical changes in CNT can be evaluated in resistor, transistor, or capacitor 
structures. As a result, SWNTs have been incorporated as sensing elements for various 
types of molecules, such as toxic chemical vapors and bio-macromolecules [270, 291-
293]. The surface modification and treatment of CNT, covalently or non-covalently, 
has enabled targeting specific free molecules and even proteins on surface of cell 
membranes, receptors [133, 294, 295]. Here we will review number of works that used 
CNT for applications such as gas sensing, biosensing, and capturing/tagging of 
molecular complexes.  
2.3.1. CNT FOR GAS SENSING 
 In 2000, Kong et al. for the first time demonstrated nanotube sensing 
experiment in Hongjie Dai’s Stanford laboratory. In this experiment they exposed a 
back-gated nanotube transistor to NO2 gas and observed an increase in threshold 
voltage △ 𝑉𝑡ℎ ≈  4 𝑉, while exposure to NH3 caused a decrease in threshold voltage 
△ 𝑉𝑡ℎ ≈ −4 𝑉, Figure 16 [290]. In summary, a non-functionalized semiconducting 
SWNT exposure to gases causes the entire IDS vs. VG response curve to be translated 
with respect to VG, which was described as a shift in the threshold voltage of the 
device. This change in the case for NO2 is due to the fact that NO2 is a strong oxidizer, 
attributing to the increase in threshold voltage and charge transfer from the CNT to 
NO2 molecules, or in other words p-doping the CNT. On the other hand, NH3 has a long 
electron pair that it can donate, n-doping the CNT. However, based on their density-
functional theory calculations they showed no affinity between NH3 molecules and the  
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Figure 16. Chemical gating effects to the semiconducting SWNT by gaseous NH2 and 
NO2. Each gas causes a large threshold voltage shift in the IDS vs. VG curve. The 
measurements with these gases were carried out successively after sample recovery 
[290]. 
 
CNT, therefore they suggest that it is indirectly affecting the CNT through the SiO2 
substrate or through preadsorbed oxygen on the CNT.  
 Similar n-doping effects from other amine compounds was again observed by 
Kong and Dai [296]. Bradley from Nanomix Inc., confirmed the previous results. Here, 
he used CNT devices in which the metal contacts were covered with SiO2 and showed 
that the effect is not related to these contacts [297]. Using the previous result, Liu et al. 
modulated the band structure of SWNTs spatially by covering parts of the CNT and 
letting the exposed area be doped by gaseous NO2 or NH3 [298]. Later, Novak et al. 
showed an application of this sensing mechanism by demonstrating the ability to 
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specifically detect dimethyl methyl phosphonate (DMMP), an electron donor similar to 
the nerve agent gas sarin, by coating the CNT with a chemoselective polymer film 
[299]. With this device, he observed a shift in the threshold voltage △ 𝑽𝒕𝒉 ≈ −𝟐 𝑽. 
 Additionally, electronic properties of bare CNTs have shown extreme 
sensitivity to oxygen. In ultrahigh vacuum, CNTs are n-type, but they become p-type 
when in air or in pure oxygen environments [234]. Initially, this was ascribed to charge 
transfer from CNT to adsorbed O2, but Cui and co-workers later suggested that the O2 
instead changes the energy alignment at the metal-nanotube contacts [300].  
 A shift in CNT’s voltage threshold was also shown in response to alcohol 
vapors such as ethanol [301]. Later Snow and his colleagues demonstrated kind of CNT 
vapor sensing experiment that looks at the change in the capacitance between the CNT 
and the silicon back gate, instead of just studying the conductance response.  Here they 
reported 10-100 times larger change in capacitance than the corresponding change in 
conductance, when CNT was exposed to most vapor [302]. As part of these studies, 
they concluded that the adsorbed gas molecules form a polarizable layer that increases 
the nanotube capacitance which scales roughly with molecular dipole moment [303]. 
They additionally reported that the change in signal is dominated by adsorption at 
defect sites and they can increase sensitivity by introducing defects by controlled 
oxidation [304]. 
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2.3.2. CNT FOR BIOSENSING 
 The promising studies using CNT for sensing gaseous molecules has led the 
researchers to further investigate the potential and application of CNT for sensing other 
molecules. The majority of these efforts have focused on biological sensing 
applications to potentially optimizing existing sensors, making them fast, low cost, and 
sensitive using CNT technology. Biosensing techniques are currently dominated with 
complex and multiple processes involving optical detection, techniques using only 
electrical measurements are presenting to be a great alternative overcoming many of the 
current challenges.    
 CNTs have comparable dimeter, size, and carrier density to the size and surface-
charge density of bio-macromolecules, therefore chem-resistor or transistor structures 
based on CNTs can be utilized as ultrasensitive transducers in biosensors [293, 305-
307]. Biomolecules, such as proteins and DNA, can bind to the surfaces of SWNTs by 
π-π stacking, hydrophobic interactions, and even amino-affinity of CNTs to alter the 
conductance of CNT thin films [308]. This opens the possibilities for CNTs to present 
themselves as efficient material for label-free detection of biomolecules [309, 310]. 
Additionally due to these same properties, CNT’s surface can be functionalized with 
organic and biomolecules (i.e. linker molecules with antibodies) for more specific 
interaction with target biomolecules and proteins [270, 311]. Utilizing such strategies, 
CNTs have been used to detect different biomolecules, such as DNA, proteins, 
enzymes, and neurotransmitters [293]. 
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 Koehne et al. demonstrated detection of DNA targets using aligned MWNTs in 
low-density nanoelectrodes within SiO2 matrix [312].  MWNTs forming glassy carbon 
electrode were also used for enhanced detection of DNA hybridization [313]. In 
addition, SWNTs DNA sensor based on conductance change was also developed based 
on hybridization of DNA conducting onto gold electrodes [314], Figure 17. 
 Kim et al. demonstrated detecting target prostate specific antigens (PSA) 
protein, a common biomarker for prostate cancer, by linking PSA antibodies to a 
SWNT-FET, Figure 18 (A). They were able to increase the sensitivity of the device by 
putting spacer molecules between the covalent linkers that were bound to antibodies, by 
decreasing surface coverage. The extra space between antibodies allowed for more 
flexibility so the interaction could occur within the Debye length. Yu et al. also showed 
CNT based method for PSA detection. He demonstrated multi-label strategy using 
secondary antibodies attached to MWNTs and horseradish peroxide (HRP) labels for 
sensitive detection of PSA, Figure 18 (B) [315]. Here, SWNTs forest with PSA 
antigens attached to them were assembled on a conductive substrate. Sandwich 
immunoassay in form of capturing PSA antigens by the primary and secondary 
antibodies were measured by adding a mediator and hydrogen peroxide to activate the 
peroxidase cycle that resulted in increasing current under constant voltage. Bovine 
serum albumin (BSA) and Tween-20 were used to control nonspecific binding by 
blocking the immunosensor during signal amplification step. 1-(3-(dimethylamino) - 
propyl)-3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysulfosuccinimide
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Figure 17. CNT DNA sensor and sensing mechanism, (a) optical image of the central 
region of a single sensor chip with four SWNT devices (scale bar 200 µm). (b) 
Schematic illustration of a single device during electrical measurement. 
Complementary ssDNA oligos hybridize to thiolated ssDNA coimmobilized with 
mercaptohexonal (MCH) on the gold electrodes. Real-time monitoring of 15mer (c) and 
30mer (d) DNA hybridization in PBS, pH 7.4, is shown. The conductance of a 
nanotube device functionalized with thiolated ssDNA exhibits selective response to the 
addition of complementary ssDNA showing decrease in conductance at the time of 
sample addition [314]. 
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Figure 18. (A1) Schematic diagram of a CNT-FET for protein detection. Antibody is 
bound to the CNT and binding to the target electrostatically gates the transistor, causing 
a change in conductance of the CNT. (A2) The electrochemical signal, plotted as 
normalized conductance, is shown when different concentrations of prostate specific 
antigen (PSA) are introduced to the device (arrow). Concentrations as low as 1ngmL
−1
 
can be detected [316]. (B) Immunoassay detection principle using CNTs to immobilize 
multiple labels and secondary antibodies for signal amplification. HRP catalyzes H2O2 
and generates electrons for amperometric based measurement. (B1) conventional single 
HRP labeled secondary antibody (B2) multiple HRP and secondary antibody on carbon 
nanotube for signal amplification [315]
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(NHSS) were used here to link and attach the primary and secondary antibodies on the 
CNTs through amide bonding. 
 CNT has also been utilized for sensing enzymes. In one example, Yang et al. 
fabricated an enzyme sensor on an electrode where aligned CNT were grown [317]. 
Platinum (Pt) nanoparticles were used on CNT electrode and chitosan-cadmium sulfide 
quantum dots were used to immobilize glucose oxidase (GOx) on the top. 
Oxidation/reduction peaks were observed only when Pt nanoparticles were present with 
a detection limit around 50 μM. Dekker’s group developed an enzyme-coated CNT 
platform as single molecule biosensor [270], Figure 19 (A). They demonstrated the use 
of individual semiconducting SWNTs as versatile biosensors. Linking molecule was 
used to attach GOx to the CNT sidewall. Enzyme coated CNT acted as a pH sensor 
with large and reversible changes in conductance upon changes in pH. This device 
showed a step like response that can be monitored in real time as glucose is added to 
the substrate of GOx, suggesting the capability of measuring enzymatic activity at the 
level of single nanotube.  
 Additionally, CNT-immunosensors have shown to be able to trap whole cells by 
targeting known proteins on the cell membrane.  Panchapakesan et al. used SWNTs 
interconnects between patterned metal electrodes for the detection of live breast cancer 
cells. When the cells were captured by the specific antibodies on the SWNTs a decrease 
in conductance was detected. A small change in conductance was observed for control 
cells, but the cancer cells produced a larger decrease [295]. However, exclusion of non-
specific binding will need to be improved. In another study, CNT-FET approach was  
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Figure 19. (A) Top panel shows a schematic picture of two electrodes connecting a 
semiconducting SWNT with GOx enzymes immobilized on its surface. (A) Bottom 
panel shows real time electronic response of the glucose, the substrate of GOx. Milli-Q 
water sample was added to the liquid at 100 sec (red arrow), and at 200 sec 0.1 mM 
glucose in milli-Q water was added to the liquid (blue arrow). The conductance of the 
GOx-coated SWNT is observed to increase upon addition of glucose to the liquid. Inset 
(a) shows the same measurement on a second device where the conductance was a 
factor of 10 lower. Inset (b) displays the same measurement on a semiconducting 
SWNT without GOx. As expected, no conductance increase is observed here [270]. (B) 
Shows the cell detection by metal-cluster-decorated CNT biosensor. The normalize 
conductance plot here shows the change in signal during exposure to A. 
anophagefferen. The insert at top is an optical image of A. anophagefferens. The inset 
at the middle shows a schematic illustrations of cells on the devices with metal-clusters 
[318].  
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used for cell detection. Here, CNTs were decorated with metal cluster and then metal 
electrodes were deposited [318], Figure 19 (B). The device was functionalized with 
monoclonal antibodies for A. anophagefferens, an alga cell, and a change in gate 
conductance was detected when the algae cells bound to the surface of the device, cells 
could be detected at concentrations of 10
4
 cells mL
-1
 with time response of 10 s. Here 
also, the non-specific binding remains the biggest limitation.  
 In a different approach, the Wang group sensed cancer cells by detecting 
differences in ferricyanide detection after adsorption of cells [319]. Their electrode was 
a TiO2/MWNT paste that was applied to a carbon paper electrode. Surprisingly, a 10-
fold higher signal for ferricyanide was observed at the electrode after leukemia cells 
were bound. The enhancement was attributed to ferricyanide being attracted to the 
hydrophilic cells whereas it may have been repelled by the hydrophobic TiO2/MWNT 
surface. However, no non-cancerous or other types of cancerous cells were tested, so it 
is not known if this technique is really selective for specific cancer cells. Without a 
molecular recognition element, it is doubtful that a simple adsorption experiment would 
be able to selectively detect only cancer cells. 
2.3.3. CNT FOR OTHER BIOLOGICAL APPLICATION 
 CNT has also been used for non-sensing biological applications, such as drug 
delivery, and cancer targeting and therapeutics [294, 320-322].  
 Liu et al. introduced functionalization of SWNT by chemically partitioning the 
surface of nanotubes to attach various species non-covalently for potential drug 
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delivery applications [320]. To obtain aqueous soluble SWNTs, nanotubes were first 
functionalized with PEG derivatives. The unoccupied sites on the prefunctionalized 
SWNTs were used to bind with cancer chemotherapy drug, doxoyrubicin (DOX). 
Release of DOX drug was also studied by varying the pH for controlled delivery of 
molecules bound on CNTs. 
 Xiao et al. utilized SWNTs to develop an antibody-CNT complex for detection 
and destruction of cancer cells, using two unique optical properties of CNT (strong 
Raman signal and near-infrared (NIR) absorbance), in an in vitro model consisting of 
HER-2-expressing SKBR-3 cells and HER-2-negative MCF-7 cells [321]. The anti-
HER-2 was covalently conjugated to carboxylated SWNTs and targeted at cancer cells. 
Raman spectroscopy showed significantly greater signal coming from HER-2-positive 
cancer cells vs. control HER-2-negative cells. NIR irradiation was performed at 808 nm 
wavelength for 2 min and results showed selective destruction of complex-treated 
breast cancer cells without harming receptor-free cells.  
 Shao et al. utilized SWNT functionalized with antibodies specific to breast 
cancer cells to carried out phototherapy [294]. SWNTs were selectively targeted at 
cancer cells through selective binding of antibodies specific to the cancer cells. 
Applying infrared photons at ~ 808 nm wavelength led to the destruction of these 
cancer cells due to the concentration of the SWNTs present at the site. In the case of 
non-specific antibodies treated with SWNTs, 80% of the cells remained alive. The 
SWNT and antibody conjugation was achieved through amide bonding using 1-
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pyrenebutanoyl succinimide. Polyethylene glycol was then used to insulate the surface 
of the SWNTs from nonspecific interactions. 
 CNTs have shown great promise for biological applications. In this thesis, we 
will utilize CNTs to develop a micro-array platform for biosensing and cancer cell 
capture applications based on SWNT ultra-thin films. 
2.3.4. DISCUSSION AND ANALYSIS  
 In this section we examined many examples of chemical and biological sensing 
with carbon nanotube transistors. These sensors are divided into two different device 
architectures, both utilizing carbon nanotubes that connect the source and drain 
electrodes, and have been developed and explored by various groups working in this 
area. In one device architecture, a single nanotube connects the source and the drain, 
example seen in Figure 19 (A). Such devices have been utilized for biosensing, and 
they offer excellent sensitivity [323]. There is, however, substantial variation between 
the different devices that are fabricated; such variation reflects the (geometry-
dependent) variation in the electronic characteristics of individual nanotubes as 
discussed earlier in this chapter, In addition, the interface between the nanotube and the 
metallic contact, Schottky barrier, may vary substantially from device to device. In 
alternative device architecture, the devices contain a random array of nanotubes 
functioning as a conducting channel, example seen in Figure 19 (B). Current flows 
along several conducting channels that determine the overall device resistance. In this 
configuration, the device operation depends upon the density of nanotubes. For a dense 
array, screening of the gate voltage by the conducting nanotube is important, in a 
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fashion similar to gate voltage screening due to a metal layer deposited on the device. 
For a rarified array, such screening is not significant and the array can serve as the 
source-to-drain conducting channel. It is expected that arrays close to and on the 
conducting side of the two-dimensional structure will have appropriate transistor 
characteristics. Under such circumstances screening effects are expected to be small, 
but conduction is still provided by the nanowire network. Therefore, ultra-thin single 
layer, continuous, conducting nanotube array network are of great interest. Devices 
with nanotube network conducting channels, while less sensitive than single nanotube 
devices, offer reproducibility and manufacturability. Due to the reproducible and 
manufacturable nature of carbon nanotube array network, we have elected this 
architecture containing a random array of nanotubes functioning as a conducting 
channel to fabricate our carbon nanotube micro-array devices for the purposes of this 
thesis. This also enables us to fabricate larger active nanotube array area suitable for 
cell capture, which would not be possible with single nanotube architecture. 
 In both device architectures, the parameter that is used for detection is 
dependent on the source-drain current, IDS (for a fixed source–drain voltage VDS and 
gate voltage VG). The change in conductance of nanotube or nanotube array as a result 
of analyte interaction can be explained in two general ways: the carrier mobility can be 
decreased, causing a suppression of conductance at all gate voltages, Gnew(VG) = 
Gold(VG)/a, or the carrier density can be changed, causing a shift in the conductance 
with respect to gate voltage, Gnew(VG + ΔVth) = Gold(VG) [307]. The former is 
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commonly seen in experiments with functionalized nanotube sensors, but almost all 
experiments with non-functionalized nanotubes result in the latter signal. 
  A change in carrier density in a nanotube can be caused either by electron 
transfer from the analyte to the nanotube or by capacitive gating, in which the analyte 
changes the local electric field [324].When a total charge Δq is transferred to the 
nanotube, it will cause a threshold voltage shift ΔVth given by Δq = CΔVth, where C is 
the combination of the electrostatic and quantum capacitances. In the second case, the 
analyte changes the carrier density not by directly transferring electrons to or from the 
nanotube, but by changing the electrostatic potential near the nanotube, which pulls 
more electrons onto the nanotube from the contacts (or vice versa); this effect changes 
the nanotube conductance in the same way as gating the transistor through a back gate 
or through the electrolyte, as discussed in Section 2.2. On the other hand change in 
carrier mobility is caused by potential scattering of charge carriers by the scattering 
potential created by analyte, reducing or increasing the carrier mobility thereby the 
conductance [307].  
 All of the experiments reported in this thesis, however, were performed with 
nanotubes lying on an SiO2 surface, and Artyukhin et al. [324] have shown that this 
complicates the capacitive gating signal, making it more difficult to originate the 
change in signal. However, we can still assume the change in CNT electrical property is 
a combination of change in carrier mobility and carrier density.  
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CHAPTER 3 
CHARACTERIZATION AND METHODS 
 
 In this chapter the design, fabrication and characterization of the CNT films, 
micro-arrays devices, and the testing platform setup will be reviewed in detail.  
 The fundamentals behind the design and fabrication methods will be reviewed 
as part of the three generations of the CNT device micro-arrays. This is consisting of 
fabrication and characterization of CNT thin films, explaining the vacuum filtration 
process and the protocol for generating an ultra-thin film. In regards to micro-array 
CNT devices, we will review device design parameters and microfabrication protocol. 
Next, we will present the characterization of physical (i.e. absorbance, transmittance, 
and Raman spectroscopy) and electrical (i.e. sheet resistance, mobility, on-off ratio) 
properties of CNT, thin films and micro-array devices. Here, we will review the effect 
of CNT film concentration, network density, on CNT device electrical property, 
utilizing percolation theory, and elect the working concentration for the objectives of 
this thesis. Finally, the testing platform on which the CNT devices were tested on will 
be described here. 
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3.1 CNT DEVICE DESIGN AND FABRICATION 
 The CNT devices are a simple two-terminal design at their core, with a carbon 
nanotube thin film network connecting the source and drain nickel-gold (Ni/Au) 
electrodes on each end, on top of a silicon/silicon-dioxide (Si/SiO2) substrate. The 
electrodes are then covered and insulated with a photoresist polymer, SU-8, as 
illustrated in Figure 20. The prototyping of a CNT device includes preparing a CNT 
thin film and transferring it on a silicon wafer substrate followed by multiple photo-
lithography and reactive ion etching steps as part of microfabrication process. In this 
section we will review this process from start to finish.  
 
 
Figure 20. Schematic of a basic structure of carbon nanotube (CNT) device after 
microfabrication process. CNT film bridging the two source and drain Ni/Au electrodes 
on top of a Si/SiO2 substrate. Source/drain electrodes are covered and insulate with a 
photoresist polymer later, SU-8. 
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3.1.1 VACUUM FILTRATION AND CNT-NETWORK FORMATION 
 The first step in the process of making a CNT device is assembling the carbon 
nanotube thin film network. In the last chapter we described why we have elected to 
fabricate our CNT micro-arrays using nanotube arrays instead of single nanotube 
architecture, as they are more reproducible, manufacturable, and allow for larger active 
CNT area suitable for cell capture. The ideal CNT array network would be made of 
purely semiconducting nanotubes with universal chirality. This would be consisting of 
defined number of aligned single wall carbon nanotubes connecting the source and 
drain electrodes, forming a single layer directionally aligned nanotube film. This ideal 
array of nanotubes would have all the CNTs exposed to the surface with zero 
underlying conductive channels.  This ideal CNT network would give the most 
reproducible and sensitive results. In an attempt to produce a nanotube array network 
closest to its ideal form, we have utilized vacuum filtration method which enables us to 
close down on many of these parameters, such as semiconducting nanotube purity, 
almost single layer film, and reproducibility as a function of CNT film mass. 
 Vacuum filtration is one of the most preferred methods for making macroscopic 
and transparent randomly oriented/highly aligned carbon nanotubes thin films and 
transistor devices [325].  The film can be formed by using stock solutions of known 
concentrations. Vacuum filtration of SWNT suspension creates a concentration gradient 
due to the fluid velocity across the membrane [326]. With appropriate bulk solution 
concentration and fluid velocity, one can form either isotropic or highly oriented 
nanotube films [326].  The CNT network is formed as the filtration action elevates 
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CNT concentration near the membrane [327, 328]. While vacuum filtration has been 
used, in general, to make randomly oriented bucky papers, recent work by our group 
has demonstrated the isotropic-nematic transition of semiconducting nanotube films at 
ultra-low concentrations than what was thought to be achievable [326]. These 
semiconducting nanotube films are finding applications as thin film transistors with 
high mobility and ON/OFF ratio’s [326], nanotube liquid crystal elastomer based light-
driven actuators [329] and as chemical and biological sensors as presented in this 
thesis. Our films were very low concentrations (1–6 μg) and most of our films were 
isotropic with 2–6 μg sample concentrations, partially transitioning into the nematic 
domains [326]. Also, the nanotube network in these films are mostly single layers 
laying on the substrate as shown in the scanning electron microscope (SEM) image in 
Figure 21 (D and E). 
 Based on the solvents used and CNT solution concentration, different network 
structures of nanotubes can be achieved, isotropic to highly oriented nematic, Figure 21 
(D and E). High weight percentage (5 x 10
-5 
wt-%) CNT solutions suspended in 
aqueous surfactant solutions can produce networks with nematic domains and at lower 
concentration (2 x 10
-6 
wt-%) uniform isotropic network of CNT forms [326]. In this 
research our interest is in the ultra-thin, single layer, continues isotropic 
semiconducting SWNT-networks. Our objective is to have a uniform conductive 
network that exposes all the nanotubes on the surface and minimizes the current flow of 
under layers. In this section we will review the protocol for making the optimum ultra-
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thin CNT film that has been used for the experiments of this thesis, unless specified 
otherwise.  
 To form a CNT thin network films, an in-house vacuum filtration system was 
used, Figure 21 (A). First a carbon nanotube source is acquired, in this case a 99% 
weight, IsoNanotubes-Semiconducting single wall carbon nanotube mixture was 
purchased from NanoIntegris Inc. (Menlo Park, CA). Nanotubes are listed at 1.2-1.7 
nm diameter (1.4 nm mean diameter) and 300 nm to 5 microns length (~1 µm mean 
length). Nanotubes were suspended in an aqueous surfactant solution at 0.01 mg mL
-1
 
and used as received. Dilutions of CNT suspension were prepared. For example, for 
preparing a 2 x 10
-6
 wt-% film, 200 µL of the stock solution, 2 µg of CNT, was added 
to 85 mL DI water and ~15 mL of 1% wt/v sodium dodecyl Sulfate (SDS) (sigma-
Aldrich, Cat. No. 436143) to achieve 2 μg/100 mL concentration. Prepared solution 
was sonicated for 15 minutes. The 100 ml solution is then vacuum filtered over a 
nitrocellulose membrane, 0.05 μm pore size and 90 mm diameter (Millipore, Cat. No. 
VMWP09025), then rinsed with 25 mL of isopropanol and 300 mL of water. This 
method self-regulates the deposition rate of nanotubes on the membrane to produce an 
evenly distributed network [326], Figure 21 (B). The network is then pressed onto a 4 
inch (100 mm diameter) silicon wafer, 500 µm thick, with dry oxidized layer (300 nm 
thickness), Purewafer Inc., for 30 minutes. Next the wafer is transferred onto an 
acetone vapor bath which dissolves the membrane, leaving behind the CNT film 
attached on the wafer. After this step CNT film transfers onto the Si wafer, Figure 21 
(C). Next the wafer with the film on top is rinsed in liquid acetone and methanol baths 
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Figure 21. CNT film fabrication process. (A) Vacuum filtration setup, (B) CNT stock 
solution before dilution, left side. CNT transferred onto nitrocellulose filter membrane 
(NCFM) after vacuum filtration (red circle), right side. CNT film diameter after 
filtration = 75 mm.  (C) Shows the CNT film transferred onto 4” Si/SiO2 wafer after 
acetone vapor bath step, red circle. SEM images (D and E) showing the structure of two 
different CNT films in the nano-scale on Si/SiO2 wafer after the completion of CNT 
film fabrication process. (D) Shows a nematic and (E) Isotropic CNT film network. 
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for 15 minutes each. Finally the CNT film suspended on silicon wafer is place in DI 
water bath overnight. The rinsing and baths processes remove any residual filter 
membrane and remaining surfactant molecules. Similar protocol can be utilized 
processing CNT suspended in organic solvent solutions (i.e. ethanol, and isopropanol). 
 For simplicity, from here on in this thesis the concentration of CNT used in 
each film will be referred to as the total CNT mass used in that CNT film, as the area of 
the film is constant throughout at 4418 mm
2
, d = 75 mm, the only varying component is 
the CNT mass. For example the CNT film described in the protocol in this section 
would be referred to as a 2 µg CNT film, since the total CNT mass making the film is 2 
µg. The area of the CNT film is related to the dimensions of the filter membrane, 90 
mm diameter, that capture the nanotubes during the vacuum filtration process. As the 
filtration setup fixture covers the edges of the membrane, the actual diameter of the 
active area of filter membrane capturing the nanotubes is 75 mm, Figure 21 (B), which 
is a constant and fixed for all CNT film samples described in this thesis. 
3.1.2. CLEAN ROOM PROCESSING 
 The silicon wafer with the CNT film on top is next taken to microfabrication 
cleanroom facility, University of Louisville Micro/Nano Technology Center, to be 
further processed to fabricate CNT micro-array devices, illustrated in Figure 20.  The 
microfabrication process consists of patterning the CNT film, depositing metal 
electrode, and covering the metal electrodes with photoresist polymer, Figure 22. In the 
case of the back gated CNT-FET, an additional step is added to etch a window through 
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the SiO2 into the body of a doped Si substrate. The silicon wafers used for back gated 
devices were similar to all other wafers used here, in addition they were p-type boron 
doped, < 0.005 resistivity. 
 Patterning of the CNT film, electrodes, and insulating layer are done by 
photolithography in a Class 100 cleanroom. SC1813 photoresist is used to mask the 
nanotube film areas needed for the device elements. Table 3 presents the specific 
setting at which SC1813 photoresist is spun on the wafer using a standard spin-Coating 
system. Next the sample is soft baked for 60 seconds at 90 °C before getting exposed to  
Table 3. Spin-Coater setting for SC1813 photoresist. 
Step Ramp(RPM/s) Speed(RPM) Time(s) 
1 100 RPM/s 450 RPM 2s 
2 1000 RPM/s 4140 RPM 10s 
3 1000 RPM/s 0 RPM 0s 
UV light (10 mW/cm
2
 at 365 nm) on a mask aligner for 8 seconds. The wafer is then 
developed in MF-319 until excess photoresist has been removed entirely, exposing 
parts of the CNT film. 
 Exposed nanotubes are etched away in a march reactive ion etcher for 90 s at 
200 W power with oxygen plasma. The excess nanotubes are removed and wafer is 
rinsed and cleaned off the photoresist using acetone, methanol, and DI water. After 
drying the wafer, SC1827 photoresist is again used to mask the electrode patterns in the 
same fashion as above. Electrodes consist of a 15 nm Ni adhesion layer and a 90 nm Au 
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layer, and are deposited by sputtering in a Leskar PVD 75 system, 300 W DC power. 
The excess Au/Ni layer is lifted off in acetone bath. Next, to further improve the CNT 
film sheet resistance and CNT-metal contact resistance, wafers are annealed for 2 hours 
at 250 °C inside a vacuum oven.  Lastly, devices are covered with SU8-2005, a 5 μm 
thick photopolymer layer. Table 4 shows the specific setting at which SU8-2005 
photoresist is spun on the wafer using a standard spin-coating system. After this step  
Table 4. Spin-Coater setting for SU8-2005 photoresist. 
Step Ramp (RPM/s) Spin Speed (RPM) Time (s) 
1 100 500 10 
2 300 3000 30 
3 1000 0 0 
wafer is soft baked for 4 minutes at 95 °C and then exposed in the mask aligner (10 
mW/cm
2
 at 365 nm) for 15 seconds. Post-exposure bake is done next, 4 minutes at 95 
°C. The wafer is developed in SU-8 developer to remove excess photoresist. Lastly 
wafer is hard baked at 150 °C for 5 minutes.  A window over each of the nanotube 
sensor elements is developed but the electrodes remain insulated beneath the SU8. 
Schematic in Figure 22 illustrates the device fabrication process from start to finish. 
 Series of wafer arrays were processed further by opening a window through the 
silicon dioxide into the p-type doped silicon body by a standard buffered oxide etch 
technique. This was done to analyze the CNT-FET characteristics of the CNT device 
through back-gating in addition to liquid gating the CNT device using an ionic buffer 
and the Ag/AgCl reference electrode.  
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Figure 22. Micro-array device micro-fabrication process. (a) 4” silicon wafer. (b) Dry-
thermal oxidation. (c) CNT film transfer. (d) First photolithography step followed by 
patterning CNT film, Reactive-ion etching. (e) Second photolithography for patterning 
electrodes. (f) Sputtering Ni/Au and lift-off, in yellow. (g) SU-8 photoresist is spun on 
top of wafer, in green. (h) Third photolithography step is performed to open window 
through SU-8 layer and expose the CNT network. (i) Shows an optical microscope 
image of devices at the end of photolithography 1 (d), sputtering left-off (f), and 
photolithography 3 (h) steps. 
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3.1.3. CNT DEVICE GENERATION I, II, AND III 
 Three fundamental factors that need to be addressed in designing the ideal 
sensor for detection and capture are: Settling time, sensitivity and selectivity. Settling 
time is the time it takes the analyte to diffuse to the CNT surface or for a cell to settle 
on the active area of a sensor. As the device active area increases, the settling time 
decreases resulting in a quicker detection of the target. With cells the size of the active 
area can have a direct impact on cell capture as an active area smaller than the cell 
itself, < 20 μm, will eliminate the chance of cell-sensor interaction diverging settling 
time to infinity. The second factor, sensitivity is defined by the least number of targets 
to initiate a signal. In this case the number of targets needed to generate the same signal 
from the device increases with increasing device geometry, active area. As one can see, 
smaller device geometry will increase sensitivity; however, also increasing settling time 
which can be of a disadvantage. Lastly, selectivity, the ability to respond to a particular 
target without interference from others, is fundamental and if not addressed the other 
two factors lose their significance.  
 To accommodate for the objectives of this thesis, three generations of devices 
were designed and developed for small and large count cell capture and for protein 
detection, Figure 23. The nature of the fabrication of all three generations of CNT 
devices are similar as described in the previous section. The only difference is the 
dimensions to accommodate for settling time and sensitivity of the device with respect 
to the specified target. 
 Generation I is consisted of 60 devices on a single 4” wafer, Figure 23 (A). The 
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CNT window on these devices is 100X80 µm. The parameters were optimized for 
single and small concentration cell capture. The device area was minimized to its limit 
with respect to cell size, ~20 μm, to increase sensitivity; however, cell concentration 
had to be increased for these devices to accommodate for settling time. Generation I 
devices were both used for cell capture and CNT film characterization. At these 
dimensions, generation I device can capture up to ~1-25 cells on a single device.  
 Generation II CNT devices were an upgrade to generation I, Figure 23 (B). By 
optimizing the design, number of the devices increased to 76 per 4” wafer from 60. 
Additionally, the CNT window is significantly larger at 3000X3000 µm to improve 
settling time and increase the number of cells that can interact with the active area. This 
device was specifically designed to accommodate for high cell count, for samples with 
high concentration of cells such as blood samples. In this design each device has the 
potential to interact with up to ~30,000 cells at one time. However, such large increase 
in device geometry and active area impacts the sensitivity of the device. As a result 
even though more cells can be captured but more cells need to interact with the device 
to generate the same signal as generation I devices. This generation of devices was used 
for cell capture only with blood samples described in Chapter 9.  
 Generation III of CNT devices were designed with protein sensing as the main 
objective, Figure 23 (C). Proteins are much smaller in size than cells and diffuse 
through the solution and onto the active area much more efficiently, therefore they 
don’t require a large sensing surface area. The CNT window was miniaturized
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Figure 23. Generation I, II, and III of CNT devices, all are microfabricated on 4 inch 
silicon wafer. (A) 60 devices per wafer, CNT window on each device is 100X60 μm. 
(B) 76 devices per wafer, CNT window on each device is 3000X3000 μm. (C) 80 
devices per wafer, three sensors per device for a total of 240 sensors. CNT window on 
each sensor is 20X20 μm. 
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accordingly to 20X20 μm. Each device is consisting of three sensors, sharing a common 
drain electrode. Overall, there are 80 devices per 4” wafer in this design with three 
sensors on each device, totaling in 240 sensors per 4” wafer. This generation of devices 
was used for protein sensing experiments presented in Chapter 5 and 6.   
3.2. CNT ULTRA-THIN FILM 
 As discussed in Section 3.1.1, depending on the concentration of CNTs and the 
solvent type they are suspended in the quality and the structure of the CNT film can 
vary significantly, Figure 24. For the purposes of this thesis, CNTs were suspended in 
two types of solutions, organic solvent and surfactant base solution. It was observed 
that CNTs dispersion in micro scale is much better in aqueous surfactant solution, 1% 
wt-v sodium dodecyl sulfate (SDS), in comparison to organic solvents such as ethanol, 
isopropanol, and dimethyl-formamide. 
 In aqueous surfactant solution, as the concentration of CNT is increased, liquid 
crystal CNT starts to form in the solution. This phase translates itself into the CNT 
films, showing nucleation of nematic sites in the isotropic fabric of the films. These 
nematic regions grow with the increasing concentration of CNT till eventually 
converting the whole film, converting it from isotropic to nematic film. Nematic phase 
films show local alignments of CNTs. Ben King and Xiaoming Fan investigated the 
potential and the alignment of these nematic liquid crystal (LC) based CNT films for 
photomechanical and transistor applications [326, 329].  
 Vacuum filtration of nanotubes in aqueous surfactant solution formed nematic 
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domains on the filter membrane surface and exhibited local ordering [330]. Work done 
by our group on the similar nanotubes showed the transmittance versus sheet resistance 
measurements of such films resulted in optical to dc conductivity of σopt/σdc = 9.01 
indicative of purely semiconducting nanotube liquid crystal network. High Ion/Ioff ratios 
from 10–19,800 and electron mobility values μe = 0.3–78.8 cm
2
 (V-s)
−1
, hole mobility 
values μh = 0.4–287 cm
2
 (V-s)
−1
 were reported. High Ion/Ioff ratios were observed at low 
order parameters and film mass. A Schottky barrier transistor model was consistent 
with the observed transistor characteristics here. Electron and hole mobilities were seen 
to increase with order parameters and carbon nanotube mass fractions. A fundamental 
tradeoff between decreasing on/off ratio and increasing mobility with increasing 
nanotube film mass and order parameter is therefore concluded. Increase in order 
parameters of nanotubes liquid crystals improved the electronic transport properties as 
witnessed by the increase in σdc/σopt values on macroscopic films and high mobilities in 
microscopic transistors. Fan et al. using these LC-CNT films in polymer composite 
demonstrated a unique and reversible photomechanical response using near infra-red 
light.  
 LC-CNTs have great potential in soft photochromic actuation, energy 
conversion and photo-origami applications to name a few, but they are also consisted of 
relatively thick ropes of multiple CNTs in multi-layer fabric network. For the purposes 
of this thesis, we are interested in maximizing the exposure of CNT surface and 
minimizing conduction channels under the surface, for higher efficiency in cell and 
protein capture and sensing. In this situation, we are interested in very thin, single later,
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Figure 24. SEM images of three different unique CNT film structure, (A) ultra-thin 
isotropic, (B) thin nematic, and (C) disordered isotropic. (A and B) are products of 
CNT suspended in aqueous surfactant solutions. CNT suspended in these solution 
produce an ultra-thin CNT films at very low concentration (A), i.e. 2 µg. These films 
are ~10-50 nm thick and uniform. Increasing the concentration of CNT in aqueous 
surfactant solution results in a much different nematic CNT films. Nematic nucleation 
of CNT films occur as concentration increases, dark region of (B1). Resulting in locally 
aligned CNT on the film (B2 and B3). CNT films made from CNT suspended in 
organic solvents are very much different in micro and nano scale. Large mass of CNTs 
in these films are trapped in tangled ropes that can get as thick as 1 µm or larger, (C2). 
As a result of this effect, much greater CNT mass is required to achieve a uniformly 
conductive film, i.e. 40 µg vs. only 2 µg for aqueous solution suspension. As a result, 
great fraction of these nanotubes are hidden and not exposed to the environment.
A1 A2 A3 
B1 B2 B3 
C1 C2 C3 
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uniform, continuous, and conductive film that expose the maximum CNT surface area. 
Number of CNT films were made and studied at different concentrations and using 
different solvents, as summarized in Figure 24, to finally achieve the optimum ultra-
thin CNT films used for the purposes of this thesis.  
 Ultra-thin films were achieved using a very small concentration of CNT 
suspended in aqueous surfactant solution that were vacuum filtered on a membrane to 
generate an almost single layer CNT film, Figure 24, as described in Section 3.1.1. 
These films were consistent in their uniformity, thickness less than 50 nm, in 
comparison to films achieved form organic solvent solution that have tangled CNT 
ropes in large masses with varying film thickness, from 100 to over 1000 nm. In the 
case of CNT suspended in organic solvent, because majority of the CNT mass is 
trapped in tangled ropes, much larger CNT mass is required, >40 µg, to achieve a 
conductive uniform film. Much more uniform and even, ultra-thin films were achieved 
with CNT suspended in aqueous surfactant solution at much lower concentration, 2 µg, 
as shown in Figure 24. In the next section we will review the effect of different film 
concentrations from surfactant based CNT suspensions on final CNT device 
characteristics.  
3.3. MEASUREMENT SETUP 
 In this section we will describe the platform on which all the electrical readings 
and characterizations were conducted on. The platform was set up on S-1160 Signatone 
probe station. Agilent 4156C Semiconductor Parameter Analyzer equipped with a 
custom LabVIEW interface was used for monitoring the sensors and data collection, 
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Figure 25 (A). Computer running the LabVIEW program connected to the parameter 
analyzer through a National Instruments card (PCI-GPIB), allowed for direct 
communication to the instrument. Three EM shielded triaxial cables connected the 
three SMU ports on the back of the parameter analyzer to each of the three micro 
probes stationed on the probe station. Each triaxle cable was converted to a coaxial 
cable using an EM shielded adaptor right before connecting to the probe to minimize 
noise. Each SMU port connected to an individual probe and was programed to either 
apply a specified source and gate voltage (DC voltages) or read the drain current, 
Figure 25 (A). Bias voltage was applied throught the source probe electrode and the 
source-drain current, ISD, was recorded for the duration of the test using the Agilent 
4156C parameter analyzer. The accuracy of the semiconductor parameter analyzer is 1 
femtoamps (fA), while most of the readings taken from the CNT devices are in the 
nanoamps (nA) region suggesting a very sensitive and accurate level of signal 
collection. The entire probe station assembly is placed on an optical table that is 
vibration isolated using air on all four legs. A metal box covers the entire assembly to 
avoid electromagnetic interference. The non-dry samples with a sample droplet were 
maintained inside a humid changer, Figure 25 (B), which preserved humidity level of 
the chamber by H2O soaked cotton balls carefully placed inside the petri dish, 
preventing the evaporation of the droplet sample during device functionalization and 
testing. The testing set up for devices with sample droplet is demonstrated in Figure 25 
(C), showing the probes contacting the electrodes through an opening on a modified 
humid chamber and Ag/AgCl reference electrode applying gate voltage via the sample 
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Figure 25. (A) Schematic demonstrates the electrical measurement setup. A DC bias 
voltage, VDS, and gate voltage, VG, was applied and the current IDS passing through the 
drain was measured using the parameter analyzer while the LabVIEW program was 
used to control the parameters on the parameter analyzer and save the data to the 
computer. (B) Shows the humid chamber used to store devices with sample droplets 
during functionalization and testing to prevent the evaporation of the droplet. This was 
achieved by controlling the humidity inside the chamber using H2O soaked cotton balls 
carefully placed on the outer edge of the chamber. (C) Showing the probe-station setup, 
including the vibration isolated base, optical microscope, and the three probes. This set-
up specifically demonstrates the platform for liquid gated testing, devices with sample 
droplets, using a modified humid chamber allowing probe access to the device. 
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droplet, liquid gating. Throughout the testing the devices were maintained inside a 
humidified chamber to prevent evaporation of the sample droplet. This set up and the 
ability of parameter analyzer to apply spectrum of voltages independently to each 
channel/probe and record output signal with great percisioun and accuracy allowed for 
collecting spectrom of data from the CNT devices including resistance, current vs. time 
with and without gating, IDS vs. VDS, and IDS vs. VG voltage sweeps namely. 
 For all the conductance readings presented in Chapters 5, 6, 7, 8, and 9, 100 mV 
DC bias was applied to the drain-source electrods, while 0 V was applied via the 
Ag/AgCl refrance electrode. The film resistance data presented in this chapter were a 
simple two terminal readings, via 100 mV source-drain bias. 
3.4. DEVICE CHARACTERIZATION 
 In this section we will review the characteristics of carbon nanotubes used for 
this thesis, CNT films, and finally the CNT micro-array devices.  
3.4.1. CHARACTERIZATION OF CARBON NANOTUBES (CNT) 
To better undrestand the fundamentals of the devices, series of characterizations 
were done on the underlying carbon nanotubes used for fabricating the CNT devices 
here. Initially the Iso-Semiconducting Nanointegris carbone nanotubes were first 
studied by AFM, SEM, Raman spectroscopy, and Spectrophotometery . In these studies 
size, shape, quality, absorbanse, transmitance, and the band gap of the CNT were 
investigated.  
The highly purified 99% wt ISO-Semiconducting single wall carbon nanotubes 
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purchased from NanoIntegris Inc. were analyzed by spectrophotometry. The optical 
absorbance and transmittance results are illustrated in Figure 26 (A and B). The 
transmittance is modulated from 0% to 29% at 400 nm and continues to rise to its peak 
of 50% at 620 nm wavelength Figure 26 (A). These results correlates with previous 
findings of similar nanotubes [325]. Absorbance diagram, Figure 26 (B) shows the 
transition regions for semiconducting nanotubes, S33 transition between ~450-630 nm. 
and S22 transition between ~900-1000 nm, confirming the semiconducting nature of 
the nanotubes as reported by the manufacturer and aligned with past reports [331]. 
Figure 26 (C) presents the Raman spectroscopic micrograph of the nanotube 
network suggesting a very large G band (1590 cm
-1
), in plane vibration of SP
2
 bonds; 
small D band (1340 cm
-1
), defective band, and large 2D band (2673 cm
-1
), twice D 
band and also known as G’ band in graphene. This suggests extremely low amorphous 
carbon content. Further, we also measured the IG/ID ratio for several networks, 
measured IG/ID ~ 30 suggesting a low density of defects and suitable for high-quality 
sensing applications. Radial breathing mode (RBM) mode was observed at r =174  
cm
-1
, interaction of the CNT diameter with the laser. Using the simple formula for 
calculating CNT diameter, dCNT = 248 / RBM , we calculated the diameter of these 
nanotubes to be ~1.4 nm, similar to what was reported by the manufacturer. The Iso-
semiconducting nanotubes had iodine as specified by the manufacturer (5% by mass 
using neutron activation analysis) in the form of iodixanol. This was observed in the 
shift in radial RBM mode r =174 cm
-1
 suggesting iodine doped nanotubes due to poly 
iodide ions or I3
-
 and I5
-
 in the RBM mode at the same excitation wavelength [332]. The 
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Figure 26. (A) Optical absorbance of Iso-semiconducting SWNT showing the S33 
(~450-630 nm) and S22 (~900-1000 nm) transition peaks. (B) Transmittance of Iso-
Semiconducting SWNT in aqueous surfactant solution. (C) Raman spectrum of Iso-
Semiconducting SWNT film on silicon wafer showing a large G band, small D band 
and 2D band. The IG/ID ~30 was observed in these nanotubes.
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iodine also decreased the tangential mode to 1590 cm
-1
 in these samples as compared to 
pristine nanotube samples (1593 cm
-1
) in line with past reports [333].   
 Figure 27 shows the SEM and AFM image of the ultra-thin ISO-
Semiconducting SWNT network (2 μg CNT film). These SWNTs are listed to have 
diameter of 1.2-1.7 nm on supplier’s datasheet. This narrow diameter distribution, 
results in SWNTs to often bundle up in form of crystalline ‘ropes’ in which single tubes 
are held together by van der Waals interaction as presented in AFM. This effect is vivid 
on AFM image, as the nanotubes bundles have a width ranging from 10 to 50 nm, 
Figure 27 (B), and height of ~4 to 8 nm, Figure 27 (C). This indicates that SWNTs 
bundling to ropes effect is present here. Based on the CNT dimensions we can estimate 
approximately 20 nanotubes per bundle on average. Additionally, knowing the 
nanotube diameter we can calculate the bang gap of the nanotubes based on eqn. 1 
presented in Chapter 2. For semiconducting nanotubes with diameter ranging from 1.2 
to 1.7 nm, calculated bandgap ranges from ~0.4 to 0.6 eV. 
 
 
Figure 27.  (A) SEM and (B and C) AFM images of ultra-thin SWNT network. 
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3.4.2. DEVICE AND THIN FILM CHARACTERIZATION  
 Following CNT devices fabrication, numbers of devices were prepared using 
different CNT concentration films on generation I device platform with source and 
drain electrode window of 100 by 80 µm. These devices were then investigated for 
their electrical properties based on imbedded CNT films. The properties of devices 
made with nematic films are presented in Figure 28. Properties for devices fabricated 
with ultra-thin isotropic films are presented in Figure 29. In these two panels, SEM 
image of the devices made from different nanotube film concentrations are shown. In 
these images CNT film bridging the source and drain electrodes are shown, in addition 
the high resolution image of the CNT network of each film is also presented.  CNT 
devices were made with two, nematic, and four, isotropic, CNT films at different 
concentrations, devices were tested for their electrical properties before and after 
annealing. It is observed that as the concentration increased so did the network density. 
For ultra-thin films, at the film concentration of ~1 µg, the nanotube-nanotube contacts 
were not established at some points, and this is reflected in their high electrical 
resistance. For samples with higher concentrations, 2-6 µg, uniform network density 
was observed. CNT devices based on nematic films had even lower device resistance as 
expected, since there are more conducting nanotubes bridging the electrodes. But these 
devices are not single layer and are consisted of multiple CNTs in rope form in multi-
layer structure that are not of interest for the objectives of this thesis as described 
earlier. We, therefore, used 4 and 6 µg films with more directional nanotubes for our 
studies in this thesis with optimized electrical properties. The film electrical resistance 
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before and after annealing was measured as presented in Figure 28 (B) and Figure 29 
(B). Annealing at 250 °C decreased the resistance of the devices universally. It was 
observed that the decrease in electrical resistance of the device with annealing was 
directly related to the concentration of the nanotube films. Devices made with 1 µg 
films registered a larger decrease in electrical resistance of ~95%, compared to devices 
with larger film concentrations (~57% and ~47% decrease in resistance for 2 µg and 4 
µg respectively). The large decrease in electrical resistance after annealing suggests 
healing and refining of nanotube network structure to enable stable electrical pathways 
associated with the device. Figure 28 (C) and Figure 29 (C) present the distribution of 
nanotube device resistance, for 14 and 58 devices, suggesting narrow distribution of 
network resistance in the 10
6
-10
7
  range, showing repeatability which is suitable for 
further sensing applications.  Table 5 presents the summary of the 4 point probe (1 mm 
probe spacing) measurements for the sheet resistance before and after annealing and 
final device resistance. The average resistances after annealing for nematic films were 
1.77x10
6
 Ω for 10 µg film and 8.32x104 Ω for 40 µg. While the low concentrations (1 
and 2 µg) yielded highly rarefied nanotubes and much higher decrease in electrical 
resistance as suggested with annealing, it was difficult to always get a conductance 
reading due to lack of connection between all the nanotubes in low concentration 
nanotube devices. Therefore, we optimized our devices for 4 and 6 µg nanotube films 
to provide stable network connectivity; these concentrations were used for all the 
studies henceforth presented unless specified otherwise.  
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Figure 28. Electrical resistance of CNT devices fabricated from nematic films. (A) 
SEM image of the actual device fabricated from 10 and 40 μg CNT films and their 
corresponding high resolution images of the CNT network; (B) film resistance before 
and after annealing at 250 °C; (C) histogram suggesting high degree of control in 
device resistance over 14 devices. 
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Figure 29. Electrical resistance of CNT devices fabricated from ultra-thin isotropic 
films. (A) SEM image of the actual device fabricated from 6, 4, 2, and 1 μg CNT films 
and their corresponding high resolution images of the CNT network; (B) film resistance 
before and after annealing at 250 °C; (C) histogram suggesting high degree of control 
in device resistance over 58 devices. 
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Table 5. Average film resistance summary 
 
 
 
 In a typical traditional FET sensor, there are conduction channels underneath 
the surface that give rise to a large background noise. Having only one conduction 
channel on a nanotube surface can raise the sensitivity even higher and increase the on-
off ratio. This is why we have elected ultra-thin CNT film at 4-6 µg levels for these 
studies. 
3.4.3. PERCOLATION THEORY VS. CNT FILM MASS 
 Percolation theory studies the formation of conducting pathways in different 
dimensions, using objects of various geometries. In one model, a random array of long 
conducting sticks were used to study the formation of conducting channels across a 
material [334]. We utilized this variation of percolation theory to model the 
conductance of our arrays as a function of CNT film mass. Ultra-thin, uniform SWNTs 
films of varying densities have been prepared and fabricated into CNT devices. The 
film resistance is fit into percolation theory as a function of CNT mass.  
 Figure 29 shows SEM images of four different samples that have been prepared 
by filtering a 1, 2, 4, and 6 µg total mass of CNT, respectively, through the filter 
membrane. Several features can be noted in these images. First, though not shown here, 
images taken at various spots along the film, sometimes separated by as much as 5 cm, 
CNT Film Concentration 6 µg 4 µg 2 µg 1 µg
Sheet resistance before annealing (Ω/sq.) 9.21E+06 4.16E+06 3.30E+07 5.82E+08
Sheet resistance after annealing  (Ω/sq) 6.66E+05 2.25E+06 1.41E+07 2.40E+07
CNT Film Resistance after annealing (Ω) 2.00E+05 5.20E+06 4.12E+07 7.28E+08
%  Drop In Resistance After Annealing 92.76% 45.92% 57.38% 95.88%
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show no noticeable difference in film characteristics, indicative of the spatial 
uniformity of the film. Also, the nanotubes, at these concentrations, appear randomly 
oriented with no preferential directions, allowing application of the percolation theory 
of a random distribution of conducting “sticks”. Notice, however, that in these 
networks, each “stick” is actually a small bundle of nanotubes, because nanotubes tend 
to be attracted to each other through van der Waals interactions as discussed in Section 
2.1. We count each bundle of nanotubes as one “conducting stick” (CS). Percolation 
theory requires only that the CS has a length that is much greater than its diameter (the 
aspect ratio of the bundles is still of order 100). By manually counting the number of 
CS present in several images, we arrive at the average density (CS per area) for each 
CNT film mass. CNT film with M = 1 µg is 5 CS/µm
2
 ,  M = 2 µg is 11 CS/µm
2
, and 
M= 4 µg is 21 CS/µm
2
. As expected, the CS density is proportional to the mass of CNT 
applied to the filter; i.e., if more nanotubes are used, a denser film results. Using this 
fact, the mass of CNT used to make each film can be directly converted into a CS 
density, using the conversion factor of 5 CS/ µm
2 
µg. 
 Before measuring the DC conductivity of the CNT film in the percolation 
region, we used generation 1, 2, and 3 devices to verify that all resistances measured 
were due to the CNT in the network and not due to the gold/CNT interface at the 
contacts. To measure the contact resistance, same CNT film mass, 2 µg, was used to 
fabricate all three generation of devices, allowing for variation only in the separation 
distance between the contacts (width between contacts was not held constant). The 
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Figure 30. (A) Shows the measured CNT film resistance versus the source drain 
distance of generation 1, 2, and 3 CNT devices, for films of the same density. All three 
generations have unique constant separation distance, generation 1: 100 µm, generation 
2: 3000 µm, and generation 3: 20 µm. inner box shows a zoom in on generation 1 and 
3. (B) Demonstrates the sheet conductance versus CNT film mass in µg, inner box 
shows the data in logarithmic form. 
 
resistance between contacts of all three devices was then measured, and plots made of 
the resistance vs the contact separation (generation 1: 100 µm, generation 2: 3000 µm, 
and generation 3: 20 µm); a typical plot is shown on Figure 30 (A). The plot shows that 
the resistance of the network at 100 µm channel length, generation 1, is ~5 times larger 
than the 20 µm channel length, generation 3, and ~29 times smaller than 3000 µm, 
generation 2. This linear relationship indicates that the resistance is dominated by the 
CNT film, with only small contributions from the nickel-gold/CNT interface at the 
contacts. 
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 For the percolation study, several CNT devices were made on identical CNT 
films, varying only the CNT mass (and therefore the CNT density), similar to what is 
presented on Figure 28 and Figure 29. CNT devices with identical metal contacts were 
prepared to produce a CNT channel 80 µm in width (W) and 100 µm in length (L), 
generation 1 design. A standard two-probe measurement was made to measure the DC 
resistance (R) between the two metal contacts. To be comparable with other works, 
resistance was converted to sheet resistance (R□), which is defined as R□ = R(W/L). 
Figure 30 (B) shows a plot of sheet conductance G (defined as 1/ R□) vs CNT film mass 
(proportional to CNT film density). 
 Standard percolation theory predicts that the density dependence on the 
conductivity is given by  
 𝜎 ∝ (𝑁 − 𝑁𝑐)
𝛼 (8) 
Here, σ refers to the conductivity in three dimensions and the sheet conductance G in 
two dimensions, N is the CS density, and Nc is the critical density corresponding to the 
percolation threshold. For the random distribution of the CS model [335], the critical 
density is given by  
 𝑙√𝜋𝑁𝑐 = 4.236 (9) 
Here, 𝑙 is the length of the CS. Equation 8 holds close to the transition; while well 
above the critical density, one expects to enter a region of linear dependence on density. 
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The critical exponent, 𝛼, depends only on the dimensionality of the space; for a film in 
two dimensions, theory predicts 𝛼 = 1.33, while in three dimensions 𝛼 = 1.94 [336]. 
The Figure 30 (B) shows a fit of eqn. 8 to our data in the percolation region, using a 
critical volume value of 1 µg. The best fit to our data yields an experimentally 
measured value of 𝛼 = 1.8, which is close to but somewhat higher than theory predicts. 
There are several reasons why the measured and theoretical values would differ. First, 
critical exponents hold in the limit that one approaches the critical point. Since our 
measurement must encompass a range of points around the critical point, the exponent 
is not guaranteed to be exactly 4/3. In fact, as we approach the critical point, including 
fewer and fewer points in our fit, the exponent converges to 4/3. Discrepancies may 
also arise because our CNT film is not perfectly two-dimensional, and one could be 
observing some crossover into three dimensions, where the critical exponent (𝛼) is 
1.94. Additionally, the channel width varies from different device generations. Theory 
also does not account for the fact that all the CNT used here are semiconducting. The 
resistance of metallic-metallic tube interconnects has been shown to be less than the 
resistance of semiconducting junctions, due to the presence of a Schottky barrier [337]. 
In this case conductance is limited by the Schottky barriers. However, as the network 
density increases, more CNT pathways are formed, yielding an increase in conduction 
with film density that is not accounted for by standard theory. Prior experiments on 
CNT found 𝛼 values of 1.2 [338], and 1.3 [339] for three dimensional CNT composite 
films and 1.5 [334] for two devotional ultra-thin film. These previous findings are 
substantially different compared to theoretical prediction of 𝛼 = 1.33, in two 
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dimensions, and 𝛼 = 1.94 in three dimensions. It is important to note that all the 
previous studies used a mixture of metallic and semiconducting CNT. For the CS 
model of a random distribution of sticks, theory predicts the value of the critical density 
Nc, given as eqn. 9. Assuming an average nanotube length of 1 µm (verified by SEM 
images and manufacturers data sheet), we calculate a theoretical critical density of 5.7 
CS/µm
2
, using eqn. 9.  Using the data obtain by counting the SEM images of films 
made at the critical volume of 1µg, we measure a density of 5 CS/µm
2
 at the critical 
point. The discrepancy between the data and theory can be accounted for by counting 
errors, or by nanotubes on the film that are not resolvable by the SEM, thus causing 
undercounting of the CS density. 
 Furthermore we can verify our formula for calculating the number of 
“conducting sticks” (CS) per unit of area as function of CNT film mass. This ratio was 
presented earlier in this section as 5 CS/ µm
2 
µg. One can calculate the number of CS 
and thereby number of CNTs per unit of area. Earlier in Section 3.4.1 we explained 
how SWNTs come together to bundle and form ropes and based on nanotube 
dimensions and our observations under AFM we estimated each rope, CS as referred to 
here, to be made up of ~20 nanotubes on average. Accordingly, we are able to back 
calculating the film mass of the film based on the number of estimated CNTs observed 
under SEM and compare it to the actual CNT mass used to make the film 
experimentally. 
 The weight of any SWNT (Wsw) of diameter d and length L can be calculated 
from the surface area of the graphene sheet [340]: 
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Figure 31. Electrical properties of CNT-FET devices (6 µg) under dry conditions with 
a p-type back-gate (A and C) and under phosphate buffer solution with Ag/AgCl 
reference electrode (B and D). A & B show the VDS sweep and C & D present the VG 
sweep characteristic of the CNT-FET devices. 
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𝑊𝑠𝑤 =
1
1315
𝜋𝐿𝑑    (𝑔𝑟𝑎𝑚𝑠) (10) 
We estimated the weight of the SWNTs we used here to be 𝑊𝑠𝑤 = 2.866 × 10
−18g 
(d=1.2 nm and L= 1 µm). Next we calculated the number of SWNTs on a 4 µg film to 
be 1.77 × 1012, knowing the 5 CS/ µm2 µg ratio, area of the film, 4.42 × 109 µm2, and 
CS to SWNT ratio, 1:20. Finally using the total number of nanotube and their 
individual weight, we estimated the CNT film mass using our model to be ~5 µg, which 
is very close to the actual 4 µg measured experimentally. This level of accuracy is 
impressive, 80%, knowing the magnitude and complexity of the system. Error is also 
expected with the number of variables and degrees of freedom within the system and 
also with assumptions made earlier. 
3.4.4. CNT DEVICE FET CHARACTERISTICS 
After microfabrication of CNT-FET devices, back-gated and Ag/AgCl reference 
electrode gated three terminal devices were characterized for their FET characteristics 
(i.e. mobility, and on/off ration). 
 Figure 31 (A and C) presents the characteristics of the CNT-FET under dry 
conditions with a p-type back-gate, Figure 31 (B and D) presents the characteristics of 
the CNT-FET in buffer solution with a Ag/AgCl referance electrode gate. The source to 
drain current (IDS) versus source to drain voltage (VDS) at different gate voltages is 
presented in Figure 31 (A and B). The source to drain current (IDS) versus gate voltage 
(VDS) at different source to drain voltages (VDS) is presented in Figure 31 (C and D). 
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The source to drain current decreased with increasing positive gate voltage. This 
suggest the device works as a p-type semiconductor, alligned with our expectation 
described in Chapter 2. We explaine this behavior in detail in Section 2.2. No leakage is 
seen at positive voltage the current is almost zero suggesting superior p-type transistor 
compared to past reports where there was still a significant drain current at zero and 
increasingly positive gate voltage [341].  
 Field effect mobility was calculated as: 
 𝜇𝐹𝐸 = 
𝐿∗𝑔𝑀𝐴𝑋
𝑊∗𝐶𝑜𝑥
∗𝑉𝑆𝐷
 
(11) 
where 𝐿 is channel length, 𝑊 is channel width, 𝑔𝑀𝐴𝑋 is maximum transconductance 
(taken from the negative transfer curve slope), 𝐶𝑜𝑥 is gate capacitance per unit area 
defined as 𝐶𝑜𝑥 =
𝜀𝑜𝑥
𝑡𝑜𝑥
 (F/cm
2
), where dielectric constant of the oxide  𝜀𝑜𝑥 = 3.9𝜀𝑜 
(permittivity of free space or air 𝜀𝑜𝑥 = 8.85𝑋10
−14 F/cm), and 𝑡𝑜𝑥 is the oxide 
thinkness. 𝑉𝑆𝐷 is the source drain voltage. The results of the mobility calculation are 
presented in Figure 32 (A and B) as a fuction of CNT film mass. It is obvious that 
mobility increases as CNT mass increases, film density increases. With these devices, 
mobility ranged from 4.95 cm
2
/V-s for a 6 µg film to 35.1 cm
2
/V-s for a 40 µg film. 
Additionaly, Ion/Ioff  were also calculated for CNT device through back-gating, Figure 
32 (A), and electrolyte liquid-gating, Figure 32 (C). A droplet of electrolyte solution 
(1X phosphate buffered saline) was placed over the device surface and an Ag–AgCl 
reference electrode was inserted into the droplet and connected to the gate terminal. 
On-off ratio by backgating ranged from 1.55 to 11.2, for 40 µg and 6 µg films, and for 
107 
 
 
Figure 32. Transistor properties versus film mass: (A) presents mobility and on-off 
ratio of a back-gated CNT device in one plot, we can see that mobility is reversely 
related to on-off ratio. (B) Presents the mobility range for 40 µg film. (C) presents the 
on-off ratio for a top-liquid-gated CNT device, gate is applied by Ag/AgCl reference 
electrode through electrolyte solution (1X PBS).  
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top liquid gated it ranged from 134 to 186, 6 µg and 2 µg films, increasing as the CNT 
film mass decreases. The mobility and on-off ratio trends, as a function CNT film mass, 
corilate with past reports for these nanotubes [326]. 
Our CNT-FET is also definitely superior compared to past reports on using 
CNT-FET with antibody fragments which used a mixture of metallic and 
semiconducting nanotubes resulting in poor on/off ratios’ [342]. This point is important 
and needs to be emphasized as the whole sensing principle relies on the charge 
introduced at the nanotube channels either reducing or increasing the conductance with 
introduction of charged proteins. Leakage currents or poor on/off ratio’s can thus affect 
the sensing reliability if one needs to detect such ultra-low concentrations of charged 
molecules. Thus we can be confident in our experiments that at VG = 0 V, we can 
suggest that the increase or decrease in conductance with introduction of proteins or 
other molecules is as a result of binding alone and not as a result of the currents in the 
substrate. 
 After observing the CNT device properties in this section, one can see that the 
overall conductance is limited by the intertube resistance of 100 MΩ, about four orders 
of magnitude larger than the resistance of the tube themselves, 10 kΩ [334]. This same 
ratio is also obtained if one compares the mobility of single nanotube (100,000 cm
2
/Vs) 
[343] with that of network (~ 10 to 100 cm
2
/Vs). This same effect was also obsereved 
in another study by Hu et al. [334]. In conclusion, we can see that to generaly increase 
device performance for future application of these CNT devices one needs to address 
the intratube resistance of nanotubes. 
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CHAPTER 4 
CNT DEVICE FUNCTIONALIZATION AND SENSOR CHARACTERISTICS 
 
 To enable CNT device specific interact and capture of proteins such as receptor 
proteins on cell membrane, surface modification of CNT is required. Such modification 
usually is done with a linker molecule connecting the nanotube with an antibody or 
aptamer of interest, which can specifically bind to a target protein. It is important to 
conjugate these molecules and protein to the surface of the nanotube non-covalently 
without altering the molecular structure of CNTs to preserve their electrical properties. 
In this chapter we will review the functionalization process of CNT devices. Here we 
will present studies which verified the success of the functionalization process using 
different techniques. In addition, CNT devices were characterized for their sensor 
characteristics using ion molecules.  
4.1. CNT FUNCTIONALIZATION  
 As discussed previously in Section 2.1, SWNTs are molecular wires that exhibit 
interesting structural, electrical, mechanical, and electromechanical properties. SWNTs 
are unique among solid state materials in that every atom is on the surface. Therefore, 
surface chemistry could be critical to the physical properties of SWNTs and their 
applications. Thereby, the ability to functionalize the surface of SWNTs in noncovalent 
ways to preserve the sp
2
 CNT structure and thus their electrical properties is very 
important. SWNT sidewall functionalization is important to soluble nanotubes, self-
assembly on surfaces, and chemical sensor. For the objectives of this thesis, CNT 
functionalization plays a big role for capturing free proteins and cells.  
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 Chen et al. reported a very effective and simple approach for noncovalent 
functionalization of  CNT surface using 1-pyrenebutanoic acid, succinimidyl ester 
(PASE) linker molecule which can attach to CNT surface on one end and bind to amine 
group on proteins (i.e. antibodies and other molecules with active amine groups) on the 
other end conjugating them to the nanotube surface [344], Figure 33. Even though there 
are other methods of CNT functionalization such as carboxyl groups [345, 346] and 
hydroxyl groups [347] (covalently), but PASE functionalization remains an very 
attractive robust non covalent functionalization method for biosensing applications 
[348]. PASE irreversibly adsorbs onto the inherently hydrophobic surface of SWNTs in 
an organic solvent such as methanol or dimethylformamide (DMF), Figure 33 (B). The 
pyrenyl group, being highly aromatic in nature, is known to interact strongly with the 
basal plane of graphite [349, 350] and sidewalls of SWNTs via π-stacking [344]. The 
PASE molecule includes a pyrene fragment which consists of four condensed six-
membered aromatic rings. This fragment interacts with the CNT surface with a non-
bonding π- π interaction. The pyrene and succinimidyl fragments are connected in 
PASE by an alkyl chain whose structure is highly flexible, the distance between the 
pyrene molecule and the nanotube surface is about 3.2 Å [351]. As a result, the 
succinimidyl ester groups are functionalized to SWNTs, succinimidyl ester groups are 
highly reactive to nucleophilic substitution by primary and secondary amines that exist 
in abundance on the surface of most proteins. This process includes a nucleophilic 
substitution of N-hydroxysuccinimide by an amine group on the protein, resulting in 
the formation of an amide bond [344], Figure 33 (A). Using this technique, we were 
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Figure 33. (A) 1-Pyrenebutanoic Acid, Succinimidyl Ester (PASE) reacting with the 
amine groups on a biomolecule (i.e. protein) to form an amine bond resulting in a 
PASE-biomolecule complex. (B) PASE irreversibly adsorbing onto the sidewall of 
SWNT via π-stacking. (C) Amine groups on a biomolecule reacting with the anchored 
succinimidyl ester to form amide bonds to immobilize PASE-biomolecule complex on 
CNT surface.  
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able to immobilize a wide range of biomolecules such as antibodies, aptamers, and free 
proteins on the sidewalls of SWNTs with high specificity and efficiency, Figure 33 (C), 
which we will review in more detail in this section. 
4.1.1. GENERAL CNT FUNCTIONALIZATION PROTOCOL 
 Depending on the specific study, CNT thin film or CNT devices were 
functionalized with a specific biomolecule by 1-pyrenebutanoic acid, succinimidyl ester 
(PASE) linker molecule to meet the objectives of the study. The pyrene rings of PASE 
molecule (AnaSpec, Cat. No. 81238) adsorb onto carbon nanotube sidewalls by π- 
stacking. The ester on the other end of the molecule provided an attachment point for 
antibodies. PASE was dissolved in methanol at 1 mM. Devices were incubated in the 
PASE solution for 2 h at room temperature, and then rinsed with methanol three times. 
Devices were then incubated with the proper biomolecule (i.e. antibodies), at a defined 
concentration and suspended in buffer solution such as 1X PBS, for 2 h at room 
temperature. After incubation, devices were rinsed in a fresh buffer solution, for 
example 1X PBS, three times. For protein or cell studies, next Tween20 was used to 
block unfunctionalized/bare nanotube sidewalls to minimize non-specific interactions. 
Devices were incubated with 0.5% v-v Tween20 suspended in buffer solution (1X 
PBS) for 2 h at room temperature. After incubation, devices were rinsed in 1X PBS 
solution, and then incubated in a droplet of 1X PBS in a humid chamber at 4 °C for 
further studies. 
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4.2. GOLD NANOPARTICLES (NP) STUDIES 
 In exploring the use of such multiplexed nanotube devices for measuring 
differential cellular response and capture, the functionalization of antibodies that are 
specific to the receptors, their coverage on the surface, and their eventual interaction 
with the cellular receptors and free biomolecules producing an electrical signal must be 
understood in depth. To get to this understanding, it is important to understand and 
confirm the functionalization protocol, the backbone of all these studies, described in 
the previous section. In this section we demonstrate step by step verification of the 
functionalization process, PASE onto CNT (Figure 34), biomolecules (i.e. streptavidin 
and antibodies) on to PASE (Figure 35 and Figure 36), and finally the interaction of 
free biomolecule with the functionalized CNT complex (i.e. streptavidin functionalized 
CNT with biotin, Figure 35), using conjugated gold nanoparticles (NPs) for visual 
verification, via SEM imaging, of functionalization process and demonstration of NP 
capture on CNT surface via specific interaction. 
4.2.1. GOLD NPs FUNCTIONALIZATION METHOD 
 Similar to general functionalization protocol described earlier in this section, 
devices were prepared and functionalized. Instead of using a biomolecule with an 
amine group, an antibody conjugated gold NPs (Nanopartz, Cat. No. C11- 15-TX-50), 
amine-polymer conjugated gold NPs (Nanopartz, Cat. No. C11- 15-TA-50), or 
streptavidin conjugated gold NPS (Nanopartz, Cat. No. C11- 15-TS-50) were used to 
functionalize with the PASE linker molecule. The NPs, 15 nm in diameter, were diluted 
1:250 in 1X PBS and incubated on top of the device for 2 h. Finally, devices were 
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Figure 34. Functionalization of PASE. Demonstrating the successful functionalization 
of PASE molecule onto CNT side walls, by binding of amine polymer conjugated gold 
NPs to the side walls of PASE functionalized CNT. (A) Schematic showing the 
Schematic of the PASE functionalization protocol and binding of amine NPs onto CNT 
surface by PASE linker molecule. (B and C) SEM images of CNT devices after NPs 
functionalization. (B) SEM image of positive control, PASE functionalized CNT, 
amine conjugated NPs are clearly binding to the PASE functionalized CNTs. (C) SEM 
image of negative control, bare CNT, showing no significant interaction between amine 
conjugated NPs and the bare CNT surface. 
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rinsed with 1X PBS three time and samples were taken for SEM imaging. 
4.2.2. RESULTS 
 In the first study, PASE functionalization of CNT and binding of amine 
conjugated NPs, the prepared SWNT devices were functionalized with PASE molecule. 
The pyrene rings of the 1-pyrenebutanoic acid, succinimidyl ester (PASE) adsorb on to 
the sidewalls of the SWNT through π stacking and produce a stable nanotube-PASE 
composite. The ester on the other end of the PASE provides the attachment site for the 
amine group. The amine polymer conjugated NPs bind to the ester end of PASE after 
incubation for 2 hrs. Schematic in Figure 34 (A) visualizes this functionalization 
process. The results from PASE functionalized and bare CNT clearly verify the 
presents of PASE on the CNT sidewalls and its effect on the attachment of amine 
polymer, thereby NPs, to the CNT surface via PASE, Figure 34 (B and C). 
 In the next study, the functionalization process of PASE onto CNT was 
followed up by functionalization of streptavidin molecule to PASE forming a 
streptavidin-PASE-CNT complex, Figure 35 (A). Biotin has a high affinity binding to 
streptavidin which is a protein with active amine groups [352]. Biotin conjugated NPs 
were used to bind to streptavidin on CNT surface and verify the successful 
functionalization process of streptavidin-PASE-CNT complex. The results for biotin 
NPs incubated with functionalized and bare CNT is presented in Figure 35 (C and D). 
 We demonstrated the functionalization of PASE molecule onto the CNT side 
walls and attaching biomolecules with amine group to the PASE forming a CNT 
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functionalized surface complex. Furthermore, we showed the ability to attach a free 
protein to the CNT complex by specific interaction, streptavidin biotin.  
 Finally we show the successful functionalization of antibodies to the surface of 
the CNT using similar functionalization protocol. The prepared SWNT sensors were 
functionalized with anti-EpCAM antibodies through a pyrene linker molecule. The 
pyrene rings of the 1-pyrenebutanoic acid, succinimidyl ester (PASE) adsorbed on to 
the sidewalls of the SWNT. The ester on the other end of the PASE provides the 
attachment to the antibodies as presented in Figure 36 (a) schematic. Antibody 
conjugated gold nanoparticles (15 nm) were targeted to the PASE functionalized 
nanotubes and imaged in a SEM to assess their binding to nanotube. The antibody 
conjugated nanoparticles were observed to be arranged on the nanotube side wall as 
presented in Figure 36 (b). A negative control experiment was conducted by targeting 
antibody conjugated gold nanoparticles to bare nanotube surface without PASE 
functionalization to the nanotube surface. The results in Figure 36 (c) conclusively 
suggest that antibody functionalized nanoparticles attached to the nanotube side wall by 
binding to PASE while no functionalization occurred between bare nanotubes and 
antibody conjugated nanoparticles without the presence of the PASE linker molecule. 
Overall the PASE conjugation was proven to provide a stable platform for all protein 
and cell sensing and capture needs of this thesis. The efficiency of streptavidin–biotin 
conjugation chemistry, Figure 35, and Au-amine-polymer-conjugation chemistry, 
Figure 34, were compared with antibody–PASE functionalization in Figure 36 (d).  
 As a result of these studies, it was found that the antibody–PASE 
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Figure 35. Functionalization of streptavidin. Demonstrating the successful 
functionalization of streptavidin onto CNT by PASE molecule, by showing the specific 
binding of biotin conjugated gold NPs to the side walls of streptavidin functionalized 
CNT. (A) Schematic showing the interaction of biotin conjugated NPs with the 
functionalized CNT surface. (B) Schematic showing the bare CNT presenting no 
binding site for biotin conjugated NPs. (C and D) SEM images of CNT devices after 
NP functionalization. (C) SEM image of positive control (A), biotin conjugated NPs are 
clearly binding to the streptavidin functionalized CNTs. (D) SEM image of negative 
control (B) showing no significant interaction between biotin conjugated NPs and the 
bare CNT surface. 
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functionalization gave the most promising results with ∼76 particles per μm2, followed 
by streptavidin–biotin conjugation chemistry of ∼71 particles per μm2, followed by Au-
amine-polymer functionalization of ∼21 particles per μm2. Non-specific controls 
yielded about ∼1–6 particles per μm2. Standard deviation of the particle count by each 
method was plotted suggesting high degree of control and reproducibility of the 
functionalization and attachment of antibody to the PASE molecule. The devices 
presented here had channel length of 100 μm and width of 80 μm. Assuming 1 antibody 
site per particle, this would translate into 608,000 sites for antibody binding to PASE 
for the entire device. Similarly, for the streptavidin–biotin chemistry, this would 
translate into 568,000 binding sites and for the amine-polymer-Au nanoparticle 
functionalization protocol, this would translate into 168,000 binding sites. For non-
specific controls this would translate into 8000–48 000 binding sites. Typically, a 
cancer cell surface has 250,000 receptors overexpressed all over the surface compared 
to normal cells which has less than 10,000. With 608,000 sites, this is a ratio 2.4 
antibody available per receptor for interaction. Based on these results, functionalization 
protocol developed here is very suitable for free protein and cell capture. 
 4.3. CNT DEVICE SENSOR CHARACTERISTICS 
 As a result of the functionalization studies in the previous section, it was 
demonstrated that the CNT devices developed here can also be investigated for sensor 
application. It was shown that the functionalized CNT complex can be customized with 
different complex biomolecules and antibodies to interact, bind and capture targeted 
specific proteins and nano particles. This characteristic is essential for any biosensor. In 
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Figure 36. Functionalization of antibodies. (a) Schematic of the PASE 
functionalization protocol; (b) SEM image of positive control suggesting high degree of 
antibody functionalization; (c) SEM image of negative control suggesting no 
functionalization; (d) comparison of different functionalization protocols including 
PASE–antibody, streptavidin–biotin and amine-polymer-NP conjugation.  
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this section we will review the studies done on how introduction of free charges to the 
surface of the CNT device can affect its electrical properties. The source of charge 
potential affecting the CNT in a solution can be induced by free ion injected in the 
solution or carried by proteins binding to the CNT surface. In this section we will 
utilize ionic solutions to characterize the properties of CNT device as sensors.  
4.3.1. UNDERSTANDING SEMICONDUCTING CNT FOR CHEMICAL SENSING 
 Understanding the network structure and how they behave reproducibly is 
highly important in assessing complex biochemical reactions. Towards this, series of 
experiments were conducted in Hg
2+
 and NH4
+ ions to understand the change in 
electrical characteristics of the bare CNT devices. HgCl2 in DI water was prepared to 
create Hg
2+
 ions with concentrations ranging from 30 pM to 13 μM. Similarly, NH4OH 
in DI water was prepared to create  NH4
+ with concentrations ranging from 300 nM to 
1.5 mM. Figure 37 (a) presents the real time monitoring of both  NH4
+ and Hg
2+
 ions 
with each spike is a measure of increasing concentration from 300 nM to 1.3mM for 
NH4
+ ions and 30 pM to 13 μM for Hg2+ ions respectively. Surprisingly, we found that 
both Hg
2+
 and  NH4
+ ions increased the conductance of the nanotube network as the 
concentration of ions increased. It is seen that for some intermediate concentrations, the 
amplitude of the spike decrease suggesting saturation of the sensor but they are also 
seen to recover as the amplitudes increase with time at higher concentrations. This is 
clearly observed in Hg
2+
 ion sensing. In past Hg
2+
 has been shown to increase the 
conductance of nanotube device [353], while  NH4
+ ions decreased the conductance of 
the device [354]. The increase in conductance with concentration for both Hg
2+
 and 
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NH4
+ ion are as a result of doping. Typical electron–acceptor dopants such as I2, and Br2 
are expected to transfer electrons from the carbon π states in the tubes to the dopant 
molecules, creating an increase in hole carriers in the SWNTs [333]. This can increase 
the conductivity due to charging when positively charged molecules such as NH4
+ and 
Hg
2+
 interact with the nanotube thereby increasing the current of the p-type nanotube. 
The shift in the RBM and G mode of the Raman spectrum presented, Figure 26 (C), 
also agrees with the presence of iodine as dopant in these nanotubes. An interesting 
result is that our doped nanotube devices did take the level of detection of both Hg
2+
 
and NH4
+ ions to ∼30 pM and ∼300 nM respectively, which is significantly higher in 
sensitivity compared to past reports on pristine nanotubes where the limits of detection 
has been shown to be ∼10 nM for Hg2+ [355]. Voltage sweeps as presented in Figure 
37 (b) shows a shift in threshold voltage towards more positive VG suggesting p-type 
behavior. The real time Hg
2+
 and NH4
+ chemical sensing therefore correlates well with 
the voltage sweeps. Figure 37 (c) presents the change in IDS versus VG for different 
concentrations of Hg
2+
 and NH4
+ ions. As the concentration increases, so does the 
current suggesting an increase in hole carrier density for both types of ions. A ΔG/G0, 
normalized conductance, versus log [A] is presented in Figure 37 (d) suggesting a 
Langmuir-adsorption isotherm with a linear response centered around [A] = 1/K. The 
higher (ΔG/ G0) for our doped nanotubes (y-axis) presented here in the Langmuir 
adsorption isotherm compared to past networks of mixed metallic and semiconducting 
nanotube [353] also suggests the increased sensitivity of the iodine doped 
semiconducting nanotube sensors and lower limits of detection. The mechanism of 
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Figure 37. Understanding semiconducting nanotube network. (a) Real time response of 
device to concentrations of NH4
+, 300 nM to 1.3 mM, and Hg
2+, 30 pM to 13 μM, ions; 
(b) voltage sweep before and after exposure to NH4
+  and Hg
2+
 ions; (c) concentration 
sensitivity of voltage sweep for NH4
+  and Hg
2+
 ions; (d) normalized signal conductance 
versus concentration of Hg
2+
 ions suggesting Langmuir adsorption isotherm. The inset 
shows the percentage sensitivity versus concentration for Hg
2+
. Similar results were 
seen for NH4
+
  ions suggesting same sensing mechanism. 
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sensing ions for both NH4
+ and Hg
2+
 is therefore due to an increase in carrier density of 
iodine doped nanotubes. The same increase in conductance for the same type of charge 
also suggests similar mechanism and predictable sensor response of the doped 
nanotubes sensor devices. One application of these iodine doped nanotube networks 
with 30 pM sensitivity for Hg
2+
 could be in screening drinking water (Hg
2+
 ions set by 
most governmental EPA is ∼10 nM [355]).  
 In the next chapter we will build on the findings here and utilize the CNT 
devices for capturing and sensing free proteins.  
4.3.2. Hg
2+
 AND NH4
+ ION EXPERIMENTATION METHODS  
 HgCl2 (Sigma-Aldrich, Cat. No. 215465) in DI water was prepared to create 
Hg
2+
 ions with concentrations ranging from 30 pM to 13 μM. Similarly, NH4OH 
(Sigma-Aldrich, Cat. No. 338818) in DI water was prepared with concentrations 
ranging from 300 nM to 1.5 mM. Array of un-functionalized bare devices were 
prepared with initial 5 μl droplet of DI water suspended on top. 100 mV source drain 
bias and 0 V gate voltage applied by reference Ag/AgCl electrode. Device current was 
monitored as ion concentrations were increased on the devices every 180 s. In addition 
voltage-sweep readings were taken after addition of each ion concentration. 
4.3.3. LANGMUIR ISOTHERM MODEL FOR BIOSENSORS 
 After conducting ion sensing with the CNT device, we can propose theoretical 
model to predict the set parameters, where the target molecules are adsorbed onto the 
CNT surfaces via the Langmuir isotherm process and the conductance of the sensor 
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transducer via capacitive coupling or charge transfer. Figure 38 shows a schematic 
diagram depicting the experimental setup and Figure 37 (d) shows the ion data fitted to 
the theoretical model for the CNT network sensors. 
 For the theoretical model, we assume that analyte “A” in bulk solution was 
adsorbed onto a finite number of binding sites “B” on the CNT surfaces following a 
Langmuir isotherm model, Figure 38. In the Langmuir isotherm model, it is assumed 
that analyte molecules in solution bind to a finite number of binding sites on solid 
substrates, and the analyte molecules in solution and those bound to the binding sites 
form an equilibrium. In the case of specific biosensors based on CNT FETs, specific 
receptor molecules fixed on CNT surfaces work as binding sites [270]. Let [A], [B], 
[AB], and [B]max represent the concentration of analytes in bulk solution, the surface 
density of binding sites on CNT networks, the surface density of adsorbed analyte 
molecules, and the maximum surface density of binding sites on CNT networks, 
respectively. Then, the surface density of adsorbed analytes can be expressed following 
a Langmuir isotherm, Figure 37 (d), as: 
 
[𝐴𝐵] =  [𝐵]𝑚𝑎𝑥 ×
[𝐴]
[𝐴] + 1/𝐾
 (12) 
with equilibrium constant K = k1/k-1, where k1 and k-1 are the association and 
dissociation constants, respectively [355]. Since CNTs respond to analytes only within 
the distance of Debye length in ionic solutions due to the screening effect, [342] we can 
assume that the sensor response of our sensors is mostly due to the analytes adsorbed 
onto the CNT channels.  
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Figure 38. Schematic diagram depicting the measurement and the bases for the 
theoretical model. Showing the CNT device as described in Chapter 3 with a liquid 
droplet on top containing the analytes [A]. CNT film is functionalized with the binding 
sites [B]. [AB] shows the binding of analyte to the binding site on CNT surface.  
 
 CNT network-based channels are usually composed of multiple CNTs 
overlapping on each other to form junctions. In this case, we can expect rather diffusive 
charge transport due to the short mean free paths. Thus, we can ignore any coherent 
gating effect and assume that the current change ΔI in the channel is affected by the 
adsorbed analyte concentration [AB] on CNT surfaces via electric coupling like 
 ∆𝐼 =  𝐺𝐿 × ∆𝑉𝐴 ≈ 𝑔𝐿𝑉𝑑𝑠 ×
∆𝑞𝐴
𝐶0
  (13) 
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= 𝑔𝐿𝑉𝑑𝑠 ×
𝑞𝐴[𝐴𝐵]
𝐶0
 
= 𝑔𝐿𝑉𝑑𝑠 ×
𝑞𝐴
𝐶0
 [𝐵]𝑚𝑎𝑥 ×
[𝐴]
[𝐴] + 1/𝐾
 
where GL represents the liquid gate transconductance; ΔVA the liquid potential change 
around the CNTs caused by the adsorbed analyte molecules; 𝑔𝐿 the normalized 
transconductance defined by 𝑔𝐿 ≈ 𝐺𝐿/𝑉𝑑𝑠; ΔqA the total electric charge contributed by 
the adsorbed analyte molecules to the CNTs; qA the electric charge contributed by the 
unit surface density of the adsorbed analyte molecules to the CNTs; and C0 is the 
coupling constant between the analyte molecules and CNT surfaces [342]. 
 Based on previous reports, electric field gating [269] and direct charge transfer 
[308] are the most common mechanisms about how charged analytes near the CNT 
surface can affect the conductance of CNT network channels. For CNT devices qA and 
C0 are determined by the type of analytes and should not be affected by the CNT device 
structures [342]. 
 From eqn. 13, the sensor response, defined as the conductance change (ΔG = 
ΔI/Vds) with respect to initial conductance G0, becomes 
 ∆𝐺
𝐺0
=
𝑔𝐿
𝐺0
×
𝑞𝐴
𝐶0
 [𝐵]𝑚𝑎𝑥 ×
[𝐴]
[𝐴] + 1/𝐾
 (14) 
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 It is worth mentioning several important aspects of this equation. First, 
𝑔𝐿
𝐺0
 
represents the electrical characteristics of the CNT device and should be independent of 
the analyte species. It can be estimated by simple electrical measurement on the CNT 
device without performing actual sensing experiments. Second, 
𝑞𝐴
𝐶0
 [𝐵]𝑚𝑎𝑥 and K 
represent the electric coupling and the adsorption properties of the analyte molecules 
onto CNT-based sensor surfaces, respectively. Considering [B]max as a constant, both 
can be determined only by the analyte type and do not depend on the CNT device 
structures or nanotube chirality. 
 In a previous report Lee et al. reported that the sensor response can be 
expressed in a linear form to logarithmic concentration in certain range of concentration 
[356]. Accordingly, for this linear region we can write 
 ∆𝐺
𝐺0
~
1
4𝑙𝑜𝑔10𝑒
(
𝑔𝐿
𝐺0
) ×
𝑞𝐴
𝐶0
 [𝐵]𝑚𝑎𝑥 × [𝑙𝑜𝑔10[𝐴] + 𝑙𝑜𝑔10[𝑒
2𝐾]] (15) 
by setting x = log10 [A] and y = ΔG/G0, we can arrive to the following equation  
 𝑦~𝛼[𝑥 − 𝑦] (16) 
where 
 
𝛼 (≡
1
4𝑙𝑜𝑔10𝑒
(
𝑔𝐿
𝐺0
) ×
𝑞𝐴
𝐶0
 [𝐵]max) (17) 
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this way 𝑦(≡ −𝑙𝑜𝑔10(𝑒
2𝐾)) represent the slope and x-intercept of the sensor response 
graph, respectively, as indicated in Figure 37 (d).This model is effective, but it is 
important to note that slightest variation in CNT film distribution may cause a slight 
variation of surface binding site density and channel conductance of the CNT devices. 
Furthermore, even for the devices with uniform CNT density, the conductance of the 
devices shows some distribution due to the variation of the network connectivity as 
reported by other researchers also [357]. 
 The model explained above can be used to validate the experimental results. 
The measured response from the CNT device were plotted to the logarithmic 
concentration of analytes, and the linear region was fitted using eqn. 16, as presented in 
Figure 37 (d). The equilibrium constant K can be estimated from the x-intercept 
𝑦 ≡ −𝑙𝑜𝑔10(𝑒
2𝐾) of the fitting curve. K is defined as [A] = 1/K, with [A] obtained 
from the center point of the fitting curve, as shown on Figure 37 (d). In this case, K 
(equilibrium constant) value for Hg
2+
 analyte was estimated to be 𝐾 = 5 × 103.
129 
 
CHAPTER 5 
CNT DEVICES FOR CAPTURE AND SENSING OF CANCER BIOMARKER 
PROTEINS  
 
 Following CNT device characterization and functionalization, in this chapter we 
will investigate the capability of the CNT device micro-arrays for capturing and 
profiling electrical signature of free proteins. In our first attempt here, we will analyze 
the effect of the streptavidin biotin binding on the CNT surface and its effect on CNT’s 
electrical properties, namely conductance and voltage threshold. Following the 
successful functionalization protocol of streptavidin on the CNT surface using PASE 
molecule and capturing biotin conjugated gold nanoparticles on the surface of the CNT 
through the high-affinity interaction and binding of streptavidin and biotin. Next we 
will apply the same logic based on our antibody functionalization protocol, discussed in 
detail in Chapter 4, to capture and profile digital signature of cancer biomarker protein 
epithelial cell adhesion molecule (EpCAM). 
5.1. INTRODUCTION  
 Single wall carbon nanotubes are ideal candidates for label-free sensing; every 
atom is on the surface hence their electronic properties are very sensitive to the 
surrounding charge environment [226].  Many reports have described carbon nanotube 
sensors for detection of free proteins [344, 358, 359], DNA [360-362], viruses [363, 
364] and even cancer cells [133, 365, 366]. For many of these, the sensing mechanism 
is the gating effect of the target proteins as they bind to the antibodies, bringing them 
near the CNT within the Debye length of the fluid, ~ 1 nm in 1X PBS [367, 368]. 
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5.2. RESULTS 
5.2.1. DETECTION OF BIOTIN ON CNT DEVICES  
 In this section we report the study of biotin interaction on a streptavidin 
functionalized CNT device. Biotin-streptavidin interactions are chosen to demonstrate 
the first CNT device system on our platform because they are well studied binding 
partners that interact with very high affinity [352]. We compare two sets of CNT 
device: a) CNT devices that are functionalized with streptavidin using PASE linker 
molecule, and b) CNT devices that are not functionalized, bare CNT. We will compare 
the electrical signature of the devices as a function of change in current vs. time.  
 The functionalized devices were exposed to 1ng/mL biotin (Sigma Aldrich, Cat. 
No. B4501) in 1X PBS. The result of this experiment is shown in live conductance 
readings in Figure 39 (A). We observe that the change in conductance is equal or less 
than 2% for negative controls, not functionalized bare CNT devices, and greater than 
2% for positive controls, CNT devices functionalized with streptavidin, showing an 
increase in device current as a result of a biotin interaction with streptavidin on CNT 
surface. Additionally, the changes in the voltage sweep of the devices were also 
recorded. The bare devices (red line) and streptavidin functionalized devices (green 
line) were exposed to 1ng/mL biotin in 1X PBS. Voltage sweep was taken before and 
after the biotin target molecule injection on the device. The result of this experiment is 
shown in Figure 39 (B). 
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Figure 39. (A) Normalized live response of six CNT devices, three functionalized with 
streptavidin (positive control in green) and three not functionalized bare CNT devices 
(negative control in red). 5 µL of biotin solution, 1ng/mL in 1X PBS, was added to 
each device at 60 seconds and the electrical current of the device was recorded for the 
remaining 240 seconds. The functionalized devices current increased after biotin 
introduction suggesting negatively charged biotin molecules interacting with CNT 
surface while, the bare devices show no significant change thereby no specific 
interaction. Schematics in the right hand side of the figure illustrated the device 
functionalization state and its interaction with biotin molecule. (B) Shows the V-sweep 
response for before and after biotin introduction to the device. Functionalized positive 
control device, in green, shows a shift in the positive direction, correlating with the live 
current reading while negative control, ion red, shows no change.  
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5.2.2. DETECTION OF FREE EpCAM ON CNT DEVICES  
 Figure 40 and Figure 41 presents the results from three terminal devices on 
molecular EpCAM. Liquid gating, as shown in Figure 40 (A), Ag/AgCl electrode was 
used to apply gate voltage. In this study, we first attempted to ascertain shift in gate 
voltages due to specific versus non-specific interactions. Therefore, we used free 
proteins due to the simplicity of interactions. Figure 41 (A) Demonstrates the testing 
without antibody, IgG and anti-EpCAM. It is seen that for anti-EpCAM, there is a shift 
in the gate voltage after the addition of EpCAM indicated by blue line. Figure 40 (B) 
and Figure 41 (B) presents the ability to monitor each step (including PASE, anti- 
EpCAM functionalization, Tween 20 blocking and finally EpCAM). It is seen that 
exposure of EpCAM proteins caused a decrease in threshold voltage values decreasing 
the nanotube conductance due to interaction. This is the mechanism of sensing of 
proteins. Up to 1 ng/ml was detected using such device as shown in Figure 41 (C). The 
graph in Figure 41 (C) clearly shows the shift in gate voltage for different 
concentrations from 1 ng/ml to 1000 ng/ml done consecutively. This also suggests that 
the device does not get saturated over range of clinical concentrations (diagnostic gray 
zone: 4 ng/ml for Prostate-specific antigen (PSA) [289]). 
5.3. CONCLUSION AND ANALYSIS  
 In this chapter we demonstrated the biosensing capabilities of the CNT devices 
via streptavidin-biotin interaction and with antibody-biomarker interaction, EpCAM 
cancer biomarker. We showed detection of 1ng/mL of biotin and free EpCAM protein 
in the PBS solution environment. The nature of this interaction and its effect on CNT’s
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Figure 40. (A) The schematic of a protein/CTC detection scheme. The entire device 
except the active nanotube layer is sealed off using SU8 polymer. (B) CNT device 
history from bare to functionalization process and introduction of EpCAM molecule is 
presented in one graph as a function of V-sweep.  
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Figure 41. (A) Showing the typical V-sweep for three groups of devices, from left to 
right, not functionalized, IgG functionalized, and anti-EpCAM functionalized. In each 
case, initial sweep before EpCAM protein introduction and after sweep post EpCAM 
(1µg/mL) introduction to the device is presented. Both not functionalized and IgG 
functionalized showed no change with the introduction of EpCAM but anti-EpCAM 
functionalized showed a shift. (B) CNT device history from bare to functionalization 
process and introduction of EpCAM molecule is presented in one graph as a function of 
V-sweep. (C) Presents concentration dependent device response, showing detection of 
molecular EpCAM up to 1 ng/mL.  
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electrical property, modifying the device conductance and threshold voltage, can be 
explained in two general ways: the change in carrier mobility and carrier density as 
described in Section 2.3.4. We clearly demonstrated a shift in device conductance and 
threshold voltage as a function of analyte interaction with the CNT. Based on our 
observations we can assume that the change in device electrical property is a result of 
specific interaction of free protein with the CNT surface and change in carrier density 
of the nanotubes as discussed in Section 2.3.4. In the next chapter we will further 
investigate the biosensing capabilities of the CNT devices using aptamer molecules as a 
substitute for antibodies.  
5.4. EXPERIMENTAL    
5.4.1. CNT DEVICE FABRICATION  
 CNT thin film was assembled on a silicon/silicon dioxide wafer, 400 nm wet 
oxide, and micro-arrays were fabricated as described in Section 3.1. CCVD 
synthesized, single wall/double wall CNT mixture (99% weight) was purchased from 
Cheap Tubes Inc., 1-2 nm outer diameter and 3-30 μm length. CNTs were suspended in 
IPA at ~45 μg/mL and sonicated for 90 min. The solution was then diluted to~3.5 
μg/mL and sonicated for 3 hours to completely disperse the nanotubes. 40 μg CNT film 
was generated using this solution, Figure 24 (C). Generation 3 device design was used 
for these experiments.  
5.4.2. CNT DEVICE FUNCTIONALIZATION  
 CNT devices were incubated with 1-Pyrenebutanoic acid, succinimidyl ester 
(PASE) linker molecule for 2 hours. Next, they were incubated with streptavidin 
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(Sigma Aldrich, Cat. No. S4762) or anti-EpCAM antibody (Millipore, Cat. No. OP187) 
accordingly, at 10 µg/mL in 1X PBS, for 2 hours at room temperature, forming a CNT-
PASE-streptavidin complex. Finally, a surfactant, Tween20, was used to block 
functionalized nanotube sidewalls or PASE sites to minimize nonspecific interactions. 
The devices were incubated in 0.5% Tween20 for 2 h at room temperature. At the end, 
devices were cover by a droplet of 1X PBS and store in a humid chamber at 4 °C for 
further testing. For greater detail of the functionalization process please refer to Chapter 
4.  
5.4.3. EXPERIMENTAL SET-UP   
 Experimental set up is previously described in Section 3.3. The testing protocol 
started with a hydrated device, and a 5 μL droplet of 1X PBS which was placed 
immediately after functionalization. The bias was applied and the sensor was monitored 
for the initial 1-3 minutes, then 5 μL droplet of sample solution was pipetted directly 
into the standing 5 μL droplet. Devices were monitored for 120-360 seconds after each 
addition of a new sample solution. The total duration of one test varied from 180 to 
1980 seconds. To compare results among devices, ISD data were normalized to obtain 
the ΔG/G0 values for conductance. VG sweeps were recorded on each device before 
and after injection of the target sample.  
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CHAPTER 6 
ULTRASENSITIVE AND LABEL-FREE SENSING OF IL-6 BASED ON PASE 
FUNCTIONALIZED CARBON NANOTUBE MICRO-ARRAYS WITH RNA-
APTAMERS AS MOLECULAR RECOGNITION ELEMENTS 
 
6.1. INTRODUCTION    
When using antibodies as recognition elements, the large size of the antibody 
can enable the target protein to interact outside the space charge layer or the Debye 
length of the sensor. This could reduce the sensitivity and specificity of the biosensor. 
Thus, antibody binding fragments [342],  and aptamers [341] have been proposed for 
sensing very small concentrations of proteins. In the past nanotube-aptamer technology 
has been used to detect the binding of thrombin, IgE, and VEGF [369-371]. Previously 
researchers demonstrated IL-6 detection using antibody-nanotube systems with 
multiple label and amplification strategies [372-374].  Here for the first time we 
demonstrate label-free nanotube micro-array platforms using PASE conjugated 
aptamers for detection of IL-6 protein, an important cancer biomarker. 
6.1.1. APTAMERS   
 Aptamers are analogous to antibodies in their range of target recognition and 
variety of applications; here we will review several key advantages over their protein 
counterparts. Aptamers are self-refolding, single-chain, and redox-insensitive.  They 
also lack the large hydrophobic cores of proteins and thus do not aggregate.  They 
tolerate, or recover from, pH and temperatures that proteins do not [375]. Aptamers are 
easier and more economical to produce, especially at the affinity reagent scale.  In stark 
contrast to peptides, proteins and to some small chemicals, oligonucleotides, DNA 
138 
 
aptamers are made through chemical synthesis, a process that is well defined, highly 
reproducible, sequence independent and can be readily and predictably scaled up.  
Their production does not depend on bacteria, cell cultures or animals [375]. In contrast 
to antibodies, toxicity and low immunogenicity of particular antigens do not interfere 
with the aptamer selection.  Further, highly custom or “orphaned” targets can be 
addressed rapidly and cheaply [375]. Aptamers in general are capable of greater 
specificity and affinity than antibodies [376]. Additionally, they can easily be modified 
chemically to yield improved, custom tailored properties.  For instance, reporter and 
functional groups and PEG can easily be attached to the aptamer in a deterministic way. 
More specifically for the purposes of studies in this chapter, aptamers were modified 
with PASE functional molecule. Aptamers can also even be combined with antibodies 
if necessary [377, 378].   
 Aptamer’s small size leads to a high number of moles of target bound per gram, 
and they may improve transport properties allowing cell specific targeting and 
improved tissue penetration [379-383]. They are much more stable at ambient 
temperature than antibodies yielding a much higher shelf life, and they can tolerate 
transportation without any special requirements for cooling, eliminating the need for a 
continuous cold chain. As result, aptamers are attractive alternatives to replace 
antibodies for sensing applications in the long run. 
6.1.2. INTERLEUKIN-6 (IL-6)  
 Interleukin-6 (IL-6) is a multi-functional cytokine characterized as a regulator 
of immune and inflammatory responses [384, 385].  IL-6 plays a crucial role in tumor 
139 
 
microenvironment regulation in number of cancers namely breast, oral, prostate, and 
pancreas cancers to name a few [386-392]. Higher levels of IL-6 in the blood of 
patients have been associated with advanced/metastatic cancers [386, 393-395]. 
Overexpression of IL-6 receptor has also been shown in cervical cancer cells [396]. 
Such findings have increased the interest in development of anti-IL-6 therapeutics to 
target many of related diseases [397-401]. In this environment an efficient, simple and 
reliable diagnostics technique would be of significant interest and nanotube micro-
arrays can be equipped for sensitive detection of IL-6 biomarker.   
 Detection of IL-6 is only applicable at low concentrations, 12-300 pg/ml, for 
practical clinical utility in metastatic cancers [394, 402-405]. Electrochemical sensing 
of IL-6 has been reported using different methods namely gold nanoparticles, carbon 
nanotube forest electrodes and ferrocene loaded polyelectrolyte nanoparticles [372-
374]. Detecting very small amounts of biomarkers using CNT-FETs has been a 
challenge due to the complication that relative large size of antibodies creates in 
regards to Debye length. The effect on the mobile charge on the material is not realized 
if the target molecule is placed Debye length away from the surplus charge [406], 
which can be the case in the ionic environment that the CNT-FET biosensors operate in 
for biological applications with reference to the antibody size. To solve this issue 
aptamers have been used for biosensing of immunoglobin E (IgE)  using CNT-FETs 
and showed improvement in sensor performance compared to an antibody coated 
nanotube channel under similar conditions [341]. Using aptamers we have 
demonstrated the ability to detect IL-6 at concentrations as low as 1 pg/ml by using  
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Figure 42. Schematic showing, (A) the reaction of PASE onto aptamer, (B) PASE 
conjugated aptamer functionalized CNT structure and aptamer interaction with IL-6 
protein on the surface of the CNT. (C) Schematic illustration of the blocking of CNT 
surface with tween-20 molecule. (D and E) AFM image showing a phase image, (D), 
and Z-Axis image, (E), of bare CNT, (a) and (b), functionalized CNT with IL-6 
aptamer, (c) and (d), and IL-6 protein binding to aptamer/CNT structure,(e) and (f). 
Images were obtained using dry tapping mode (Nanosurf NaioAFM system). Scale bar 
= 100 nm. 
nm 
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nanotube micro-arrays. 
6.2. RESULTS 
 In this chapter, we demonstrate the detection of ultra-low levels of IL-6 protein 
using PASE conjugated IL-6 aptamer functionalized on the nanotube channels. The 
RNA-aptamer specific to the IL-6 protein was used as the recognition element. The 
pyrene rings of the 1-pyrenebutanoic acid, succinimidyl ester (PASE) adsorb on to the 
sidewalls of the SWNT through  stacking [344]. The PASE conjugated IL-6 aptamers 
composite (Length: 32 nts, Base Pair Biotechnologies, Cat. No. 575702; 5’- NH2 
modification) was adsorbed on to the side wall of the SWNT transistor to produce a 
stable nanotube-PASE-aptamer composite as presented in Figure 42 (A). The amine 
group on the PASE provides an attachment site for the NH2 modified aptamers similar 
to past reports [341]. Atomic Force Microscopy (AFM) was used to image the bare 
nanotubes, PASE-aptamer functionalized nanotube and the binding of IL-6 on the 
functionalized nanotube surface. Figure 42 (D and E) presents the Z-axis and the AFM 
phase image of bare nanotubes (blue), PASE-aptamer conjugate adsorption to the 
nanotube side wall in red and the IL-6 binding to the functionalized CNT surface, in 
green . The phase image visually distinguishes the bare nanotube, Figure 42 (a), from 
nanotube surface with aptamer, Figure 42 (c), and aptamer-IL-6 complex, Figure 42 (e). 
Z-axis AFM image color codes the CNT surface as a function of its height. Figure 42 
(b), shows the bare nanotube height at ~6 nm. Figure 42 (d), shows a similar nanotube 
after aptamer functionalization, here we can observe a change in texture and height, ~9 
nm, of the nanotubes. The ~3 nm increase in CNT height after aptamer 
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functionalization is in scope with expected aptamer size, 1-3 nm diameter sphere 
(~14,000 Da) provided by supplier (Base Pair Biotechnologies). Finally, Figure 42 (f) 
demonstrate functionalized nanotube surface after injection of IL-6 target protein (10 
pg/mL), here we can see the interaction and binding of the IL-6 protein to the IL-6 
aptamer on the surface of the CNT as a function of its height , ~ 19 nm, and texture. 
These results shows that the surface height of the CNT increased by about 10 nm as a 
result of this specific interaction. The green color of the IL-6 binding shows almost 
complete coverage on the nanotube surface suggesting the devices may have high 
sensitivity based on PASE-functionalization protocol. As a result of these AFM studies 
we can suggest that the functionalization protocol and specific targeting of IL-6 protein 
was a success.  
 SWNT devices were fabricated using vacuum filtration of carbon nanotubes and 
device processing inside a clean room [133]. Figure 43 presents the wafer scale image 
of the 240 element array of nanotube network sensors, generation 3. The sensor arrays 
were developed using a combination of vacuum filtration of carbon nanotube network 
film onto oxide coated wafers followed by multiple photo-lithography and reactive ion 
etching as described in Section 3.1. Our films were low concentrations (4 µg) and most 
of our films were isotropic and also mostly single layers laying on the substrate as 
shown in the SEM image of Figure 43 (F). Figure 44 presents the characteristics of the 
CNT-FET in buffer solution. The source to drain current (IDS) versus source to drain 
voltage (VDS) at different gate voltages is presented in Figure 44. The source to drain 
current decreased with increasing positive gate voltage. This suggest the device works
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Figure 43. Device characterization showing optical images of the sensor array 
platform, (A, B, C and D), Raman characterization (E) and SEM image (F) of the CNT 
film imbedded within the sensors. 
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as a p-type semiconductor in 1X PBS. No leakage is seen at positive voltage the current 
is almost zero suggesting superior p-type transistor compared to past reports where 
there was still a significant drain current at zero and increasingly positive gate voltage  
[341]. Our CNT-FET is also definitely superior compared to past reports on using 
CNT-FET with antibody fragments which used a mixture of metallic and 
semiconducting nanotubes resulting in poor on/off ratios [342]. This point is important 
and needs to be emphasized as the whole sensing principle relies on the charge 
introduced at the nanotube channels either reducing or increasing the conductance with 
introduction of IL-6 protein. Leakage currents or poor on/off  ratio’s can thus affect the 
sensing reliability if one needs to detect such ultra-low concentrations. Thus we can be 
confident in our experiments that at VG = 0 V, the increase or decrease in conductance 
with introduction of protein is as a result of binding alone and not as a result of the  
 
Figure 44. Electrical properties of CNT-FET devices before PASE-aptamer 
functionalization in phosphate buffer solution (1X PBS, pH 7.4). 
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currents in the substrate. 
 Figure 45 (A and B)  presents the real time sensing of IL-6 protein (BioLegend, 
Cat No. 575704) on the PASE-aptamer functionalized nanotube. First 5 l droplet of 1 
mM MgCl2  1X PBS was placed on the functionalized device. The change in 
conductance was recorded followed by introduction of 1 pg/ml of IL-6. As soon as IL-6 
was introduced, the conductance decreased and reached a saturation value as shown in 
blue color line of Figure 45 (A). Introduction of plain PBS or BSA on the 
functionalized surface showed little/no change and is shown in red and grey lines. 
Figure 45 (B) presents the time dependence of the normalized conductance on 
introducing 1 pg/mL IL-6 to the bare unfunctionalized nanotube channel. The increase 
in conductance of the CNT-FET was clearly observed after introduction of 1 pg/mL of 
IL-6 onto bare CNT-FET without aptamers. Since IL-6 were non-specifically interacted 
with the bare CNT channels, the entire molecule must be placed inside the Debye 
length. IL-6 was negatively charged under our experimental conditions (pH 7.4), which 
was relatively higher than the isoelectronic point of IL-6 (pH(I) ~6.96). The increase in 
conductance is therefore expected as the negative charge on the IL-6 is equivalent to 
applying a negative gate voltage, assuming capacitive gating effect [341].  
 Figure 45 (C, D, and E) presents the transistor device characteristics for PASE 
aptamer functionalized nanotube device. All the devices were p-type with average 
Ion/Ioff of ~180 and the nanotubes were semiconducting carbon nanotubes [133]. On 
introduction of PBS as well as BSA controls on the functionalized nanotube surface 
there was no significant shift in the I-VG curve. However, on introduction of 1 pg/ml of 
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Figure 45. (A-C) Sensor response of the CNT-biosensor at source-drain bias of 0.1 V 
and at the gate bias of 0 V. (A) indicates the response after the introduction of  20nM 
BSA (red line), 1mM MgCL2 1X PBS (gray line), 1pg IL-6 target protein (blue line) to 
functionalized CNT-biosensor and (B) 1 pg IL-6 target protein to bare unfunctionalized 
CNT-biosensor (green line). (C) Shows response of tween-20 blocked CNT-biosensor 
to IL-6 protein (blue line), and BSA (red line). Arrow indicates the point of sample 
injection. (D-H) Before and after IDS-VGS characterization of IL-6 aptamer 
functionalized CNT-biosensor with (D) 1 pg  and 1 ng IL-6 protein injection, (E) blank 
1mM MgCL2 1X PBS samples, and (F) 20 nM BSA. (G and H) show IDS-VGS response 
of tween-20 blocked CNT-biosensor to BSA (G), and IL-6 protein (H).
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IL-6 and 1 ng/ml of IL-6 on two different devices with similar initial characteristics, 
there was a change in the I-VG curve. The I-VG curve shifted down with increasing 
concentration suggesting positively charges by IL-6 decreased the conductance of the 
nanotube device.  This is equivalent to applying a positive gate voltage and has been 
seen in previous reports [341]. The conjugated negatively charged IL-6-aptamer was 
placed inside the electrical double layer in the buffer solution, local positive charge in 
IL-6 molecules in the Debye length was detected as a decrease in conductance 
[341]. The specificity of the device is observed from the controls where both PBS and 
BSA showed no response of the nanotube sensor. Thus the results suggest that non-
specific binding was successfully supressed using aptamer functionalized nanotube 
surface. 
 Figure 46 (A) presents the real time response of the nanotube sensor from 1 
pg/ml to 10 ng/ml of the Il-6. Each concentration of the IL-6 was seen with a 
characteristic spike as well as decrease in conductance as seen in all the experiments 
before. The change in normalized conductance ratio of the device went from 1.0 to less 
than 0.80, suggesting interaction between IL-6 protein and aptamer-PASE 
functionalized CNT and screening of the nanotube surface as a result of this interaction. 
The device saturated beyond 100 ng suggesting all the binding sites were depleted 
above these concentrations on the device and thus a saturated response. Figure 46 (B) 
presents the sensitivity as a fuunction of concentration. The  linear range at low 
concentration suggest sensitivity for 1-100 pg which could be useful for biomarker 
testing. 
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Figure 46. (A) Time dependence of normalized source-drain current of the CNT-
biosensor at the source-drain bias of 0.1 V and at gate bias of 0 V after the introduction 
of IL-6 target protein at various concentrations onto the IL-6 aptamer functionalized 
CNT-biosensor. Arrows indicate the points of IL-6 target protein injection. (B) The 
Sensitivity of IL-6 aptamer CNT-biosensor as a function of IL-6 protein concentration 
(1pg to 10 ng /mL)   
 
6.3. DISCUSSION AND CONCLUSIONS  
 The ability to detect IL-6 at low concentrations in serum can have implications 
in the clinic. IL-6 levels in serum >12 pg/ml have been correlated with large tumor size 
and elevated Serum-C Reactive Protein (CRP) levels for colorectal cancers [407]. In 
another study, patients with undetectable levels of IL-6 in the serum had a mean CRP 
level of 27 mg/liter, whereas it was 43 mg/liter for patients with detectable IL-6 levels 
(~300 pg/ml) [408].  Patients with IL-6 levels >300 pg/ml exhibited CRP levels of 
117mg/liter [408].  IL-6 is detected in blood due to the secretion of IL-6 from the  
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cancer cells and thus very low detection thresholds can lead to life saving measures. 
 In the past the gold nanoparticle immunosensor gave a detection limit (DL) of 
10 pg /mL of IL-6 in 10 L calf serum [372].  The sensitivity of SWNT forest 
immunosensor was 0.5 pg/ml as their lowest detection level for the same assay 
protocol, however here multi-label detection techniques were used which is still 
disadvantages  and inferior compared to our label-free technique [373, 374]. Our 
nanotube-FET with 1 pg/ml sensitivity is thus capable of achieving 10 pg/ml sensitivity 
in serum. These are our next steps in being able to use these micro-arrays in unaltered 
blood that can detect both levels of IL-6 and circulating tumor cells. The big question 
that is not yet answered: is there a correlation between levels of IL-6 and CTCs in 
blood which could be indicative of the metastatic condition. Past reports have shown 
increased level of serum IL-6 in some patients with lung cancer has been reported 
previously and shown to be part of an inflammatory response [409]. Detecting both 
CTCs and IL-6 simultaneously would require an assay where both can be detected 
easily with minimal sample preparation and testing. The nanotube micro-arrays with 
the PASE functionalization protocol thus pave the way to detect these two important 
targets for diagnosis, treatment and progression of cancer. 
 To conclude, we have presented an approach to detect an important cancer 
biomarker namely IL-6 using semiconducting nanotube channels. IL-6 in the level of 1 
pg/ml to 10 ng/ml was detected successfully using a PASE conjugated IL-6 aptamer as 
the molecular recognition element. The nanotube micro-array is thus capable of 
capturing cancer cells using antibodies and detecting IL-6 using aptamers. An assay 
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that could detect both proteins and cells simultaneously can lead to an understanding 
between the serum levels of IL-6, CRP levels and the number of CTCs in blood.  
6.4. MATERIALS AND METHODS  
6.4.1. DEVICE FABRICATION   
  The sensors are a three-terminal design. Each device shares a common source, 
and each has separate drain electrodes, generation 3. A carbon nanotube network 
connects the source and drain Ni/Au electrodes and the electrodes are covered by an 
insulating layer of SU8 photopolymer. Gate voltage is applied through an external 
Ag/AgCl reference electrode. 4 µg film preparation and microfabrication of generation 
3 devices are described in detail in Chapter 3. 
6.4.2. DEVICE FUNCTIONALIZATION 
 CNT biosensors were functionalized with 1-Pyrenebutanoic Acid Succinimidyl 
Ester (PASE) conjugated IL-6 aptamers (Base Pair biotechnologies, Cat. No. 
ATW0077) at 20 μg/mL in 1mM MgCL2 1X PBS buffer solution for 2 hours at room 
temperature. Devices then were functionalized with tween-20.  Devices were rinsed 
three times in 1mM MgCl2 1X PBS and were stored with 5 μL droplet of 1mM MgCl2 
1X PBS for testing. For greater detail of the functionalization protocol please see 
Chapter 4. 
6.4.3. TESTING  
 Bare non-functionalized and IL-6 aptamer functionalized devices were 
prepared. Both batches of devices were tested with 2 μL droplets of 1mM MgCl2 1X 
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PBS (blank buffer solution), BSA (20 nM in buffer solution) and IL-6 target protein (1 
pg to 10 ng/mL in buffer solution) individually.  
 100 mV source-drain bias and 0 V gate bias applied across the sensor and the 
source drain current, IDS, was monitored vs time. 2 μL droplet of sample solution, 1mM 
MgCl2 1X PBS, BSA, or IL-6 protein was pipetted directly into the standing 5 μL 1mM 
MgCl2 1X PBS droplet on top of the devices. The change in current flow was 
monitored for the next three minutes.  Devices were tested on a Signatone probe station 
platform using an Agilent 4156C semiconductor parameter analyzer with a Lab View 
Software. The entire probe station assembly is placed on an optical table that is 
vibration isolated using air on all 4 legs. A metal box covers the entire assembly to 
avoid electromagnetic interference. The probes are connected to the parameter analyzer 
using a triaxial cable that is EM shielded. Throughout the testing the devices were 
maintained inside a humid chamber to prevent evaporation of the sample droplet. For 
more detail on testing set-up please see Section 3.3. 
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CHAPTER 7 
NANOTUBE DEVICES FOR CAPTURE AND DIGITAL PROFILING OF 
CIRCULATING TUMOR CELLS 
 
7.1. INTRODUCTION  
 Circulating Tumor Cells (CTCs) were first discovered in 1869 in blood of 
patients suffering from metastatic disease by Australian physician Thomas Ashworth 
using optical microscopy [10]. Current understanding is that these CTCs are thought to 
mediate spread of cancer at distant sites including lung, liver, bone and brain. CTCs are 
shed by primary and metastatic cancers in the range of 5-77,200/ml [410]. Recent 
clinically approved techniques for CTC detection include Veridex from Cell Search 
[411], CTC chip [33], and ADNA test [73, 412]. While these methods are impressive 
none of them are handheld point of care device where the test can be administered in 
clinic and results obtained in few minutes both for CTCs and cancer biomarkers. 
Therefore, with this objective in mind, we present our approach on development of 
nanotube devices for detection of both protein biomarkers, presented in Chapter 5, and 
CTCs using nanotube devices. 
 In this chapter, we will examine the interaction and response of the CNT micro-
array devices to living cells, extending the results presented in the previous chapter on 
free protein interaction with devices; here we will more specifically examine the 
interaction of the receptor proteins on cell membrane with the functionalized nanotube 
surface. As seen in Figure 47 , a living cell membrane is much more complicated than a 
free standing protein. In a cell, the bilayer contains a complicated structure of 
membrane proteins/receptors that are of critical importance for cellular functions such  
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Figure 47. Illustration of a cell membrane [413]. The plasma membrane is composed 
of many proteins, receptors, and channels embedded in a fluid bilayer of phospholipids. 
 
As communication with other cells, adhesion to external structures, and exchange of 
nutrients and wastes. It would be exciting to be able to locally capture the receptor 
protein structure on the cell membrane, by targeting tens of thousands of over 
expressed receptors that are present on the cancer cell membrane (i.e. EpCAM and 
HER-2), and anchoring the cell on the surface of the CNT through this interaction. 
7.2. CELL CULTURE 
 Three breast adenocarcinoma cell lines, MCF-7, MCF-10A and SKBR-3 
(ATCC, Cat. No. HTB-22; CRL-10317; HTB-30) were prepared for cell culture studies 
in this thesis. The general culture, preparation, and characterization of these cells 
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reviewed in this section apply to all cell studies from here on: spiked cells in 1X PBS 
buffer solution (Chapter 7), buffy coat (Chapter 8), and blood (Chapter 9). 
 Michigan Cancer Foundation-7 (MCF-7) is an adherent breast cancer cell line 
isolated in 1970 from a 69-year-old Caucasian woman. MCF-7 cells were extracted 
form an invasive primary ductal carcinoma breast tumor and over expresses EpCAM 
receptors [414].  
 Michigan Cancer Foundation-10 A (MCF-10A) is a non-tumorigenic epithelial 
cell line derived from adherent breast tissue cells from a 36 years old Caucasian female 
[415].  
 SKBR-3 is an adherent cell line isolated by the Memorial Sloan-Kettering 
Cancer Center in 1970. This cell line was derived from a 43 year old Caucasian female 
mammary gland, breast tissue, by pleural effusion due to an adenocarcinoma 
originating in the breast. The SKBR-3 cell line over expresses the HER-2 gene product 
including HER-2 membrane receptors [416].  
 The breast adenocarcinoma cell lines, MCF-7, MCF-10 A and SKBR-3 (ATCC, 
Cat. No. HTB-22; CRL-10317; HTB-30), were received frozen and cultured under 
conditions as recommended by the supplier, MCF-7: Eagle’s Minimum Essential 
Medium (ATCC Cat. No. 30-2003), SKBR-3: McCoy’s 5a Medium Modified Medium 
(ATCC Cat. No. 30-2007), and MCF-10A: MEGM kit (Lonza/Clonetics Corp. Cat. No. 
CC-3150) with the proper additives as recommended by ATCC and 10% fetal bovine 
serum (FBS), inside a cell culture incubator at 37 °C, 5% CO2, and 95% air, Figure 48.
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Figure 48. (A, B, and C) optical microscope image showing the cells cultured at ~80% 
confluency. Cells are detached at this point to be counted and prepared for testing. (D) 
Shows an optical microscope image of the detached SKBR-3 cells (right) on a 
hemocytometer counting device (left).   
 
These immortal cell lines were subcultured and cryopreserved to be used for all the cell 
experiments in this thesis.   
7.2.1. IMMUNOFLUORESCENT STAINING AND CONFOCAL MICROSCOPY 
 MCF-10A cells are non-tumorigenic and are EpCAM negative. MCF-7 and 
SKBR-3 are EpCAM positive cell lines. SKBR-3 is additionally positive for HER-2 
[417]. IgG is negative all across three cell lines. Series of immunofluorescent staining 
and confocal microscopy studies were done to confirm the overexpressed receptors 
mentioned above with all the cells used for the objectives of this thesis.  
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 SKBR-3, MCF-10A, and MCF-7 cell lines were each suspended on a separate 
coverslip. The coverslips were prepared and stained with anti-EpCAM primary 
antibody, anti-mouse IgG-TR Texas Red conjugated secondary antibody, and DAPI 
according to the standard immunofluorescent staining protocol. Confocal laser scanning 
microscopy images were obtained on a Nikon Eclipse T. with coverslip corrected 
objective focused at 600X. Three images were obtained for each event through separate 
channels of DAPI, Texas Red, Alexa Green, and bright field accordingly. Merged 
images were created within the Nikon software as necessary. Results of these studies 
are presented in Figure 49, showing presence of DAPI on all three cell lines confirming 
a present of intact nucleus and viability of the cells. Additionally, MCF-7 and SKBR-3 
cells are positive for EpCAM and MCF-10A is negative.  
 In a separate study, SKBR-3 and MCF-7 cells were also stained for IgG, stained 
with secondary antibody Texas Red, and cytokeratin, stained with secondary antibody 
Alexa Green, Figure 50 (A), showing positive results for cytokeratin and negative for 
IgG on both cell lines. MCF-10A was also stained for IgG, stained with secondary 
antibody Alexa Green, Figure 50 (B), and showed negative results. Thereby we can 
conclude carcinoma cells used here were positive for cytokeratin and all cell lines used 
in studies for this theses were negative for IgG, aligned with previous reports [417].  
 In a separate study, SKBR-3 cells were investigated for overexpressing HER-2 
receptor. In this study SKBR-3 and MCF-10A, negative control, were both stained for 
HER-2 and DAPI and the results are presented in Figure 51. These results confirmed 
the over expression of HER-2 on SKBR-3 and its negative presence on MCF-10A cells. 
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Figure 49. Confocal microscopy images of MCF-7, SKBR-3, and MCF-10A cell lines 
immunostained for EpCAM and DAPI. MCF-7 and SKBR-3 cells are positive for both 
EpCAM (in red or green) and DAPI (in blue) while MCF-10A cells are negative for 
EPCAM.  
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Figure 50. Confocal microscopy images of SKBR-3, MCF-7, and MCF-10A. (A) 
Presents SKBR-3 and MCF-7 cells immunostained for DAPI, IgG, and cytokeratin. 
SKBR-3 and MCF-7 cells are positive for cytokeratin (in green), and DAPI (in blue) 
while negative for IgG. (B) SKBR-3 and MCF-10A cells immunostained for DAPI, 
EpCAM, and IgG. EpCAM is positive for SKBR-3 and negative for MCF-10A, both 
cell lines are negative for IgG. IgG shows to be a universal negative control across cell 
lines.   
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Figure 51. Confocal microscope image of the SKBR-3 and MCF-10 cells 
immunostained for DAPI and HER-2. SKBR-3 is positive for HER-2 and DAPI. MCF-
10A in negative for HER-2 and positive for DAPI. First and third columns present 
culture of cells and second and forth raw demonstrate single cell staining.  
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7.2.2. CELL CULTURE PREPARATION FOR TESTING 
 Cells were grown in a culture medium for 3-4 days to reach ~80% confluence, 
Figure 48 (A, B, and C). The cells were then detached using Accutase solution (Sigma, 
Cat. No. A6964), cell detachment solution of proteolytic and collagenolytic enzyme, 
centrifuged and re-suspended in 1X PBS, counted using a hemocytometer, Figure 48 
(D), and prepared at a proper concentration. 
 For the purposes of the studies in this chapter, MCF-7, SKBR-3, MCF-10A 
cells were each separately prepared at 10,000 cells/µL in 1X PBS buffer solution. The 
prepared concentrations of cells were used for testing the CNT devices for cell capture 
and detection as discussed in the results section.  
7.3. RESULTS  
 Figure 40 (A) presents the schematic of the device for testing. The nanotube 
devices that were produced using vacuum filtration followed by film transfer, 
lithography, etching, and post processing were functionalized with PASE and antibody. 
The silver (Ag)/silver chloride (AgCl) reference electrode was used as the third gate 
electrode. The entire device except the active nanotube layer is sealed with an SU8 
polymer. Figure 52 (A) presents optical image of the testing platform of the first-
generation, wafer with 60 devices, also presented in Figure 23 (A), and Figure 52 (B) 
shows an optical microscope close up image of the device with the spiked sample on 
top. The active area of the single device is 100 X 80 μm to enable the capture and 
detection of cells. Figure 52 (C) shows a confocal image of a single cell on the device, 
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indicating the viability of the cell and showing the active EpCAM receptors on the cell 
membrane at the time of testing.  
7.3.1. NANOTUBE DEVICE ARRAY TESTING IN CELL CULTURES 
 Cellular detection with these devices is less understood and also quite rare 
because of the heterogeneity of the cell surface. CNT -immunosensor detection of cells 
via their surface markers has only been reported with devices containing nanotubes 
immobilized in a 1-μm gap between electrodes. A decrease in conductance was 
attributed to straining of the nanotube due to the attachment of the cell [208]. To test 
larger, more clinically relevant cell samples and volumes, we have developed CNT 
micro-array devices with an 8000 μm2 area thin film per device. The CNTs are 
functionalized with anti-EpCAM mouse monoclonal antibodies. EpCAM is a well-
studied cancer biomarker, which functions in mediating homophilic cell–cell adhesions 
[295]. EpCAM was chosen as a model system because it is present in nearly all 
adenocarcinomas and squamous cell carcinomas [54, 418]. In the development of the 
sensors, we observed that gas molecules in the air were doping the CNT and obscuring 
the sensor readings. We corrected for this and tested these sensors with EpCAM-
positive and EpCAM-negative cells and identified a unique electrical signature for the 
two different cell types. 
 Testing in different cell lines yielded highly intriguing results on the 
measurement of normalized electrical conductance G/Go over various cell lines. In 
these experiments several cell lines namely normal breast cell line (MCF-10A), breast 
cancer cell lines (SKBR-3 and MCF-7) were used. Anti-EpCAM antibodies were used 
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Figure 52. (A) Showing the CNT device testing set up with source, drain, and 
reference electrodes in contact on the device during testing on microarray chip. (B) 
Optical microscope image of a sensor device with a spiked SKBR-3 cancer cell sample 
droplet, scale bar 100 µm. (C) Confocal image of a SKBR-3 cancer cell on the device 
stained for EpCAM, in red, and DAPI, in blue.   
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as specific control while anti-IgG antibody was used as non-specific control. Both 
SKBR-3 and MCF-7 overexpress EpCAM while MCF-10A normal cells do not, as 
described in Section 7.2. Surprisingly, two differential signals were generated between 
positive and negative controls. The positive controls such as targeting EpCAM on 
SKBR-3, Figure 53 (a), and MCF-7, Figure 53 (b), produced characteristic spikes in the 
electrical signatures with positive slopes that stabilized after few seconds. It is also 
noted that the stabilized conductance levels even after 60 seconds are higher than initial 
value before the sample addition suggesting an irreversible change in the electrical 
signature or forward reaction kinetics for the formation of the antibody-receptor 
complex. Similarly, the negative controls namely targeting EpCAM in MCF-10A, 
Figure 53 (c), and targeting IgG in all the cells, Figure 53 (d), and even PBS produced 
similar spikes with negative slopes and stabilized after several seconds. It is also noted 
that the final conductance after cell addition was higher than the initial conductance 
value and stabilized at that value. In determining the statistical significance, the average 
slope of ~0.5 seconds following the inflection point was calculated for each signal. 
Both data sets were determined to be random and of equal variance. A final p value of 
0.0011 < 0.05 was calculated showing a statistically significant difference between all 
positive and negative controls as presented in Table 6.  It should be noted that the 
positive controls consisted of two different cell lines MCF-7 and SKBR-3 targeted for 
EpCAM mentioned as G1 and G2 respectively in Table 6. Similarly the negative 
control consisted of EpCAM-MCF-10A, and IgG-(MCF-7, MCF-10A, and SKBR-3) 
mentioned as G3 and G4. The p values in the Table 6 suggest that there is a significant 
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Figure 53. Testing in Cell Cultures: (a) Normalized device conductance of anti-
EpCAM functionalized device with SKBR-3 cancer cells; (b) Normalized device 
conductance of anti-EpCAM functionalized device with MCF-7 cancer cells; (c) 
Normalized device conductance of anti-EpCAM functionalized device with MCF-10A 
normal cells; (d) Representative graph of normalized device conductance of anti-IgG 
functionalized device with SKBR-3, MCF-7 and MCF-10A cells. 
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Table 6. Statistical comparison between specific and control signals in cell cultures. 
 
 
statistical difference between specific and non-specific electrical signatures based on 
the slope of the conductance after sample injection. It is also observed that within the 
same group, the p values do not reflect a significant difference suggesting natural 
partitioning of specific and non-specific signals.  This suggests that the nanotube sensor 
is capable of differentiating between two different cell populations which are similar 
except for their surface markers.  The similar results over a wide range of cell lines and 
antibodies suggest specific interactions gave rise to characteristic spikes in electrical 
signatures due to their cooperative binding of antibodies to their receptors on the cell 
membrane. The ability to distinguish between cancerous and non-cancerous cell 
populations based on their surface markers with statistical significance in fast manner 
as presented here is thus a significant accomplishment for any nanotube thin film 
sensor. On-chip confocal microscopic analysis without removing cells could potentially 
lead to no CTC loss. A typical chip surface can have anywhere between 1 and 25 cells 
landing on the surface, and all of them can be counted easily. However, doing that in 
blood may be difficult, and this type of device could be useful for buffy coats where all 
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RBCs are removed before testing. Integrating such a device as demonstrated here with 
isolation protocols could enable handheld isolation and detection of CTC. However, 
these devices are also useful for cancer biomarker testing at the level of 1 ng/ml (below 
the diagnostic gray zone) as described in Chapter 5 and 6. 
7.4. KOHLRAUSCH-WILLIAMS-WATTS (KWW) FUNCTION MODEL 
 Kohlrausch Williams Watts (KWW) function is a stretched exponential function 
and the most popular function applied to fit the time-domain relaxation data [419]. 
Kohlrausch first proposed the stretched exponential in 1854 to describe the relaxation 
of charge from a glass Leiden jar [420]. Investigating the nature of specific and non-
specific interactions, CNT micro-array devices demonstrated specific and non-specific 
interaction electrical signature that was fitted as per the KWW function for specific 
interaction: 
 
∆𝐺𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 =  1 + 𝑒𝑥𝑝 [−(
𝑡
𝜏
)
𝛽
] (18) 
and non-specific interaction [419]: 
 ∆𝐺𝑛𝑜𝑛−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 =  1 − 𝑒𝑥𝑝 [− (
𝑡
𝜏
)
𝛽
] 
(19) 
 Figure 54 (A) presents the normalized, ΔG/G0, drain current, IDS, signal of 
specific and non-specific controls fitted to the KWW functions for both specific and 
non-specific interaction respectively. The time constants were observed at τspecific = 
1.094, for specific, and τnon-specific = 20.99, for non-specific interaction. The difference 
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in time constant (τ) is a great indicator showing a signature difference between specific 
and non-specific signals. Specific interaction is seen with interaction exponent βspecific = 
0.1558 and for non-specific interaction βnon-specific = 0.2878. The stretched exponential 
function contains just two free parameters: the “equilibration” time τ and the fractional 
“interaction” exponent β, which satisfies 0<β≤1. Figure 54 (B) presents the modeling of 
the signal response for specific and non-specific interaction based as a function of 
interaction coefficient, β. The upper limit of β = 1 corresponds to simple exponential 
decay or mild interaction, while lower values of β are indicative of a more complicated 
non exponential interaction process or multi-cell interaction, as the conductivity of the 
device is greatly manipulated and has to be due to large change in free energy that one 
can correspond to number of cells interacting with the device. Results here suggest that 
potentially one can correlate the β factor to number of cells interacting to the device 
and define it as coefficient multiplication of the number of cells on the device.  
 We monitored and recorded the number of cells on each device after the end of 
each test, no direct correlation with β coefficient, intensity of the IDS signal, was 
observed with respect to the number of cells observed on each device. However, this 
does not rule out our original hypothesis completely, the number of cells interacting 
with the device can be different at the time of interaction and the time of microscopic 
observations as there was a few minutes of gap in-between. Also, not all the cells 
observed on top of the device could be interacting with the device. A more robust 
method is needed to control the number of cells on each device; perhaps using a piezo- 
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Figure 54. Principle of electrical signal response of CNT micro-array devices. (A) 
Specific and non-specific interactions. (B) Interaction exponent modeled for range of β 
for both specific and non-specific signal. 
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controlled manipulator to pick up individual cells and place them on the device can 
help gain a higher understanding of this interaction and the device response. 
7.5. CONCLUSIONS 
 CTC detection and analyses in blood or body fluids may provide insights into 
the progression of cancer and treatment effectiveness. CTCs are only in the range of 
10
−7
 to 10
−3
 among normal blood cells, making them rare [411]. The current CTC 
detectors are based on a mechanical cell sorting devices, which uses magnetic and shear 
forces inside a microfluidic channel to isolate cells. This chapter presents an electronic 
device that could be developed for point-of-care testing of CTCs. There are several 
significant challenges to be addressed, however, before full realization of the present 
device for CTC detection, which, once fully developed, could be a more powerful 
approach and may provide higher information content both on proteins and cells and 
therapeutic response. The device-related difficulties such as dispersion of individual 
nanotubes within the network for higher sensitivity, lithographic patterning, and density 
of nanotubes in devices, functionalization protocols, oxygen adsorption on the tubes, 
and cellular interaction within the Debye length can affect sensor conductance. With 
progress in device development, we have shown a 60-element array for the 
development of a point-of-care diagnostics type of device for cancer biomarkers and 
CTC. Using a PASE functionalization technique and testing with cells showed specific 
versus nonspecific binding with up to 95% confidence intervals with an average of 5–
25 cells per sensor surface in 5 μl of fluid. Instead of adding 1 ml of fluid to 
microfluidic device, fractionating the 1 ml body fluid into 5 μl drops can result in 
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potentially no loss of CTCs during the testing process. However, they would require 
200 devices that are individually addressable electronically. An application- specific 
integrated circuit could potentially interrogate all of the sensors and give a read out 
within few minutes, which could include a gamut of information from proteins, 
circulating tumor DNA, mRNA, and CTCs. Further, reaction chambers on chip for 
reverse transcription polymerase chain reaction can potentially analyze CTCs for 
specific gene sequences. These could be a part of the entire clinical process involving 
surgery, chemotherapy, radiation, and hormonal therapy. The nanotube platform is 
versatile, and hundreds of sensors patterned using clean-room processing techniques 
enable a different philosophical approach in detecting cancer biomarkers and CTCs and 
could potentially be a powerful tool for clinic in the future. 
7.6. EXPERIMENT  
7.6.1. CARBON NANOTUBE SENSOR FABRICATION  
 The CNT devices are a simple two-terminal design with liquid gating capability, 
each wafer include 60 devices (generation 1), Figure 23 (A). The structure and 
fabrication methods for the micro-array devices are previously described in Section 3.1. 
Catalytic chemical vapor deposition (CCVD)- synthesized, single-wall/double-wall 
CNT mixture (99% weight) purchased from Cheap Tubes Inc., 1–2-nm outer diameter 
and 3–30-μm length, were used for these experiments. The nanotubes were suspended 
in isopropyl alcohol (IPA) at ~45 μg/mL and sonicated for 90 min. The solution was 
then diluted to ~3.5 μg/mL and sonicated for 3 h to completely disperse the nanotubes. 
11.5 mL of the suspension was then further diluted with 85 mL of IPA and vacuum 
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filtered over a cellulose membrane, 0.22-μm pore size. This method self-regulates the 
deposition rate of nanotubes on the membrane to produce an evenly distributed 
network, ~40 µg film, Figure 24 (C). The network was then transferred onto an 
oxidized (400-nm thickness) silicon wafer and taken for microfabrication, Section 3.1. 
7.6.2. CNT FUNCTIONALIZATION  
 The finished CNT sensors were functionalized with the antibody, via a pyrene 
linker molecule, and Tween-20 as previously described in Section 4.1. After 
functionalization, devices were incubated in a 2-μL droplet of PBS inside a humid 
chamber at 4 °C before testing.  
7.6.3. EXPERIMENTAL SET-UP   
 Experimental set up is previously described in Section 3.3. The testing protocol 
started with a hydrated device, and a 2 μL droplet of 1X PBS which was placed 
immediately after functionalization. The bias was applied and the sensor was monitored 
for the initial 60 seconds, then 5 μL droplet of cancer cell spiked or plain PBS sample 
solution was pipetted directly into the standing 5 μL droplet. Devices were monitored 
for 120 seconds after each addition of a new sample solution. The total duration of one 
test was 3 minutes long. To compare results among devices, ISD data were normalized 
to obtain the ΔG/G0 values for conductance. 
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CHAPTER 8 
LABEL-FREE CAPTURE OF BREAST CANCER CELLS SPIKED IN BUFFY 
COATS USING CARBON NANOTUBE ANTIBODY MICRO-ARRAYS 
 
8.1. INTRODUCTION  
 Commercially available nucleic acid microarrays allow sensitive identification 
of thousands of DNA sequences simultaneously [421-425]. However, they cannot 
capture many changes in cellular response and function in many cases which are 
carried out by proteins.  The cellular proteomic profiles, which is directly relevant for 
disease detection, label-free high-throughput diagnostics has, however, remained a 
challenge and sample handling to get a complete proteomic profile is also challenging 
and enormous in some cases [426].  
 Techniques that have been developed for protein analysis include: flow 
cytometry [427], fluorescent reporting of antigen–antibody binding [428], time-of-
flight mass spectroscopy [429], electrophoretic separation [430],  label-free detection of 
changes in surface mechanical properties due to antigen–antibody binding using micro-
cantilevers [208], change in electronic properties using silicon nanowires  [431] and 
carbon nanotubes due to biomarker interaction [432]. The cellular proteomic analysis 
that is important for auto-immune diseases, label-free devices are rare [365]. Some of 
these devices have focused on understanding how device properties change on cellular 
attachment or detachment after growth on the substrates and the drug interaction [433].   
 Recent progress in area of isolation of rare cells has used different techniques 
namely immunomagnetic methods [33], microfluidic chips [434, 435], laser scanning 
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cytometry [436], and nano-Velcro array [437] to name a few and has created the need 
for capturing and molecular profiling of cells based on their biomarkers for targeted 
therapy. While these above mentioned devices have used large volumes of blood (~7.5 
ml) to isolate circulating cancer cells using microfluidic devices, magnetic devices for 
fine needle aspirates (1 l) has also been reported to capture and analyse single cells 
[438], thereby showing the importance of capturing cells and profiling their biomarkers 
in small and large volume samples.  Current technologies namely ELISA or Western 
blots for measuring protein concentrations are painstakingly slow and need skilled 
personnel for accurate results. Therefore, devices that can capture single cancer cells in 
highly complex medium such as blood/buffy coats in rapid, low cost and high 
throughput fashion with the capability to profile them for their biomarker can result in 
significant clinical impact.  
 In this study we present capture of breast cancer cells spiked in buffy coats 
using carbon nanotube micro-arrays functionalized with anti-EpCAM antibodies and 
their stratification based on their electrical signatures using classifier based on Dynamic 
Time Warping (DTW). Epithelial Cell Adhesion Molecule (EpCAM), is  a 
mesenchymal marker that is overexpressed in all epithelial cancer cells [439, 440]. 
EpCAM is overexpressed in carcinomas and also is upregulated in metastases thereby 
making it a highly valuable diagnostic marker [441]. A multiplexed micro-array of 
nanotube sensors functionalized with anti-EpCAM antibodies enables measurement of 
electrical signatures of specific and non-specific interactions as characteristic spikes in 
conductance versus time data. These signatures are then analyzed using Dynamic Time 
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Warping (DTW) technique to develop heatmap with integrated dendrogram to enable 
classification of the electrical signatures and relate it to their sample condition (MCF-7 
spiked buffy or plain buffy), for the ease of reference, we call cases and controls. The 
experiments demonstrated “spikes” in electrical device signatures in cell cultures and 
cancer cells spiked in buffy coats with natural partitioning between plain buffy coats 
and spiked buffy coats using nanotube-antibody arrays. To predict classification 
between cases and controls, the training set data indicated ~100% sensitivity, ~90% 
specificity, and ~96% accuracy in classifying devices that corresponded to un-spiked 
and spiked buffy coats based on their electrical signatures. A blinded test to classify 
case and control samples revealed ~91% sensitivity, ~90% specificity, and ~86% 
accuracy.  Staining of captured cells on the device based on electrical signatures using 
confocal microscopy revealed the overexpression of EpCAM with each device capable 
of capturing anywhere from 1-25 cells per device suggesting single cell sensitivity. Our 
demonstration of the combination of multiplexed micro-arrays, sensitive nanotube 
elements and statistical data mining enables a new line of thought in developing 
devices for isolation of cells based on their mesenchymal biomarker profiles both in 
fine needle aspirates and for large volume samples in isolation and analysis of 
circulating tumor cells. The study presented in this chapter was approved by the 
University of Louisville Institutional Review Board, IRB#10.0428, and the IRB at 
Worcester polytechnic Institute, IRB#00007374. 
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Figure 55. Schematic of Sensing Mechanism: Cooperative binding of anti-EPCAM 
antibodies to their corresponding receptors in cells on top of nanotube biosensors 
creates “spikes” in electrical conductance. 
 
8.2. RESULTS  
 Figure 55 presents the schematic of the sensing technique. Biomolecular 
reactions are driven thermodynamically by the reduction in free energy of the system. 
For specific interactions, the reduction in free energy should be higher than non-
specific interactions as presented in equation 20 [442].  It is this thermodynamic 
advantage of specific interactions that is the hall mark of living systems which enables 
a high degree of control in biological processes. Otherwise, non-specific interactions 
would prevail resulting in loss of cellular specificity and directionality in function 
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[442]. One can use a spectrum of energy domains to transduce the change in the free 
energy of the specific interactions into mechanics, electricity, thermal or magnetism 
[442]. While label-free sensors have been developed for measuring ultra-low protein 
concentrations as mentioned before, the measurement of specific versus non-specific 
binding events in cells as electrical spikes in a fast manner and the ability to stratify 
them rapidly are rare. If such cellular arrays that are fast, label-free and one that can 
detect specific versus non-specific interactions at the level of single cells and relate the 
electrical signatures to their biological condition using advanced classifiers developed, 
could revolutionize the disease paradigm for isolation and analysis of rare cells.   
 𝐺𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐  >>>  𝐺𝑛𝑜𝑛−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐  (20) 
Since the reduction in free energy is universal for specific and non-specific pairs, we 
hypothesize that this should be true for detection of specific versus non-specific 
interactions in cells. Extracellular overexpressed receptors namely EpCAM interacts 
with their corresponding anti-EPCAM antibodies on the nanotube surface. The 
cooperative specific interaction of thousands of extracellular receptors with specific 
antibodies on nanotube surface creates spikes in the normalized electrical conductance 
versus time [366]. Non-specific samples such as plain buffy coats also create such 
spikes in the electrical conductance versus time data with differences in their slopes.  
The philosophy behind this work is whether such spikes in the signals could carry 
meaningful information about the sample condition/interaction that could be indicator 
of disease status. 
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8.2.1. FABRICATION OF NANOTUBE SENSOR ARRAYS  
 Figure 56 (a) presents the wafer scale image of the 60 element array of nanotube 
network sensors. The sensor arrays were developed using a combination of vacuum 
filtration of carbon nanotube network film onto oxide coated wafers followed by 
multiple photo-lithography and reactive ion etching, covered in detail in Chapter 3. 
CNT films used here were very low concentration (4 µg) isotropic and also mostly 
single layers laying on the substrate as shown in the SEM image of Figure 56 (b).  
 Figure 56 (c) presents the Raman spectroscopic micrograph of the nanotube 
network suggesting a very large G band (1590 cm
-1
), small D band (1340 cm
-1
) and 
large 2D band (2673 cm
-1
). This suggests very low amorphous carbon content. Further, 
we also measured the IG/ID ratio for several networks measured IG/ID ~30 suggesting a 
low density of defects and suitable for high-quality sensing applications. The Iso-
semiconducting nanotubes had iodine as specified by the manufacturer (5% by mass 
using neutron activation analysis) in the form of iodixanol. This was observed in the 
shift in radial RBM mode r =174 cm
-1
 suggesting iodine doped nanotubes due to poly 
iodide ions or I3
-
 and I5
-
in the RBM mode at the same excitation wavelength [332]. The 
iodine also decreased the tangential mode to 1590 cm
-1
 in these samples as compared to 
pristine nanotube samples (1593 cm
-1
) in line with past reports [333]. Figure 56 (d) 
shows an array of devices and compares them to a penny with the source, drain, 
reference Ag/AgCl electrode and sample droplet all in one set-up.   
 4 µg CNT films were used for all the studies henceforth presented. Full 
characterization of these films and devices are reviewed in detain in Chapter 3. 
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Figure 56. Device Characterization: (a) Optical image of the wafer with 60 devices 
manufactured using photolithography, metal deposition and etching; (b) scanning 
electron micrograph of carbon nanotubes; (c) Raman spectrum of semiconducting 
carbon nanotubes showing a large G band, small D band and 2D band. The IG/ID ~30 
was observed in these nanotubes; (d) Test set up showing 6 devices on a chip and 
compares it to a penny. The source, drain and reference electrodes are observed. 
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8.2.2. ANTIBODY FUNCTIONALIZATION 
 In exploring the use of such multiplexed nanotube devices for measuring 
differential cellular response, understanding the functionalization of antibodies that are 
specific to the receptors, their coverage on the surface and their eventual interaction 
with the cellular receptors producing an electrical signal must be understood in depth. 
The prepared SWNT sensors were functionalized with anti-EpCAM antibodies through 
a pyrene linker molecule, as described in detail in Chapter 4. Overall the PASE 
conjugation provided a stable platform for all sensing in cell cultures and buffy coats.   
 
Figure 57. Representative graph of the testing protocol. First drop of 5-10 µl PBS is 
added to the sensor followed by wait period of several hundred seconds, followed by 
second PBS drop followed by wait period of several hundred seconds followed by 
addition of spiked buffy or plain buffy coat. This ensures the sample is behaving the 
same way over a time period before addition of the actual sample. 
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8.2.3. TESTING IN BUFFY COATS AND DEVELOPMENT OF A STATISTICAL 
CLASSIFIER FOR LIQUID BIOPSY  
 If nanotube thin film sensors were to be used for any diagnostic/prognostic 
value in the clinic, testing in more complex medium such as buffy coats/blood would 
be necessary.  The ability to capture cancer cells and analyze their biomarkers in 
complex medium both in large and small volumes can have profound translational 
impact. Biosensors that produce electrical signals or other time series data present a 
unique challenge for researchers attempting to use such sensors to classify biological 
samples.  The analysis of such data is complicated by undesirable variation in the time 
domain between samples of the same class in addition to variability in the characteristic 
patterns that may be shared between samples of the same class. Further, use of such 
complex medium such as buffy coats with white blood cells and other proteins makes it 
highly complicated and cannot be simply differentiated based on simple time domain 
electrical signatures. Currently, there exists no statistical classifiers for “liquid biopsy” 
samples for both small and large volumes of samples.  
 We used ANOVA balanced design to reduce any systematic variability. Factors 
in ANOVA design includes medium (Bare, Igg, and EpCAM) and three types of 
samples (PBS: control 1, Buffy: control 2 and Spiked Buffy: case) with fixed number 
of replicates. With the same design two data sets were generated for training set and 
then for test set. As summarized in Cambon et al.,[443, 444], there are different 
approaches to classification of higher dimensional data sets based on biosensor signals. 
In the recent past, group classification of cervical cancer versus control samples were 
done based on differential scanning calorimetry thermograms. The excess specific heat 
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capacity versus temperature were measured from both cervical cancer sample and 
control samples. These were then classified using a parametric classifier with 96.7% 
classification rate. Compared to the newly developed parametric method,  the I-
RELIEF method that is commonly used to classify higher dimensional data sets only 
showed a classification rate of 73.3% [445]. Here, we use Dynamic Time Warping 
(DTW) for classification as the biosensor signals and patterning techniques are quite 
different.  
 To demonstrate the ability of the devices to discriminate between buffy and 
spiked buffy signals, we used a training-test approach to building a k-nearest neighbor 
classifier using DTW [446]. The training data consisted of ten buffy coat samples and 
17 spiked buffy coat samples. k-fold cross-validation parameter selection was 
conducted using tenfold cross-validation on 10,000 bootstrapped samples from the 
training set of 27 signals for which the class (buffy vs spiked buffy) was known. The 
tuning parameters selected were those that minimized the mean and variance of the 
misclassification rate. Once tuning parameters had been selected, 22 test signals (of 
class unknown to the personnel constructing the classifier) were classified using a 
DTW distance-based k-nn classifier using the training signals as reference signals. The 
test set misclassification rate, classifier sensitivity, and classifier specificity were then 
used as criteria to measure the success of the devices in discriminating between positive 
and negative samples. To evaluate if devices could differentiate between MCF-7 
positive samples and MCF-7 negative samples, both were tested utilizing the devices. 
The negative samples consisted of a buffy coat sample from the biorepository without  
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Figure 58. Plots of representative electrical signatures from samples used in 
construction of a k-nn DTW distance-based classifier for breast cancer surface marker 
profiling. (A) Two plain buffy coat samples. (B) Two spiked buffy coat samples.  
 
the presence of breast cancer cells. The positive samples consisted of the same buffy 
coat sample that was spiked with MCF-7 breast cancer cells (10,000/l) as a proof of 
concept.  The drain current from the nanotube devices was recorded continuously 
throughout each experiment. A representative figure of the testing protocol is presented 
in Figure 57 and two MCF-7 positive and two MCF-7 negative samples are depicted in 
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Figure 58. The resulting data consisted of time series with characteristic “spikes" 
occurring after the application of the sample as shown in Figure 59 for the training set.  
8.2.4. CONSTRUCTION OF THE CLASSIFIER  
 A set of training signals from the devices was used for selecting the optimal 
tuning parameters for the classifier. An independent set of mixed signals was then 
classified using the classifier. Sensitivity, specificity, and the misclassification rate of 
the classifier on the test set were then used to evaluate performance.  
 To describe the construction of the classifier, we first introduce some notation. 
We represent a device signal as a time series, y = [yt, t ∈ T], where 𝑇 is a finite set that 
indexes time. To indicate that the signal is the 𝑖th replicate from the 𝑗th group (Buffy vs. 
Spiked buffy) we use the notation y𝑖,𝑗. Before a classifier could be constructed, the raw 
signals were processed so that the signals had comparable a sampling rate, length, and 
intensity. The signals y𝑖,𝑗 were first averaged so that each signal had the same sampling 
rate of one sample per second. The signal was then truncated by removing series values 
between the first value and five seconds after signal most extreme peak—resulting in a 
new 𝑡0 for each signal. Experimental variation in the timing of the replicate drops 
contacting the device resulted in non-uniform length time indices. For length 
standardization, the signals were then truncated at 253 seconds. The final processing 
step was mean and variance standardization so that each signal had mean 0 and 
variance 1.  
184 
 
 
Figure 59. Merge of sensor arrays with statistical classifiers in training set: Normalized 
conductance versus time data from the arrays grouped into two categories. (a) Plain 
buffy coat; (b) buffy coat spiked with MCF-7 cells. 
 
 
Figure 60. Merge of sensor arrays with statistical classifiers in blinded set: Normalized 
conductance versus time data from the arrays grouped into two categories. (a) Plain 
buffy coat; (b) buffy coat spiked with MCF-7 cells. 
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 To compare signals and develop a classifier, a measure of signal similarity is 
needed. The technique employed to develop a similarity measure in this analysis is 
known as Dynamic Time Warping (DTW) [447-452]. 
 DTW is a method of aligning two-time series so that a traditional distance 
metric (such as the Euclidean metric) can be used as a measure of similarity. To 
measure the similarity between two signals  y1 and y2, we compute two matricies 
Δ ∈ ℝ𝑚×𝑛 and Γ ∈ ℝ(𝑚+1)×(𝑛+1). The first matrix Δ has entries representing the 
pairwise distances between points in the series, that is:  
 𝛿(𝑡, 𝑡′) = 𝑑(𝐲1,𝑡 , 𝐲2,𝑡′) (21) 
where  𝑑 is a distance metric. For this analysis we chose to use the Euclidean distance 
metric. Once this distance matrix was defined, we determined the elements of 𝚪 using a 
recurrence relation that weights steps through a cumulative distance matrix. Two 
formulations for this matrix were considered using the following recursions:  
𝛾1(𝑖, 𝑗) = min{𝛿(𝑖, 𝑗) + 𝛾1(𝑖 − 1, 𝑗), 𝛿(𝑖, 𝑗) + 𝛾1(𝑖 − 1, 𝑗 − 1), 𝛿(𝑖, 𝑗) + 𝛾1(𝑖, 𝑗 − 1)}, 
 𝛾2(𝑖, 𝑗) = min{𝛿(𝑖, 𝑗) + 𝛾2(𝑖 − 1, 𝑗), 2 × 𝛿(𝑖, 𝑗)
+ 𝛾2(𝑖 − 1, 𝑗 − 1), 𝛿(𝑖, 𝑗) + 𝛾2(𝑖, 𝑗 − 1)}. 
(22) 
Once the cumulative distance matrix Γ has been defined, we seek a warping curve that 
aligns the time indices for each time series:  
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 𝜙(𝑘) = (𝜙𝑠(𝑘), 𝜙𝑠′(𝑘)), 𝑘 ∈ {1,⋯ ,𝐾},
𝜙(𝑘) ∈ {1,⋯ ,𝑚} × {1,⋯ , 𝑛}. 
(23) 
This warping curve was chosen such that once 𝐲1 and 𝐲2 are aligned, the cumulative 
distance between the series is minimized. To find such a curve, we find the lowest 
scoring path through the cumulative distance matrix 𝚪 subject to the following 
constraints: 
 (1)                                               𝜙(1) = (1,1) 
(2)                                        𝜙(𝑇) = (𝑚, 𝑛) 
(3)           (𝜙(𝑘) − 𝜙(𝑘 − 1)) ∈ {(1,1), (1,0), (0,1)} ∀𝑘 > 1. 
(24) 
Constraint (1) and (2) ensure that the beginning and the end of the signals y1and y2 are 
aligned. Constraint (3) ensures uniform length of step sizes and that the warping curve 
is monotonic increasing. An illustration of the alignment process for a pair of 
qualitatively similar and qualitatively different signals are presented in Figure 61 and 
Figure 62 respectively. Once a warping path has been defined, the Dynamic Time 
Warping distance between two signals (not a formal distance metric) is given by: 
𝑑𝐷𝑇𝑊(𝐲1, 𝐲2) = ∑ 𝚫(𝜙(𝑘))
𝑇
𝑘=1
. (25) 
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Figure 61. Two qualitatively similar spiked signals. The bottom left figure shows the 
alignment of their time indices. The bottom right figure demonstrates the small DTW 
distance (in gray) between the two DTW aligned signals. 
 
 
 
 
188 
 
 
 
Figure 62. Two qualitatively different signals from different groups. The bottom left 
figure shows the alignment of their time indices. The bottom right figure demonstrates 
the large DTW distance (in gray) between the two DTW aligned signals. 
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For each step pattern, a dissimilarity matrix using DTW distance as the dissimilarity 
measure was constructed for the signals using the DTW package in R [453].  
 A training-test approach was used to develop a k nearest neighbor (k-nn) 
classifier [450] from the DTW distance dissimilarity matrices. The training set 
consisted of 10 Buffy signals and 28 Spiked Buffy signals. 10-fold cross-validation 
[450] was employed using 10,000 bootstrapped samples from the training set to 
determine which step pattern (symmetric 1 vs symmetric 2) and a number of nearest 
neighbors yielded the lowest misclassification rate Figure 63. The misclassification rate 
is defined as: 
 
𝐸𝑟𝑟 = ∑𝐼(𝑌𝑖 ≠ 𝑌?̂?
𝑁
𝑖=1
) (26) 
where 𝑌𝑖 denotes the true class of the signal y𝑖 and 𝑌?̂? denotes the k-nn classifier 
predicted class for y𝑖.  
 Once the optimal step pattern and classifier design had been selected, the 
classifier was evaluated on the 22 signals of the test set. The study personnel who 
conducted the classification on this test set were blinded to the true class (Buffy vs 
Spiked Buffy) of the signals. 
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Figure 63. Cross-Validation Results. For each choice of k, 10,000 bootstrapped 
datasets were used to measure the misclassification rate. 
 
8.2.5. TRAINING SET CLASSIFICATION  
 A training validation test set approach was used to construct DTW distance 
based probabilistic modeling of surrounding observations (such as th- nearest 
neighbors) [446]. The training data consisted of plain PBS (not shown), 10 buffy coat 
samples, Figure 59 (a), and 17 spiked buffy coat samples as presented in Figure 59 (b). 
A -fold cross-validation parameter selection was conducted using 10-fold cross 
validation on 10,000 bootstrapped samples from the training set of 27 signals for which 
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the class (buffy vs. spiked buffy) was known. The tuning parameters selected were 
those that minimized the mean and variance of the misclassification rate. The test set 
misclassification rate, classifier sensitivity, and classifier specificity were then used as 
criteria to measure the success of the devices in discriminating between positive and 
negative samples. The statistical table for training set is presented in Table 7. A positive 
predictor value (PPV) = 94% and negative predictor value (NPV) = 100% with 
accuracy = 96.3% was obtained for training set. One data was misclassified and was 
false positive or type I error. No false negatives were observed in training set.  
8.2.6. BLINDED TEST CLASSIFICATION  
 Figure 60 (a) and (b) presents the electrical signals for the blind test. Based on 
the training set, the tuning parameters were selected, 22 test signals presented in Figure 
60 (a) and (b) (of class unknown to the personnel constructing the classifier) were 
classified using the training signals as reference signals. Table 8 presents the 
corresponding classification table for the blind test. A PPV=83%, NPV=90% and 
accuracy =86% was observed. A misclassification rate of ~14% was observed in these 
blind testing. 3 samples over 22 samples were misclassified. Two samples that were 
misclassified were false positive or type I error and one sample that was misclassified 
was false negative or type II error. This suggests the classifier is capable of 
differentiating electrical signals between samples that were plain buffy coat or buffy 
coat with cancer cells which is the first accomplishment for any nanotube biosensor 
device. 
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Figure 64. Heat map. Summary of the relationship between electrical signatures and 
the cellular-proteomic features namely overexpression of EpCAM in spiked buffy coats 
versus buffy coats. The statistical classifier naturally partitions the buffy versus spiked 
buffy coats suggests specific interactions are quite unique in their electrical signatures 
compared to non-specific interactions and establishes a relationship between electrical 
conductance data with proteomic features. 
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Table 7. Training classification of biosensor signals based on dynamic time warping. 
 
Table 8. Blinded set classification of biosensor signals based on dynamic time warping. 
 
 
8.2.7. HEAT MAP 
 Figure 64 is the heat map of the between signal DTW distances for the signals 
used in the k-fold cross-validation tuning parameter selection and as reference signals 
for the classifier. 10-fold cross-validation on the bootstrap samples resulted in a final 
DTW distance based on -nn classifier utilizing a symmetric 2 step pattern and 3 
nearest neighbors. In the margins of this figure a dendrogram of the complete-linkage 
agglomerative hierarchical clustering of the same is shown [450]. This demonstrates 
that on the training data, DTW distance as a dissimilarity measure, naturally partitions 
the sample data into two distinct clusters (with one misclassification) according to 
sample class. The statistical classifier partitions the buffy versus spiked buffy coats 
suggesting specific interactions are quite unique in their electrical signatures compared 
to non-specific interactions and establishes a relationship between electrical 
conductance data with biological and possibly proteomic features (presence or absence 
of cancer cells in buffy coats versus presence or absence of mesenchymal marker
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Figure 65. Cell Capture using EpCAM functionalized Nanotube Devices based on 
Optical Microscopy: (a) Optical microscopy of spiked cells in buffy coats using 
nanotube devices; (b) Optical microscopy of plain buffy coats. 
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EpCAM). 
8.2.8. CELL CAPTURE WITH SINGLE CELL SENSITIVITY AND CONFOCAL 
MICROSCOPY 
 The devices that gave positive signatures were then further processed to assess 
the ability to capture spiked MCF-7 cells from buffy coats. Figure 65 are the images 
from 22 processed samples from the blind test with both buffy and spiked buffy coats. 
Each image was taken of the device immediately after taking the electrical signature 
measurement. For easier presentation, the spiked buffy coats are presented in Figure 65 
(a), the plain buffy coats are presented in Figure 65 (b) and Table 9 consisting of 
number of cells captured on the device in Figure 65 (a) and (b). The cells could be 
counted after imaging in a Nikon Eclipse optical microscope in the buffy coat using 
imaging software. The images show the ability to capture 1 to 20 cells per device and 
their positive/negative electrical signatures assessed from the classifier.  Our buffy coat 
was mainly proteins and denatured hematologic cells, we were able to identify the 
MCF-7 cells which were quite distinct as these were spiked cells. The single cells 
captured in the plain buffy coat are believed to be one or two hematologic or white 
blood cells that were bound to the device. 
 Six devices were removed and also imaged using confocal microscopy as 
presented in Figure 66 (only 4 shown). The samples were washed three times to assess 
binding and stained for DAPI and EpCAM. A cover slip was placed on the device and 
imaged using confocal microscope. The images from devices as presented suggest 
single cell sensitivity as well as positive for EpCAM overexpression. The results 
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Figure 66. Cell Capture using Nanotube Devices using Confocal Microscope: 
Representative confocal images from 6 devices imaged (4 shown) of captured cells in 
spiked buffy coats ranging from 1-17 cells per 5 µl sample. 
 
Number of 
cancer cells 
captured: 
____ 
_____  
2 
17 
1 
13 
197 
 
Table 9. Captured cells on each device for both case and controls using optical 
microscope. 
 
 
suggest that the samples were bound to the nanotube device through cooperative 
binding of the receptors to the antibodies.  Again, anywhere from ~1-17 cells were 
observed in confocal analysis, in line with optical microscopy observations. 
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8.3. DISCUSSION AND OUTLOOK  
 The ability of to distinguish samples that have cancer cells from samples that 
have no cancer cells in a medium such as blood/buffy coats in rapid manner for both 
large and small volumes can have significant implications in the clinic. The 
semiconducting nanotube arrays presented here is a promising technology with 
potential advantages in a clinical setting due to its simplicity. The technology requires 
minimal sample preparation, can perform assays in turbid/obscure media, can be 
adapted to profile different targets namely proteins, and cells, and has the capability for 
high-throughput operation (60-240 sensor arrays). For the first time, we have merged 
the nanotube sensor data with predictive statistical classifiers for liquid biopsy, an 
important step towards clinical translation with high sensitivity and specificity for a 
digital device. Our past work has also shown the detection of f-EpCAM up to ~1 ng/ml 
based on similar devices that were functionalized with anti-EPCAM antibodies using 
the same PASE functionalization protocol [359].  Our results on cell cultures and buffy 
coats thus suggest similarity in patterns that could potentially arise only from specific 
antibodies interacting with their corresponding EpCAM receptors. The ~91% 
sensitivity, ~82% specificity and ~86% accuracy in the blind classification test give us 
great confidence in development of this technology further for future clinical 
applications. One advantage is that our work shows the feasibility of classifying 
samples based on the device electrical signatures in short time frames (within few 
minutes), an important advantage in the clinic and considering that cells removed from 
their native microenvironment rapidly change their phenotype. Once classified, devices 
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that gave positive electrical signals can then be sent to a laboratory for further 
validation such as qPCR. With its capability for fast and sensitive cell capture, the 
nanotube arrays has the potential to become a useful tool for early screening of cancer 
cells from a drop of blood and also studies related to multiplexed drug screening and 
intracellular signaling. Although our study was focused on being able to classify signals 
from buffy coats that had cancer cells from the buffy coats that had no cancer cells 
based on nanotube micro-arrays functionalized with anti-EpCAM antibodies, the 
nanotube-assay can be expanded to integrate other complex cancer signatures and 
receptors namely HER-2 and EGFR, two important markers involved in metastases. 
Anti-HER-2 and anti-EGFR antibodies functionalized to the nanotube devices could 
potentially be useful in isolation of cells based on those markers.  The system itself can 
be further improved through larger arrays, automated sample handling and 
development of statistical classifier for blood samples and the use of custom-aptamer 
technology for high specificity which are the focus of our future work. Therefore, the 
potential for these devices are high both for fine needle aspirates and circulating tumor 
cell capture and analysis and worth pursuing given the simplicity of the system.    
8.4. METHODS  
8.4.1. CNT-NETWORK FORMATION  
 IsoNanotubes-semiconducting single wall carbon nanotubes were used to 
fabricate a 4 μg CNT film network on a dry oxidized (300 nm thickness) 4” silicon 
wafer and taken for microfabrication process. For details of this process please see 
Chapter 3.  
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8.4.2. CLEAN ROOM PROCESSING  
 Generation 1 devices were used for the studies presented here. Details of the 
device fabrication process and characterization are presented in Chapter 3. 
8.4.3. RAMAN SPECTROSCOPY   
Raman analysis was done at an excitation wavelength of ~532 nm using a 
XploRA Raman spectrometer (Horiba Scientific). The laser beam is focused onto the 
surface of the CNT film on top of a Si wafer substrate through a 50X objective lens. 
This measurement was repeated six times at different locations of the sample. The 
RBM (172 cm
-1
), Si (518 cm
-1
), D (1340 cm
-1
), G (1590 cm
-1
), and 2D (2673 cm
-1
) 
peaks were identified throughout the sample.  
8.4.4. DEVICE FUNCTIONALIZATION   
 Finished carbon nanotube sensors were functionalized with anti-EpCAM by a 
pyrene linker molecule. PASE (AnaSpec, Cat. No. 81238) were dissolved in methanol 
at 1 mM.  Devices were incubated in the PASE solution for 2 hours at room 
temperature, and then rinsed with methanol. Devices were then incubated in Anti-
EpCAM (EMD Bioscience, Cat. No. OP187) or anti-IgG (EMD Millipore, Cat. No. 
411550), 20 μg/mL in 1X Phosphate-buffered saline (PBS), for 2 hours at room 
temperature. After incubation, devices were rinsed in 1X PBS 3X. . Tween20 was used 
to block unfunctionalized nanotube sidewalls to minimize non-specific interactions.  
Devices were incubated with 0.5% Tween20 for 2 hours at room temperature. After 
incubation, devices were washed with water, and then incubated in 5 µl droplets of 1X 
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PBS in a humid chamber at 4 C before testing. For more detail of functionalization 
process please see Chapter 4. 
8.4.5. CELL CULTURE AND PREPARATION   
 The breast adenocarcinoma cell line, MCF-7, MCF-10A and SKBR-3 (ATCC, 
Cat. No. HTB-22; CRL-10317; HTB-30), was cultured under conditions as 
recommended by the supplier. MCF10 A is non-tumorigenic cells that are EpCAM 
negative and MCF-7 and SKBR-3 are EpCAM positive cell lines. Cells were grown for 
3-4 days to reach ~80% confluence. The cells were then detached using Accutase 
solution (Sigma, Cat. No. A6964) centrifuged and re-suspended in 1X PBS at 20,000 
cells/µL. This solution was used to spike the healthy buffy coat sample (James Graham 
Brown Cancer Center, Study No. C020-01) at 1:1 ratio for a final MCF-7 concentration 
of 10,000 cells/µL.  
8.4.6. CONFOCAL MICROSCOPY   
 After experimental data had been collected, the devices were saved for staining 
and confocal imaging.  The devices were first rinsed with PBS to remove excess cells 
and buffy coat fragments and then incubated with 4% paraformaldehyde (Santa Cruz 
Biotechnology Inc., Cat. No. sc-281692). After initial preparation device were stained 
with anti-EpCAM (EMD Bioscience, Cat. No. OP187) primary antibody, anti-mouse 
IgG-TR (Santa Cruz Biotechnology Inc., Cat. No. sc-2781) Texas Red conjugated 
secondary antibody, and DAPI (Molecular Probes, Cat. No. D1306)  according to the 
standard confocal staining protocol. A coverslip was placed on top of each device and 
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sealed before imaging. Confocal laser scanning microscopy images were obtained on a 
Nikon Eclipse T. with coverslip corrected objective focused at 600X.  
8.4.7. DEVICE TESTING   
 The testing platform is explained in great detail in Section 3.3. The testing 
protocol started with a hydrated device, and a 5 μL droplet of 1X PBS, which was 
placed immediately after functionalization and left overnight. The bias was applied, and 
the sensor was monitored for the initial 3 minutes, then 5 μL droplets of the sample 
solution, 1X PBS or buffy coat suspension, was pipetted directly into the standing 5 μL 
droplets. Devices were monitored for 360 seconds after each addition of a new sample 
solution. The total duration of one test varied from 540 to 1980 seconds. To compare 
results among devices, ISD data were normalized to obtain the G/G0 values for 
conductance. The sensor element was also imaged on an optical microscope to confirm 
the presence of cancer cells. The spiked buffy coat samples consisted of ~10,000 MCF-
7 cells/μL for these demonstrations. Such concentration was chosen to cover 
consistently the active sensor element surface with 0-30 cells at the sensor window for 
assessing cell capture per device. 
8.4.8. STATISTICAL CLASSIFIER   
 Statistical classification was done using DTW package in R. The sensitivity, 
specificity, and misclassification rate were then computed, considering Spiked Buffy to 
be a positive test and Buffy to be a negative test. Sensitivity is defined as 𝑇𝑃/𝑃, where 
𝑇𝑃 denotes the number of positive test outcomes, and 𝑃 denotes the number of true 
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positives. Specificity is defined as 𝑇𝑁/𝑁, where 𝑇𝑁 denotes the number of negative 
test outcomes, and 𝑁 denotes the number of true negatives.      
8.4.9. DYNAMIC TIME WARPING (DTW)   
 The first step to developing the classifier for biosensor data is the identification 
of a suitable dissimilarity measure. Time series data from CNT biosensors are marked 
by the occurrence of prototypical features that herald the class of the series. Often the 
time domain of such series is irrelevant and complicates automatic feature detection. As 
an example, two time series with similar features are shown in Figure 67 (A). The red 
series is a phase shift of the blue series with a slight vertical lift. In this situation, a 
traditional distance metric such as Euclidean distance would conclude that the series are 
very dissimilar. Yet with respect to the prototypical feature, these series are quite 
similar. As a result, “warping” of the time domains of one or both of the series (through 
the insertions of gaps) is necessary for aligning the series for proper quantification of 
dissimilarity. 
 DTW is a class of dynamic programming algorithms that have been developed 
in order to align time series in such a manner so that a traditional distance metric can be 
used to quantify dissimilarity. The resulting alignment of the two series by DTW is 
shown in Figure 67 (B). 
` To calculate the DTW distance between two time series, Rai and Trainor et al. 
[446] utilized the methods presented by Sakoe and Chiba whose original introduction  
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Figure 67. Dynamic time warping (DTW) for time series alignment. (A) Two 
qualitatively similar series. Red is a phase shift of blue with a slight vertical lift. Gray 
dashed line shows the vertical difference [446]. (The same series after dynamic time 
warping alignment.) 
 
of DTW methodology provides a nice resource for researchers interested in DTW 
[454].  
8.4.10. K-NEAREST NEIGHBORS CLASSIFIER  
 𝜅-nearest neighbor (𝜅-nn) classifier is a straightforward choice of classifier for 
measuring the dissimilarity of two series using the definition of a pseudo-distance 
metric (DTW distance) [455]. To build a 𝜅-nearest neighbor classifier, where 𝜅 ∈ ℕ, 
we denote series data as: {(𝐲𝑖 , 𝑐𝑖) ∶ 𝑖 ∈ 1, 2, … , 𝑁} where 𝐲𝑖 is a time series and 𝑐𝑖 = 𝑔 
where 𝑔 ∈ 𝐶 denotes the known class of the series. For each observation (𝐲𝑖 , 𝑐𝑖) we 
find the neighborhood N_κ (y_i ) of the κ series y_j with i≠j such that those series have 
minimal DTW(y_i,y_j ). We then have empirical estimates of the probability of class 
membership for (𝐲𝑖 , 𝑐𝑖): 
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?̂?𝑔(𝐲𝑖) =
1
𝜅
∑ 1𝑐𝑗=𝑔(
𝐲𝑗∈𝑁𝜅(𝐲𝑖)
𝐲𝑗) (27) 
 
From this set of empirical probability estimates we chose: 
 ĉi = argmax
𝑔∈𝐶
?̂?𝑔(𝐲𝑖) (28) 
In the case that there is a tie between two or more classes, the ties are broken at 
random. ĉi then represents the DTW distance based k-nn classification of the 
observation (𝐲𝑖 , 𝑐𝑖). Of course, predicting the class of (𝐲𝑖 , 𝑐𝑖) given that  𝑐𝑖 = 𝑔 is 
already known is rarely of any interest. Instead we wish to build a library of series of 
known class and use this library to predict the class of series for which the class is 
unknown. 
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CHAPTER 9 
LABEL-FREE CAPTURE OF BREAST CANCER CELLS SPIKED IN BLOOD 
USING CARBON NANOTUBE ANTIBODY MICRO-ARRAYS 
 
9.1. INTRODUCTION  
 Primary tumors release cancer cells into the bloodstream, resulting in the 
occurrence of so-called circulating tumor cells (CTCs). Number of recent studies has 
shown that detection of CTCs in peripheral blood can be useful for determining the 
spread of metastatic disease to distant sites, early diagnosis of cancer, predicting 
disease progression and suggesting therapeutic interventions [33, 48, 57, 64]. However, 
capturing and detecting CTCs in blood is very difficult because of their small 
population relative to preexisting blood cells [56, 173].  
 Several methods have already been proposed for isolating CTCs from peripheral 
blood, including density gradient [456, 457], filtration based on size and deformability, 
[84, 85, 88, 458-461], immunomagnetic beads [123, 176, 462], microfluidic mixing 
structures [78], microposts [73, 463, 464] , spiral microchannels [465], and dielectric 
properties [466, 467], laminar vortices [468]. Immunomagnetic cell sorting using 
magnetic micro beads has become the most common method for isolating CTCs 
because of its relative high accuracy and the ability to be carried out using simple 
systems. However this method requires multi-processing steps involving multi-labeling 
protocols and fluorescence post image analyses to discriminate and identify CTCs. 
CellSearch (Janssen Diagnostics, LLC) is a commercially available product that is FDA 
approved and also uses immunomagnetic technology to enrich and capture CTCs. 
However, it has a limited performance for low-purity enriched sample containing CTCs 
207 
 
and residual blood cells; the enrichment process using fluorescence imaging requires a 
prolonged time and also has high risk of error. Therefore a CTC capturing method that 
is label-free, rapid, and simple is of great interest. While the technologies explained 
above are impressive, they are not necessarily optimal for rapid identification in clinic. 
A digital device by which small drops of blood could be rapidly analyzed by 
microarrays for the detection of CTCs in the clinic would thus have great utility [133]. 
We hypothesized that a CNT micro-array device functionalized with an antibody would 
allow for the rapid detection of CTCs. These devices rely on the principle that each 
cancer cell possesses thousands of overexpressed particular target receptors, so that 
cooperative binding to cognate antibodies would yield characteristic spikes in the 
electrical signal due to free energy change. The reduction in free energy for specific 
interactions is much higher than nonspecific interactions, and one can use CNT arrays 
to transduce the change in free energy into electrical signal [133].  
 Based on our success with using CNT micro-array device for capture of CTCs 
in buffy coat, here we have optimized the process with a new device design, generation 
2, to attempt the capture and discriminate of CTCs directly in whole blood with no 
preprocessing.   
 In this chapter, we introduce a CNT micro-array device for capturing CTCs 
spiked in blood sample based on the interaction between functionalized CNT surface 
and cellular membrane receptor, similar to Chapter 7 and 8 studies, on the device. 
Additionally, we attempt to classify the electrical signal of each device based on the 
interaction type and captured CTCs on the device. To improve the capture efficiency 
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with blood samples, generation 2 device consisting of 3X3 mm sensing window, Figure 
68 (A), were utilized to accommodate for high sample cell concentration in blood. A 
droplet of CTC spiked blood sample was injected on top of each CNT device, Figure 68 
(B). Current passing through the device was monitored and recorded during this time. 
Devices were then analyzed under the optical microscope, Figure 68 (C and D), and 
further taken for immunofluorescent staining and confocal microscopic analysis of the 
captured cells. The interaction of cancer cells with antibody functionalized CNT 
surface generated a unique change in current vs. time signal. This can be explained by 
interaction of membrane receptors on the cell and the antibody functionalized to the 
surface of the nanotube resulting in change in free energy of the system [133]. This 
change in free energy can be caused by one or combination of factors, effect of 
membrane receptor proteins charge [469], cell membrane lipid bilayer interacting with 
surface of the nanotube [470] as a result of antibody-receptor binding, and surface 
stress implemented to the CNT surface and cell membrane as a result of the two 
anchoring by antibody-receptor binding which could additionally activate ion channels 
on the cell membrane introducing additional ionic charge to the environment 
surrounding the nanotube [471, 472]. These factors can eventually affect the carrier 
mobility or the carrier density of nanotubes resulting in change in conductance of CNT 
network [307]. To better understand the magnitude of these effects, statistical classifier 
method based on dynamic time warping (DTW) was developed, similar to Chapter 8, to 
identify and distinguish the electrical signature generated from each interaction leading 
to discrimination of devices with CTC spiked blood sample types. 
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9.2. MATERIAL AND METHODS 
 Detailed fabrication process and experimental setup are explained in chapter 3. 
Functionalization methods are discussed in detail in Chapter 4. Cell culture and 
preparations are explained in detail in section 7.2.  
9.2.1. DEVICE DESIGN AND PRINCIPLE 
 Generation 2 of CNT micro-array devices, as described in section 3.1.3, were 
specifically designed for the objective of this chapter. Considering the need to process 
high volume and number of cells with blood samples, larger CNT film area was elected 
to accommodate for this objective.  
 Similar to the first generation of CNT devices, the second generation devices 
are consist of a simple two-terminal design at their core with CNT ultra-thin film 
network connecting the source and drain electrodes. In this design, the sensing channel 
consist of CNT network connecting the two electrodes, 3000 µm in length and 3000 
µm in width, as seen in Figure 68 (A). As a result the sensing area of each device is 
9 × 109 µm2, allowing for ~22,500 cells, assuming average 20 µm diameter, to interact 
with the CNT device at one time. 
 The sensing area becomes very critical when we are considering processing 
blood samples as there are about 5 billion cells in 1 mL of blood. More than 99% of 
cells in blood are consist of red blood cells (RBCs), erythrocytes 93.8%, and platelets, 
thrombocytes 6.08%, which are much smaller, 2-8 µm in diameter, than the remaining 
white blood cells (WBCs), leukocytes 10-30 µm, which populate the remaining 0.13% 
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Figure 68. (A) Optical image of the wafer with 76 devices manufactured using 
photolithography, metal deposition and etching; bottom right panel shows an optical 
image of a single CNT device and top right panel shows a SEM image of the CNT 
network bridging the source-drain electrodes.(B) Test set up showing 6 devices on a 
chip. The source, drain and reference electrodes are observed with a spiked blood and 
1X PBS sample droplets on the devices. (C) Optical microscope image of a device with 
a 1X PBS ample droplet on top. Here one can see, from bottom to top, the gold 
electrode, SU-8 photoresist polymer layer covering the electrode and the edge of the 
CNT film, and the CNT ultra-thin film. Similarly (D) shows an optical microscope 
image of similar device after cancer cell spiked blood droplet injection. 
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of cells in the blood and have great similarities to CTCs in their size and shape relative 
to RBCs and platelets. In a static blood sample/droplet the cells inside the blood start to 
settle immediately due to the forces of gravity, resulting in cells coming in contact and 
interacting with the base substrate surface. The initial observations on the optical 
microscope of cancer cell spiked blood sample droplets on top of the devices showed 
that the spiked cancer cells as part of their settling process get buried under RBCs and 
on top of the CNT network stablished on silicon substrate, getting sandwiched in 
between, as illustrated in Figure 69. This phenomenon opened the avenue to further 
attempts achieving better efficiently capturing CTCs in blood by functionalizing the 
nanotubes, as we will discuss in this chapter.  
 CNT devices used for the objectives of this chapter were fabricated using a 6 µg 
CNT film. Higher relative film concentration was elected with respect to the device 
size, 3X3 mm, to maintain a uniform, continuous, and conductive CNT network. The 
fabrication process and the characterization of devices with these CNT films are 
discussed in detail in Chapter 3. To summarize, devices have an average resistance of 
0.2 MΩ after annealing, and average mobility of 4.95 cm2/V-s. On-off ratio was 
determind for these devices once with back-gating, , Ion/Ioff   = 11.2, and once with 
electrolite liquid-gating, , Ion/Ioff  = 134.  
9.2.2. DEVICE FUNCTIONALIZATION 
 CNT devices  were functionalized with anti-EpCAM, anti-HER-2, or anti-IgG 
antibodies using a pyrene linker molecule, Figure 72 (A). Devices were incubated in 
the PASE solution for 2 hours at room temperature, and then rinsed with methanol.  
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Figure 69. (A and B) Optical microscopic images of blood sample droplets on top of 
the device. (A) Three examples of spiked cancer cell blood samples. Spiked cancer 
cells are observed in the blood and marked with an arrow, one can clearly observe the 
cancer cells buried under the RBCs and on top of the substrate, CNT film. High 
concentration of RBCs is apparent on top of the marked cancer cells in “Zone 1”. (B) 
Plain blood sample. There are no cancer cells or WBCs observed in plain blood 
samples when the microscope is focused in “Zone 1” plane. On the other hand when 
image is focused in the plane of “Zone 2” WBCs are apparent in the image (right 
panel), floating above the RBCs. (C) Illustration of blood sample observations under 
the microscope, showing the arrangement of RBCs, WBCs, and spiked cancer cells and 
the classification of “Zone 1” and “Zone 2” accordingly.  
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Figure 70. (A and B) Additional optical microscopic images of blood sample droplets 
on top of the device. (A) SKBR-3 spiked blood sample. SKBR-3 spiked cancer cells are 
observed in the blood at 20X magnification focused in “Zone 1”. 15 out of the 20 
images analyzed to generate the data presented in Table 13 are shown here. (B) Plain 
blood sample. There are no cancer cells or WBCs observed in plain blood samples 
when the microscope is focused in “Zone 1” plane. On the other hand when image is 
focused in the plane of “Zone 2” WBCs are apparent in the image (right panel), floating 
above the RBCs. Scale bars on the first row correlate to all images in each column.  
 
WBC 
CTC cluster  
Single CTC 
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Devices were then incubated in anti-EpCAM (EMD Bioscience, Cat. No. OP187), anti- 
HER-2 (Cell Singnaling tech., Cat. No 2242S), or anti-IgG (EMD Millipore, Cat. No. 
411550), 20μg/mL in 1X Phosphate-buffered saline (PBS) at 20 µg/mL, for 2 hours at 
room temperature. After incubation, devices were rinsed in 1X PBS 3X. At last, 
devices were incubated with 0.5% Tween20 for 2 hours at room temperature. After 
incubation, devices were rinsed with 1X PBS, then stored inside a humid chamber at 4 
C with 20 µL droplets of 1X PBS on top. For more detailed functionalization protocal 
please see Section 4.1. 
9.2.3. BLOOD SAMPLE PREPARATION 
 Farhad Khosravi, Author of this thesis was the subject of all blood draws. Blood 
samples used and discussed in this chapter are all traced back to him as the only source 
and sole blood donor. This allowed for a control and identified blood source with the 
least degree of variation in each batch of blood samples.  
 Upon receiving approval from Worcester Polytechnic Institute’s (WPI) 
Institutional Review Board (IRB), IRB#00007374, and completing biosafety, blood-
borne pathogen, and standard microbiological practices trainings, the following 
protocol was developed under the guidance of Environmental Health and Safety 
department at WPI to collect and handle blood samples for the purposes of the 
experiments in this chapter.  
 As the blood sample volume defined for each set of testing in this chapter are 
set at 5 µL, the total blood volume needed for each day of testing did not exceed 100  
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Figure 71. Capillary blood sampling using a lancing device. (A) Prepare the skin by 
applying sterile alcohol prep pads to the entry site and allow to air dry. (B) Load the 
lancing device with an ultra-thin lancet and prepare for puncture. (C) Puncture the skin 
with one quick, continuous and deliberate stroke. (D) Achieve a good flow of blood and 
wait for a ~100 µL blood droplet to collect. (E) Collected exactly 50 µL of the blood 
droplet using a micropipette, and then apply firm pressure to the site to stop bleeding. 
(F) Transfer the collected blood using a micropipette to a storage vial for further 
preparation. Prep pads, lancets, and lancing device were purchased from CVS 
pharmacy.  
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µL. Therefore, the blood draw protocol was generated around the volumes needed to 
minimize biohazardous waste generation and to maintain the health of the blood donor 
as the blood draws had to be executed frequently throughout the 21 days of testing.  As  
a result, capillary sampling protocol provided by World Health Organization (WHO), 
“WHO guidelines on drawing blood: best practices in phlebotomy”, was adopted to 
generate a protocol to collect blood samples from a finger tip of the subject as 
presented in Figure 71. The collected blood was diluted 1:4 with blank or CTC spiked 
1X PBS. This dilution protocol prevented the blood from clotting without the addition 
of any additional chemicals and allowed for determining an exact concentration of 
spiked CTCs levels in each sample.  
9.2.4. CELL CULTURE AND PREPARATION 
 SKBR-3 and MCF-7 carcinoma cell lines, and MCF-10A, normal epithelial cell 
line, were cultured and prepared for the objectives of the studies in this chapter. The 
cell culture method and preparations are explained in detail in Section 7.2. All cell lines 
were cultured and prepared individually according to ATCC’s guidelines, next they 
were detached from the culture flask using Accutase enzyme solution and suspended in 
1X PBS buffer solution and taken for counting using a hemocytometer. Finally cells for 
each cell line were prepared at fixed concentrations of 800,000 cells/mL and 80,000 
cells/mL in 1X PBS solution. Next the cell samples were diluted in blood 3:4 for a final 
spiked cell concentration of 1000 and 100 cells/5 µL. At this stage spiked blood 
samples were stored at 4 °C for same day testing. As test samples were injected onto 
the device at fixed volumes of 5 µL, the total number of the spiked cells injected to 
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each device was fixed at 1000 or 100 accordingly. 
9.2.5. EXPERIMENTAL DESIGN AND TESTING  
 There are two main variables within the design of experiment, sample type 
(plain, spiked MCF-7, MCF-10A, or SKBR-3 blood) and device type (IgG, HER-2, or 
EpCAM antibody functionalized). In addition, two cell concentrations were defined for 
each cell spiked sample type, 100 or 1000 cells. Table 10 presents the design of 
experiments and the number of replicates. Over all there were 10 replicate for each 
combination, 20 replicates indicates 10 for 100 cell concentration and 10 for 1000 cell 
concentration for that spiked sample type. 
  As discussed previously, Three cell lines of SKBR-3, positive control (over 
expressing HER-2), MCF-7, positive control (overexpressing EpCAM), and MCF-10A, 
negative control normal epithelial cell line (not overexpressing HER-2 or EpCAM), 
were cultured and prepared for these experiments. In addition to these three spiked 
sample types, plain non-spiked blood was also tested as the forth sample type, negative 
control, with each device type. 
Table 10. Design of experiments. 
 
Plain blood
SKBR-3 spiked 
blood
MCF-7 spiked 
blood 
MCF-10A spiked 
blood 
IgG 10 20 20 20
HER-2 10 20 20
EpCAM 10 20 20
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Figure 72. Schematic illustrating the (A) three CNT device functionalization 
variations, IgG, HER-2, and EpCAM antibody, functionalized to the surface of the 
CNT via PASE linker molecule, with tween-20 molecule covering the unfunctionalized 
CNT surface and (B) showing four sample types, plain blood, spiked SKBR-3 , MCF-7, 
and MCF-10A blood samples. 
 
 CNT devices were divided into three groups; first batch was functionalized with 
HER-2 antibody, second batch was functionalized with EpCAM antibody, and third 
batch was functionalized with non-specific IgG antibody via PASE linker molecule, 
tween-20 molecule was used to cover the non-functionalized CNT surface. Figure 72 
illustrates the variations of CNT device functionalization and sample types. Table 10 
summarizes the design of experiment. There are 17 unique combinations within sample 
types, device functionalization, and cell concentration, with 170 technical replicates. 
Four combinations were designed as positive controls (SKBR-3 spiked blood vs. anti-
HER-2 functionalized CNT device and MCF-7 spiked blood vs. anti-EpCAM 
219 
 
functionalized CNT device, both at 100 and 1000 cell concentrations), with 40 overall 
replicates, shown in blue in Table 10. Thirteen other combinations shown in red were 
designed as negative controls, non-specific interaction.  
 The testing platform was set up on Signatone probe station. Agilent 4156C 
Semiconductor Parameter Analyzer equipped with a custom LabVIEW interface for 
monitoring the sensors and data collection. 100 mV VDS was applied to source 
electrods and 0 V VG was applied using a Ag/AgCl referance electrode via the sample 
droplet, source-drain current, ISD, was recorded for the duration of the test . The testing 
setup is demonstrated in Figure 68 (B). Throughout the testing, devices were kept 
inside a humidified chamber to prevent evaporation of the sample droplet. For the detail 
explanation of testing setup please see Section 3.3.  
 The testing protocol started with a hydrated device, 20 μL droplet of 1X PBS on  
top of the device, which was placed immediately after functionalization which covers 
the whole 3x3 mm device window, Figure 68 (B and C). The bias was applied, and the 
sensor was monitored for the initial 4 minutes, then 5 μL droplets of the sample 
solution, plain or spiked blood, was pipetted directly into the standing 20 μL 1X PBS 
droplets, Figure 68 (B). Devices were monitored for 360 seconds after addition of the 
sample solution. The total duration of one test was 10 minutes long. To compare results 
among devices, ISD data were normalized to obtain the ΔG/G0 values for conductance. 
After end of the test, each CNT device was taken to be imaged on an optical 
microscope to confirm the presence of cancer cells and their orientation, Figure 68 (D) 
is an example of one of these images. Additionally, numbers of devices were taken for 
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immune staining and confocal analysis. The spiked blood samples consisted of ~1,000 
or ~100 cells/5μL. This concentration of cells was chosen to be relevant to upper limit 
of clinical samples, as discussed in Chapter 1, and for proof of concept of this 
approach. Surface of the CNT device is capable of interacting with over 20,000 cells at 
one time, therefore fully capable of capturing 1,000 or 100 spiked cells.  
9.3. RESULTS  
 In this section we will review the electrical, optical, and confocal data collected 
during the duration of the experiments proposed earlier. Additionally we will review 
the statistical analyses generated by processing the electrical conductance data.  
 
 
Figure 73. Signal type classification. Zone 1 represents devices that generated an 
increase in their signal after addition of sample droplet (>2%), blue line. Zone 2 
represents devices that generated no significant change in their signal after addition of 
sample droplet (2%), black line. Zone 3 represents devices that generated decrease in 
their signal after addition of sample droplet (>2%), red line. 
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Figure 74.  Merger of device array data for 1000 cells/5 µL variation. Each panel 
correlates with one combination of sample type and device type with respect to design 
of experiment presented in Table 10, 10 replicates each. Each row correlates to one 
type of device functionalization, HER-2, EpCAM, and IgG. Plain blood samples are 
shown in red, MCF-10A in green, MCF-7 in orange and yellow, and SKBR-3 in blue 
and purple. The control buffer signal is shown in black marks in each panel as point of 
reference. If majority of signals in one panel were above or below the reference buffer 
control signal, they were plotted in marks, the rest of the data points that are not 
showing the same trend are plotted as dots. Arrow indicated the time of sample 
injection.  
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Figure 75. Merger of device array data for 100 cells/5 µL variation. Each panel 
correlates with one combination of sample and device type with respect to design of 
experiment presented in Table 10, 10 replicates each. Each row correlates to one type 
of device functionalization, HER-2, EpCAM, and IgG. Plain blood samples are shown 
in red, MCF-10A in green, MCF-7 in orange and yellow, and SKBR-3 in blue and 
purple. The control buffer signal is shown in black marks in each panel for point of 
reference. If majority of signals in one panel were above or below the reference buffer 
control signal, they were plotted in marks, the rest of the data points that are not 
showing the same trend are plotted as dots. Arrow indicated the time of sample 
injection. Plain blood panels are replicates from Figure 74, as there are no spiked cell 
concentration variations within these samples.  
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Figure 74, 1000 cells/ 5µL cell concentration variation, and Figure 75, 100 cells/ 5µL 
cell concentration variation, present the electrical current signals collected during 
spiked blood experiments. Three types of signals were observed with respect to the 
buffer control, signal that increased, decreased, or did not significantly changed with 
respect to the buffer control. These three types of signals were classified as zone 1, 2, 
and 3 as presented in Figure 73. Each panel of the data presented in Figure 74 and 
Figure 75 were analyzed separately and the signals were plotted as marks or dots within 
each panel depending on if they were part of the majority or minority of the total 
signals for that panel, respectively. Overall 17 combinations, 4 positive controls and 13 
negative controls, were defined in these experiments as they are presented in Figure 74 
and Figure 75. It was observed that majority of signals in all 4 positive controls, Figure 
74 (A and D) and Figure 75 (A and D), were located in “zone1” showing an increase in 
device conductance after the addition of the spiked samples, with respect to the buffer 
control. On the other hand majority of the signals, 11 out of the 13, in negative controls 
landed in “zone 3”, showing a decrease in their signal, device conductance, after 
addition of the sample droplet with respect to the buffer control. Table 11 summarizes 
the zone classification results for all the data presented here. Overall, we observed that 
specific interaction indicates an increase in the device conductance where non-specific 
interaction results in a decrease or no change in device conductance. These results show 
a great promise to discriminate spiked cancer cells in blood based on their effect on 
nanotubes electrical properties. In the next section we will use DTW statistical analysis 
classifier, as part of our collaboration with Patrick Trainor and Shesh Rai at University  
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Table 11. Signal classification results. 
 
 
of Louisville, to investigate if there is a significant difference between specific and non-
specific interaction with respect to the positive and negative controls presented here. 
9.3.1. STATISTICAL ANALYSIS 
 After initial evaluations, we observed that SKBR-3 spiked blood data generated 
the most vivid statistical data. To better understand these findings, we will focus on 
presenting the plain, spiked SKBR-3, and MCF-10A blood samples in interaction with 
anti-HER-2 and anti-IgG functionalized devices, in this section.  
  In order to test whether the HER-2 functionalized devices could discriminate 
between SKBR-3 spiked blood samples and controls (plain blood and MCF-10A spiked 
blood), a classifier was constructed and the area under the receiver operator curve 
(AUC) was estimated by 10-fold cross-validation [473]. Both high (1,000 /5 µL) and 
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low (100 / 5 µL) concentrations of spiked cells were evaluated, separately. The primary 
endpoint was AUC in the high concentration condition, the low concentration tests 
were conducted as an exploratory analysis. A total of 30 replicates (10 replicates with 
1,000 SKBR-3 cells / 5 µL spiked, 10 replicates with no cells added, and 10 replicates 
with 1,000 MCF-10A cells / 5 µL spiked) were used in training the high concentration 
condition classifier. To ensure balance between the SKBR-3 positive condition and 
negative condition, a random sample of 5 replicates with no cells and 5 replicates with 
1,000 MCF-10A cells / 5 µL spiked was combined as SKBR-3 negative. Whether the 
series observed with HER-2 antibody functionalized devices and SKBR-3 spiked blood 
could be discriminated from IgG functionalized devices was evaluated to determine if 
the HER-2 antibody and SKBR-3 spiked blood resulted in a specific as opposed to non-
specific antibody-antigen interaction.  
 The discrimination tests were conducted utilizing a k-nearest neighbor 
classifier; please see Section 8.4.10 for more information on k-nearest neighbor 
classifier. A kernel-based learning method such as k-nearest neighbors was employed 
given a parametric model for device response has not been developed. The kernel was 
based on a pseudo-distance metric known as Dynamic Time Warping (DTW) distance 
[446, 474, 475]. Dynamic Time Warping (DTW) is a dynamic programming algorithm 
that seeks to find an optimal global or local alignment of two series in the time domain 
to minimize the total distance between the series with respect to a traditional distance 
metric such as Euclidean distance, see Section 8.4.9. The DTW-distance can then be 
used as dissimilarity metric for training kernel-based classifiers. Further details on the 
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DTW algorithm for use in classification can be found in Rai and Trainor (2016) [446]. 
The DTW algorithm alignments used a “Symmetric 2” step pattern and enforced a 
main-diagonal windowing constraint [475]. k-nearest neighbor classifiers predicted the  
class probabilities as:   
 ?̂?𝑔(𝐲𝒊) =
1
𝑘
 ∑ 1𝑐𝑗=𝑔(𝐲𝒋)
𝐲𝒋∈𝑁𝑘(𝐲𝒊)
 (29) 
where 𝑐𝑖 denotes the sample type of the ith replicate 𝒚𝒊 represents the ith replicate 
series. 10-fold cross-validation was used to estimate the area under the receiver 
operator curve (AUC) and to select the optimal series normalization method and value 
of k. The series normalization methods evaluated were: mean-variance normalization of 
the entire series, slope correction followed by normalization, and slope correction 
followed by scaling by the value at a fixed time-point. Mean-variance normalization 
was defined as 𝐲𝒊 =
𝐲𝒊−?̅?𝑖
𝑠𝐲𝒊
  where ?̅?𝑖  represents the mean of the ith replicate series and 
𝑠𝐲𝒊represents the standard deviation. Slope correction was conducted by fitting a linear 
model to the first 75 series sampling points to estimate the machine drift of the devices. 
In addition to evaluating slope correction followed by mean-variance normalization, 
slope correction followed by scaling the series by dividing by series value at a 
standardized time-point (50) was evaluated. Prior to normalization or scaling, the series 
were truncated to have length 150, with the length symmetric about the time-point of 
droplet deposition. 
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Figure 76. (A) Cross-validation estimated AUC for discriminating a high concentration 
of SKBR-3 cells given HER-2 antibody. (B) Cross-validation estimated AUC for 
discriminating a low concentration of SKBR-3 cells given HER-2 antibody. (C) Cross-
validation estimated AUC for discriminating antibodies, anti-HER-2 and anti-IgG 
functionalized devices, given a high concentration SKBR-3 cells. 
Table 12. CV-estimated confusion matrix for high concentration SKBR-3 cells. 
 
Predicted Class 
True Class 
Negatives (Not 
spiked / MCF-
10A) 
Positives 
(SKBR-3 
spiked) 
Negatives (Not 
spiked / MCF-
10A) 
9 1 
Positive (SKBR-3 
spiked) 
1 9 
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 Cross validation (CV)-estimated AUC for the DTW distance based 𝑘-nn 
classifiers for the high concentration of SKBR-3 cells with HER-2 functionalized 
devices are shown in Figure 76 (A). The highest AUC for this condition was observed 
for the 1-nearest neighbor classifier with slope corrected normalized series. Class 
prediction using CV-estimation confusion matrix for high concentration SKBR-3 cells 
is presented in Table 12. AUC for discriminating a low concentration condition is 
shown in Figure 76 (B). AUC for the discrimination tests between antibodies (HER-2 
versus IgG) with SKBR-3 cells spiked in blood is shown in Figure 76 (C).  
 Devices functionalized with HER-2 antibody were able to discriminate between 
blood spiked with a high concentration of SKBR-3 cells (1,000 / 5 µL) and control 
blood (spiked with MCF-10A cells or not spiked, plain blood). 10-fold cross-validation 
estimated AUC for the 1-nearest neighbor DTW-distance based classifier was 0.90 after 
slope correction and normalization. One false negative and one false positive out of 10 
positives and 10 negatives were observed in the cross-validation procedure, showing 
90% sensitivity and 90% specificity. Sensitivity is defined as TP/P, where TP 
represents the number of correctly classified positive (SKBR-3 spiked) samples and P 
represents the total number of positive samples. Similarly, specificity is defined as 
TN/N, where TN represents the number of correctly classified negative samples (plain 
or MCF-10A spiked blood) and N represents the total number of negative samples. Of 
the replicates identified as true positives, 6/9 series finished higher, “zone 1”, after the 
rebound that followed droplet injection than the initial period, indicating a positive ΔG; 
of the replicates identified as true negatives, 7/9 series finished lower, “zone 3” after 
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the rebound that followed droplet injection than the initial period. This indicates that 
DTW classifier can more significantly discriminate the CTC spiked samples than a 
simple observation of change in device conductance, opening the way for a deeper 
analysis of the electrical data.  
 Devices functionalized with HER-2 antibody were unable to significantly 
discriminate between blood spiked with a low concentration of SKBR-3 cells (100 / 5 
µL) and control blood. 10-fold cross-validation estimated AUC for the 1-nearest 
neighbor DTW-distance based classifier was 0.45 after slope correction and 
normalization.  
 Fixing sample phenotype (blood spiked with a high concentration of SKBR-3 
cells) allowed for discrimination of antibody functionalization, anti-HER-2 vs. anti-IgG 
functionalized device. 10-fold cross-validation estimated AUC for the 1-nearest 
neighbor DTW-distance based classifier was 0.70 after slope correction and 
normalization. Based on the results from fixing the sample phenotype and separately 
device phenotype, we can suggest that the significant difference seen in electrical signal 
with our positive controls must be as a result of HER-2 receptor, on the cell membrane, 
interaction with the HER-2 antibody on the surface of the CNT.     
 In this section we showed that using DTW classifier, we are able to discriminate 
CTCs spiked in blood with respect to sample and device type controls defined in the 
previous section. These analyses are an indicator that specific interaction between the 
cancer cell receptor and the antibody functionalized on the surface of the nanotube can 
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potentially result in significant change in nanotubes electrical property. This is a very 
promising indicator to discriminate presents of CTCs in blood.  
9.3.2. OPTICAL MICROSCOPE IMAGE ANALYSIS  
 As a result of our observation in Section 9.2.1, with regards to blood droplets 
sample settling as illustrated in Figure 69 (C), we were able to image zone1 and further 
analyze the captured spiked CTCs using optical microscopy technique. All the devices 
were imaged under the optical microscope after the end of each test. Number of devices 
with 1000 spiked CTC samples were selected and their respective optical microscope 
images were taken for spiked cell analysis. 20, imaged at 20X magnification, and 15 
devices, imaged at 5X magnification, were selected for further processing and analysis. 
 Figure 77 (A and D) present an example set of 20X and 5X optical images taken 
for image analysis. ImageJ software was used to process each image. Original optical 
images were converted to binary image and processed using ImageJ software to 
distinguish spiked cells, shown in black circles, from the red blood cell in the 
background by using color threshold function, Figure 77 (B and E). Next, ImageJ 
software’s particle analysis function was used to count the number of cells and cell 
diameter for each set of images, Figure 77 (C and F), knowing the scale bar for each 
image. All the data from these analyses, including number of cells per image, cells per 
unit of area (mm
2
), diameter of cells, and number of cell per device calculated based on 
partial cell count and total device area, 9 mm
2
, are presented in Table 13 and Table 14.   
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Figure 77. (A and D) Show optical microscope image of devices with spiked sample 
droplet on top. (B and E) Show binary conversion of the optical microscope images, 
highlighting the spiked cells in black and separating them from the background. (F and 
I) ImageJ analyses of binary images, based on diameter and shape, showing cell count 
map of each original optical image. (G-I) demonstrate surface area comparison of the 
square shaped device vs. circular droplet covering the device. CNT device is only 
covered by ~62% of the total droplet area. 
 
 
 
 
 
232 
 
 Figure 77(G-I) shows the illustration of CNT device area vs. sample droplet 
covering the device. As shown, the sample droplet’s diameter exceeds the device 
window to assure full coverage of the device. The nature of the square shape of the 
device and circular surface area of the droplets, results in the device only covering 
~62% of the sample droplets base area. If we assume uniform and even coverage of 
spiked cells throughout the whole sample droplet’s base area, we can only expect ~62% 
of the spiked cells to land on the device surface. In the case for 1000 cells/ 5µL, we 
expect for about 620 of the cells to land on the device surface on average. As presented 
in Table 13 and Table 14, on average 624 (20X images) and 623 (5X images) cells 
were captured and counted on each device which correlates with our calculations and 
expectations with regards to device geometry and droplet shape. Figure 78 presents 
histograms of cell count per device and cell diameter. On average, cell diameter was 
measured at 13 µm for 20X images and 12 µm for 5X images. 5X images have lower 
resolution of cells and therefore one can expect information loss and smaller cell 
diameter calculations. Overall, over 90% of cell diameter measured using imageJ 
software fall within the range of 6 to 22 µm which is within our expectation for CTCs 
as discussed in Chapter 1. The measurements in the upper end, >20 µm, can be a result 
of a cluster of two or three cells as seen in optical image on Figure 77 (A) and confocal 
image in Figure 79 (second row C), resulting in a larger diameter estimates. Lower end 
of the diameter measurements, < 8 µm, have the potential to be misclassifications of 
either RBCs or WBCs miss classified as CTCs. On the other hand, these smaller cells 
can also be smaller CTC with smaller diameter due their size; loss of resolution after  
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Figure 78. Histogram of number of cells counted per device based on 5X (A) and 20 X 
(B) magnifications optical microscope images. (C) Presents the histogram of diameter 
of all cells counted. 
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Table 13. Cell count data per device based on 20X images. 
 
 
 
Table 14. Cell count data per device based on 5X images. 
 
Device number Number of cells Cells/mm2
Average 
diameter (µm)
Number of cells 
per device
1 33 78 10 706
2 31 74 11 663
3 24 57 10 514
4 24 57 15 514
5 15 36 14 321
6 33 78 14 706
7 32 76 11 685
8 22 52 13 471
9 16 38 13 342
10 32 76 13 685
11 36 86 12 771
12 24 57 14 514
13 39 93 15 835
14 30 71 16 642
15 30 71 14 642
16 25 59 15 535
17 35 83 15 749
18 49 117 14 1049
19 37 88 14 792
20 16 38 14 342
average 29 69 13 624
std. dev. 8 20 2 178
Device number Number of cells Cells/mm
2 Average 
diameter (µm)
Number of cells 
per device
1 339 61 10 552
2 441 80 12 719
3 308 56 18 501
4 340 62 10 554
5 550 100 10 896
6 376 68 13 613
7 344 62 12 561
8 496 90 12 808
9 435 79 12 708
10 300 54 15 489
11 371 67 12 604
12 335 61 11 546
13 327 59 10 533
14 392 71 11 639
15 378 69 10 617
average 382 69 12 623
std. dev. 68 12 2 111
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image processing can also reduce the diameter size calculated. Nevertheless, Optical 
image analysis presented here demonstrates a great confidence in the ability to capture 
CTCs and analyze their physical appearance using optical microscopy without 
disturbing the platform. To further understand the nature/type of cells captured, 
immunofluorescence techniques were used. 
9.3.3. CONFOCAL IMAGE ANALYSIS  
 Four HER-2 functionalized devices injected with SKBR-3 spiked blood were 
taken for immunofluorescent staining and confocal microscopy without any further 
manipulation. The staining and imaging process is similar to what has been described in 
Section 7.2.1. Figure 79 demonstrates captured SKBR-3 cells on the device stained for 
cytokeratin (positive for epithelial cells and negative for WBCs) and CD45 (negative 
for epithelial cells and positive for WBCs). It is very impressive to be able to capture 
and maintain captured CTCs on the device for confocal microscopy. The staining 
protocol involves multi-level labeling/staining protocol with vigorous rinsing steps. The 
fact that the captured CTCs are still present and attached on top of the device shows the 
strong interaction of the cells to the functionalized CNT surface. In addition we were 
able to distinguish rare presence of WBCs from CTCs attached to the device using 
confocal microscopy, CD45 positive. In any setting, negative interactions, in this case 
sticking of WBCs to the device surface, are expected. The ability to cross out any non-
specific interaction using confocal microscopy is of great advantage with our platform. 
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Figure 79. Cell differentiation using confocal microscopy: SKBR3 cells captured on 
chips from 3 devices showing positive staining for DAPI, cytokeratin (CK-19) and 
negative for CD45 and two images of leukocytes captured showing positive for DAPI 
and CD45 while negative for cytokeratin. (A) series of optical images; (B) DAPI 
nuclear stain; (C) CK19 stain for cancer cell and (D) CD45 for leukocytes and (E) 
merged image of nuclear and cytoplasmic stains.  
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9.4. CONCLUSION AND FUTURE WORK 
 In this chapter we demonstrated the ability to capture spiked cancer cells in 
blood using our CNT micro-array platform. Additionally, we were able to distinguish 
cancer cells, SKBR-3, from non-cancerous cells, MCF-10A, and plain blood with 
statistical confidence using DTW classification resulting in 90% specificity and 
sensitivity with 1000 cells/ 5µL concentration samples. Using optical image analysis 
we confirmed capture and landing of all spiked cells on the CNT device with respect to 
device geometry. Finally we confirmed capture cells as CTCs using confocal 
microscopy and were able to distinguish false positives in an event of WBC attachment 
to device which are cytokeratin negative and CD45 positive unlike CTCs that are 
positive for cytokeratin and negative for CD45. 
 It would be interesting to further investigate the device response with biological 
replicates, different blood donors, to gain a higher confidence for the specific 
interactions we observed here. In addition, testing other cancer cell lines that over 
express HER-2, such as BT474, and functionalizing devices with other antibodies, such 
as IGF1R, that target other overexpressed receptors on CTCs can help better understand 
and further validate our observations here.  
 Here, we observed nonspecific interaction of cells with the CNT surface 
resulting in decrease in device conductance. Similar findings were also reported by 
McEuen’s group with live cells [476] and lipid bilayer interaction with nanotubes 
[470]. In addition, we reported an increase in nanotube device conductance as a result 
of specific interaction of antibody functionalized CNT and cell membrane receptors in 
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blood samples. As also reported by other researchers, it is very difficult to single out 
the origin of the change in device conductance in a very complex system such as 
cell/nanotube hybrids. Identify the exact mechanism behind the changes observed in 
CNT electrical property, carrier mobility and density, as a result of these interactions 
requires sophisticated equipment in very controlled environment. Even thought our 
broad range of controls, as part of the design of experiment, demonstrated high 
confidence in confirming the relation of the electrical signal to receptor and antibody 
interaction on the CNT surface, it still would be very interesting to further investigate 
the mechanism of this effect on CNT’s electrical property. 
 A piezo-controlled manipulator pipetting system would be an effective tool to 
directly control the position and number of cells on the device and could enable 
studying the interaction mechanism and cell’s effect on the electrical property of CNT 
device. Additionally, an electrode inside the micropipette to measure or control the 
potential inside the cell using “whole-cell” patch clamp configuration in which the 
pipette breaks into the cell center, with the membrane sealed around its edges, can 
enable us to study the effect of cell charge and its correlation with device electrical 
response. In this setting capacitive gating effect on the nanotube carrier density based 
on the known charge of the cell can be studied. The fragile nature of this seal would 
complicate the cell manipulation, but this configuration would allow us to perform 
more interesting experiments, such as measuring the change in nanotube conductance 
in response to an AC signal on the wire. 
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 Although, confocal microscopy gives us an understanding on the type of cells 
captured on the device, based on presence of the over expressed receptors, It would also 
probably be fruitful to freeze a cell on a nanotube after an experiment, and coat the 
system with metal, to examine it with an SEM to get a high resolution image of the 
interaction of cell and CNT. Scanning photocurrent microscopy should also provide 
useful information about the nanotube behavior. 
 In its current form, our platform can be better integrated with an automated 
liquid handling system to fractionate 1 mL of blood to 5 µL droplets per device to 
enable for high volume clinical studies. Finally, in future design improvements, 
microfluidic technology can be utilized to control the sample and volume of blood per 
device and create an integrated lab on a chip system. 
  Furthermore, a unique advantage to our platform is that each CNT micro-array 
is a separate device, after testing positive, the device can be removed and taken for 
further analysis, such as reverse transcription polymerase chain reaction (RTPCR) and 
confocal microscopy (as presented in this chapter), to gain a deeper understanding of 
the genetic structure of the captured cells.  
 The CTC capture and electrical response that we have observed from 
semiconducting carbon nanotubes interacting with cells is an important step in the 
nanoscale electrical probing of biological systems utilizing them as multipurpose 
platform for capture and discrimination of diseased cells. Through some of the 
experiments suggested in this section, we hope that the nature of this response will be 
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elucidated, allowing nanotubes to be used for more advanced studies of cellular 
behavior. 
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CHAPTER 10 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
10.1. CONCLUSIONS   
 In this thesis we presented a carbon nanotube micro-array platform for detection 
of ions, free proteins and capture of breast cancer cells spiked in buffy coats and blood, 
Table 15. The contributions of the thesis for the broader nanobiotechnology community 
are as follows: 
 Design and fabrication of 60-240 element nanotube micro-arrays for biomedical 
applications using semiconducting carbon nanotube, PASE functionalization 
protocol and clean room batch fabrication techniques. 
 An in-depth understanding into sensing ions namely mercury and ammonium 
using semiconducting nanotube devices. 30 pM sensitivity for Hg
2+
 could be 
used in screening drinking water (Hg
2+
 ions limit set by most governmental 
EPA is ~10 nM). 
 
Table 15. CNT micro-arrays for detection and capture of proteins and cells. 
 
 
Buffy coat
Ammonium Mercury Biotin EpCAM IL-6 SKBR-3 MCF-7 MCF-7 SKBR-3 MCF-7
Device 
generation 1 1 3 3 3 1 1 1 2 2
Principle of 
detection/
capture
adhesion adhesion antibody antibody aptamer antibody antibody antibody antibody antibody
Detection 
limit 300 nM 30 pM 1 ng/mL 1 ng/mL 1 pg/mL
1-25 
cells/device
1-25 
cells/device
1-25 
cells/device
100-1000 
cells/device 
100-1000 
cells/device
Spiked breast cancer cells
PBS BloodIons Free proteins
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 Detection of cancer biomarkers such as IL-6/free proteins such as f-EpCAM 
using nanotube antibody or aptamer arrays. Detection of IL-6 at 1 pg/mL 
presents the applicability of nanotube arrays for cancer biomarker testing, IL-6 
levels in serum >12 pg/mL have been correlated with large tumor size. 
 Ability to detect and capture spiked breast cancer cells in buffy coats using 
nanotube micro-arrays with single cell sensitivity. The ability to distinguish 
samples that have cancer cells from samples that have no cancer cells in a 
medium such as blood/buffy coats in rapid manner for both large and small 
volumes can have significant implications in the clinic. 
 Capture and isolation of spiked breast cancer cells overexpressing HER-2 
receptors in blood using nanotube micro-arrays. These devices thus could be 
useful for capture and analysis of circulating tumor cells. Fractionation of blood 
sample over array of devices can enable rapid and simultaneous “liquid biopsy” 
analysis for circulating tumor cells.  
 
 As a result of these studies, we identified three key factors (film morphology, 
functionalization approach, and device geometry) which directly impact the device 
efficiency in detection and capture.  
 It was concluded that ultra-thin, < 100 nm, single layer SWNT array network is 
more sensitive to environmental changes and results in lower under layer channel 
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current fellow and higher on-off ration in comparison with thicker array networks, 
>100 nm. 
 PASE linker molecule was presented as an effective method to non-covalently 
anchor molecules and proteins to the surface of nanotube arrays. In addition, it was 
demonstrated that specific interaction of biomolecules to the surface of the nanotube 
can be further improved by using aptamer molecules instead of antibodies, thus 
increasing the binding sites and closing the gap in-between the anchored protein and 
SWNT surface due to the smaller size of the aptamer molecule. This approach 
enhanced and amplified the effect on the nanotube electrical property as result of 
analyte interaction with SWNT surface, increasing free protein detection limit from 1 
ng/mL with antibodies to 1pg/mL using aptamers.  
 Finally, we understood that there is a fundamental tradeoff between decreasing 
target settling time and increasing sensitivity with respect to device geometry, active 
area. As active area on the device increases the sensitivity decreases and also does the 
settling time, which in return increases the capture yield of cells and diffusion 
efficiency of proteins on the nanotubes. This is evident especially with cell capture 
experiments in which the capture yield and number of cells needed to generate an 
electrical signature increases from 1-25 to 1000 from generation 1 to generation 2 
devices which have ~1000X larger active area.   
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10.2. SUMMARY   
 Carbon nanotubes, with their nanoscale dimensions, high electrical sensitivity, 
ability for surface functionalization, and efficient operation in an electrolyte 
environment, can be excellent tools for probing biomolecular and cellular world. As we 
saw in Section 2.3, CNTs and transistor structures based on them have already been 
used to detect chemicals (i.e. gases), biomolecules (i.e. proteins, DNA, and enzymes), 
and even cells. In all these interactions, change in CNT conductance and/or shift in the 
CNT transistor threshold voltage was reported, but the mechanisms behind these 
responses are not always understood, especially with regards to cell interactions. 
Nevertheless, an integrated platform that utilizes CNTs in clinically relevant fashion for 
biomolecular detection, cell capture and classification is yet to be introduced.  In this 
thesis, for the first time we demonstrated using thin film carbon nanotube networks for 
capturing circulating tumor cells and utilizing CNT’s electrical properties to classify 
cell type, opening a whole new avenue for understanding and studying cellular 
interactions in clinically relevant setting.   
 To establish this platform, we fabricated an ultra-thin CNT film network using 
only ~1 mg/m
2
 semiconducting CNT, 4 µg film, utilizing vacuum filtration method, as 
described in Chapter 3. Ultra-thin CNT films described here are continues, uniform, 
conductive, and almost single layer, at <<100 nm thickness, exposing almost all 
nanotubes to surrounding environment. The vacuum filtration method allowed for a 
great degree of control on the mass concentration of CNT per film area and created a 
self-assembled network in a very simple and cost-effective way. Nano-micro material 
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preparation can be very expensive, CNTs are among the most expensive nanomaterials, 
using the vacuum filtration platform we were able to undercut the need for expensive 
and sophisticated facilities and equipment, such as chemical vapor evaporation (CVD), 
and fabricated thin films only using ~$3 worth of material per 4 inch silicon wafer, 
$800/1mg of CNT. We used these ultrathin cost effective CNT films to microfabricate 
CNT micro-array devices on Si/SiO2 wafers, as discussed in Chapter 3. Three 
generations of devices were fabricated with CNT film windows of 20X20, 100X80, and 
3000X3000 µm for biomolecular, cell culture, and blood sample studies respectively. 
We characterized and functionalized these micro-array CNT devices and understood 
their electrical response and interaction with ions and other molecules, as described in 
Chapter 4. Next, we developed and optimized a viable functionalization protocol using 
PASE linker molecule, which pie stacks non-covalently on one end on CNT surface 
and covalently binds to antibodies on the other end. Here we demonstrated capturing 
gold nano particles on the surface of the functionalized CNT by specific interaction. 
Utilizing percolation theory we modeled conductivity of the CNT devices as a function 
of CNT film mass. We integrated these devices into our humid chamber system to 
control sample droplet evaporation rate and used our probe station platform to measure 
the conductance response of the nanotubes to complex molecular interactions using an 
electrolyte gate. We characterized analyte interaction with our CNT device using the 
Langmuir isotherm model and demonstrated that the magnitude and direction of the 
shift were directly related to the ionic charge concentration and interaction on the CNT 
surface. 
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 We first presented our results with EpCAM biomarker interaction with 
functionalized CNT device complex in Chapter 5.These interactions caused a large 
threshold voltage shift and change in the conductivity of our CNT devices. We 
demonstrated that this response is directly related to the interaction of antibody, 
functionalized to the surface of the CNT, and its antigen, as non-specific antibody and 
antigen controls showed no significant change in electrical properties of the device. 
These findings went hand in hand with our earlier functionalization studies in Chapter 
4, which visualized this same interaction using gold nanoparticles (NPs). These results 
together, showcased biosensing ability of our micro-array CNT devices and their 
capability to interact and capture biomarkers, such as EpCAM, and opened the door to 
further study the cell membrane receptor interaction with CNT surface. As cells and 
cell membranes are great complex systems, capturing them on the CNT surface using 
the antibody-receptor interaction and monitoring their effect on the electrical property 
of CNT in close proximity to its surface is of great interest.  
 In Chapter 6, we proposed using aptamers instead of antibodies for capture and 
detection of biomarkers. This allowed for a closer interaction of antigen to the CNT 
surface with respect to Debye length, as was presented with our AFM studies. As a 
result, we were able to demonstrate a very sensitive device response to very small 
concentrations of antigen, IL-6 target protein (1pg/mL). Even though using aptamers 
greatly improved sensitivity of our devices and showed great promise for higher 
interaction affinity with target protein, at the end we elected the antibody platform for 
our cell capture studies, as aptamers are much less available commercially and very 
247 
 
expensive to develop. However, this opens a new avenue for future studies on CNT 
micro-array devices utilizing aptamers for cell capture and discrimination. 
 We then described the results of our experiments with living cells spiked in 
phosphate buffer solution (PBS), Chapter 7, and in buffy coat, Chapter 8. Here for the 
first time, we demonstrated capturing cancer cells on a CNT thin film network and 
observed a unique electrical signal differentiating specific and non-specific interaction 
of the cancer cells on the device. We were able to differentiate the two types of 
interaction, specific and non-specific, with statistical confidence. Additionally, we 
attempted to correlate device signal intensity to the number of cells on the device using 
a model based on Kohlrausch-Williams-Watts (KWW) function. However, this 
relationship did not line up with our collected optical and electrical data.  Nevertheless, 
further studies are needed before we can completely scratch out this relation between 
device signal intensity and number of cells on the device. To investigate this 
relationship further, we proposed live device imaging at the time of electrical signal 
collection to monitor the exact number of cells present on the device at the time of 
electrical signal generation. Additionally, manipulating number of cells on the device 
using a piezo-controlled manipulator pipette to control number of cells interacting with 
the device can shed more light on the mechanism of this interaction.  Dynamic Time 
Warping (DTW) technique was used to build a classifier based on spiked buffy coat 
interactions with the CNT device and discriminate samples with cancer cells. This level 
of success was presented here for the first time utilizing CNT devices and DTW 
classifier. These results encouraged us to further investigate the clinical utility of this 
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platform. Even though ability to capture and discriminate CTCs is of great value in the 
clinic, preparing buffy coat samples still requires level of preparation and processing in 
the laboratory setting. The ability to process whole blood samples is of greater interest 
and opens the door for off-site and portable convenient analysis of blood samples for 
CTCs.  
 In Chapter 9 we explored the response of CNT micro-array devices with whole 
blood samples. Here we broadened the spectrum of our experimental design by adding 
more CTC cell lines and biomarkers of interest. We observed very promising results 
with regards to capturing CTCs on our devices, as presented in optical and confocal 
microscopy results. In addition, we saw distinguished difference with device signal 
signature for specific vs. non-specific interactions. When we placed CTC spiked blood 
sample on the device, however, we often saw a large increase in the CNT device 
conductance that occurred after the introduction of cancer cells on the functionalized 
device surface. The results suggest that the change in signal is due to the cell receptor 
membrane interacting with functionalized antibodies on CNT surface. Such interaction 
can result in cell membrane coming in contact with CNT surface. Charge associated 
with cell membrane bilayer can influence the CNT electrical properties. In addition, 
stress implemented to CNT and or cell membrane as a result of this interaction could 
additionally affect/activate ion channels on cell membrane causing releasing of ions 
and affecting the CNT surface charge field. However, we were unable to draw 
definitive conclusion for the origin of the change in signal, further studies to understand 
CNT-cell interaction and configuration is needed. We discussed attempts to image this 
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configuration using confocal microscopy, and explained how an SEM or photocurrent 
microscopy might provide more information. In addition, we were able to statistically 
discriminate SKBR-3 cancer cell lines spiked in blood from control MCF-10A non-
cancerous cell line and plane blood with 90% sensitivity and specificity using DTW 
platform. These results are of great interest in the clinical setting. However, before 
being able to fully implement this technique in the clinic further work in regards to 
improving device sensitivity to number of cells captured from the samples is needed.  
 We also discussed a number of other directions for this study, including 
controlling the potential inside the cell through a whole-cell patch clamp configuration, 
using a piezo-controlled manipulator pipetting system to manipulate the exact number 
of cells and their orientation as they are interacting on the device, which can help gain a 
higher understanding of this interaction and the mechanism of device response. 
10.3. FUTURE DIRECTIONS 
 Our experiments have demonstrated the great feasibility of utilizing carbon 
nanotubes for biosensing, cell capture and classification. We have developed a single 
platform based on CNT thin films to capture and discriminate living circulating tumor 
cells in spectrum of solutions, from phosphate buffer solution to whole blood, with 
great level of success. We have shown that CNT micro-arrays can be used effectively 
as nanoscale probes of biomolecular and cellular samples. Here we explore the exciting 
possibilities for these devices in many future research and applications. In number of 
directions this work can be complimented in the future: device design and integration, 
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functionalization technique, sample type, statistical analysis, post capture analysis of 
CTC. 
 To increase the device output, sensitivity, and efficiency, current microfluidic 
technologies can be utilized to develop an integrated lab-on-a chip platform to process 
and separate RBCs and WBCs, [477], introducing more purified sample for capture and 
discrimination of CTCs to possibly increase sensitivity. Additionally, microfluidics can 
enable controlled sample flow, type and volume per each device. At current design, 
integrating our devices with an automated liquid handling system to fractionate 1 mL of 
blood to 5 µL droplets per device can enable our platform for high volume clinical 
studies. 
 Even though antibodies are the golden standard for specific antigen binding, 
exploring more effective functionalization method can be of interest to potentially 
increase the yield of the device. Studying capture and interaction yield of aptamers, 
affibodies, and antibody fragments in place of antibodies on our platform can introduce 
an opportunity for higher affinity interaction. Also smaller size of these molecules can 
introduce for higher number of binding sites thereby increasing CTC capture yield. 
Finally, targeting multiple biomarkers simultaneously, i.e. HER-2, EpCAM and IGF1R, 
can also increase the yield and sensitivity of the platform.   
 To better understand and validate the dynamic of the CTC capture and 
discrimination, variety of samples types can be tested. These samples types can vary by 
introducing new cancer cell type (i.e. BT474) or medium, multiple blood donors. In 
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addition to targeting cancer cells in blood, cancer cells collected by biopsy techniques 
such as fine needle aspiration can be tested and studied on our platform. Success with 
biopsy samples can be of great interest in the field of pathology opening the possibility 
of rapid on site sample analysis in the operating room. 
 More sophisticated statistical analysis can give us deeper understanding of the 
results. ANOVA model can be used further for a more robust design of experiment to 
shed more light on the origin of the interactions by closing in on the negative and 
positive controls. Dynamic time warping can be further improved to analyze biological 
replicates and to correlate gender, genetics, and family history to test results. In 
addition, work on DTW to recognize number of CTC captured from device signal 
would be of great interest. 
 The advantage of our platform is that each micro-array device is a separate unit, 
after testing positive, the device can be removed and taken for further analysis, such as 
reverse transcription polymerase chain reaction (RTPCR) and confocal microscopy, to 
gain a deeper understanding of the genetic structure of the captured cells. These studies 
can further validate and improve upon our understanding of the specific interactions. 
As discussed Chapter 9, we also suggested directions for future research to further 
investigate the mechanism behind the change in the electrical signal as a result of the 
cell interaction with nanotubes.   
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